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ABSTRACT 
Prediction of human pharmacokinetics (PK) following subcutaneous (SC) administration to animals is 
challenged by potential interspecies differences in skin anatomy and physiology. With respect to biologic or 
macromolecule drug development, the SC route is gaining substantial interest as a primary route of drug 
administration over intravenous due to convenience and cost factors. The bioavailability and time course of 
a SC administered macromolecule can potentially be influenced by local clearance (CL) processes in the SC 
space after injection, and due to size constraints, is subject to varying degrees of lymphatic uptake following 
injection. Traditional allometric techniques employed in interspecies scaling are limited to extrapolation of 
an average value for PK parameters such as clearance (CL) or volume (V), and provide no information on 
the time course of a drug after administration. In many cases, PK parameters are estimated using non-
compartmental (NCA) methods which, in violation of the assumptions of NCA, requires CL to occur via the 
sampling compartment. Dedrick plots that have been employed to predict the time course of a drug after 
administration, do not consider species differences in extravascular drug absorption processes. In contrast, 
model-based methods such as population based compartmental methods allow for an estimation of 
absorption processes, along with CL and V, in animals, which can then be scaled to human values according 
empiric allometric relationships. Physiologically- based PK (PBPK) methods allow for a mechanistic means 
of accounting for the SC time course and further allow for incorporation of local CL processes and 
lymphatic transport. Model-based drug development has the potential to minimize reliance on animal data to 
inform human clinical trial design. Moreover, models developed with an intention to translate animal 
findings to human scale offer an opportunity to streamline clinical development through trial simulation, 
thus reducing the time and cost of developing a new therapeutic product. With an aim to de-risk biologic 
and biosimilar drug development, this thesis describes the development and evaluation of  (1) a nonlinear 
mixed effect model incorporating allometric relationships and (2) a PBPK model incorporating an SC depot 
compartment, based on a single non-human primate (NHP) species, to predict the PK of a SC administered 
macromolecule. For reference, model-based methods are compared to traditional allometric and model-
independent methods employing the same data used in the model-based approaches. Single-species 
allometric scaling of CL based on an empiric scaling factor previously demonstrated to support reasonable 
extrapolation from NHP to humans (i.e. 0.85) failed to predict human CL within a reasonable and pre-
determined threshold fold error (i.e. predicted/observed falling with 0.7-1.3). Dedrick plots predicted 
secondarily-derived PK parameters such as Cmax and Tmax reasonably well, however clearly 
underperformed in predicting the early portion of the SC time course. Model-based approaches provided 
reasonable estimation of systemic exposure parameters and prediction of the time course, with PBPK 
models providing an opportunity to mechanistically appreciate influential factors in the SC time course of a 
macromolecule. As a novel development the SC time course of a macromolecule could be reasonably 
 vi 
 
simulated by a PBPK model incorporating lymphatic biodistribution and whereby the SC injection was 
parameterized as a depot compartment within the skin insterstitial space. Similarly for the first time in 
published literature, a population-based PBPK model was developed incorporating lymphatic system 
interindividual variability which was demonstrated to predict the time course of a macromolecule in a 
population of humans. 
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
  
 2 
 
  
1.1 Therapeutic Macromolecules 
The use of therapeutic macromolecules, or biologics, is increasing globally and growing at a faster rate than 
small molecules as evidenced by global prescription sales for biotech drugs which, from a 2007 report, were 
increasing by 12.5% annually, to more than USD$75 billion (1).  It has been estimated that one in eight 
prescriptions written globally is for a biologic drug and given an annual treatment cost per individual of 
more than USD$16,000, the consequence is that continued growth at such a rate will further increase the 
spending burden on payers of these therapies.(1) The term biologic drug requires distinction from 
chemically synthesized therapeutic product and includes compounds such as peptides, proteins, 
oligonucleotides, vaccines and blood products.(2) For the purpose of this thesis, only therapeutic 
macromolecules such as peptides, proteins and oligonucleotides will be discussed herein and the term 
therapeutic macromolecule and biologic drug should be assumed to be interchangeable. Therapeutic 
macromolecules can be contrasted with small, chemically synthesized molecules based on physico-chemical 
and biochemical characteristics. Table 1.1 summarizes some of the key differences between small and large 
molecule classes.  
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 Table 1.1 Differences between small molecules and macromolecules 
  
Small Molecules Macromolecules 
Molecular weight <1 kDa >1 (generally >15-20 kDa) 
Physiochemical properties Well-defined Complex 
(e.g. tertiary, glycosylation) 
Synthesis Chemical synthesis Biotechnology (e.g. recombinant) 
Purity Single entity  
Chemical purity 
Heterogeneous Mixture  
Broad specs 
Administration Oral (majority), IV, SC, IM. Parenteral (IV, SC, IM) 
Distribution Various organs/tissues Plasma and/or extracellular fluids 
Protein binding important 
Metabolism Phase 1 & 2 reactions to metabolites Catabolized to smaller building blocks 
Toxicity Specific  
Dissociated from effect 
Receptor mediated (endocytosis) Exaggerated PD 
responses 
Antigenicity Not typical Yes  
IV: intravenous; SC: subcutaneous; IM: intramuscular 
Adapted from Baumann, 2006 (3)  
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The larger molecular weight of macromolecules is a key characteristic influencing the pharmacokinetics 
(PK) of the drug. In terms of biochemical processes, biologics are typically catabolized to smaller building 
blocks such as amino acids or nucleic acids, which alters the safety profile compared to synthetic 
compounds as these building blocks are similar, or identical to endogenous compounds in some cases. Due 
in part to molecular size as well as structural aspects that can be recognized as foreign by the human 
immune system, biologics have the potential to elicit an antibody response, which can in some cases alter 
the PK and pharmacodynamic (PD) properties of the drug.   
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1.2 Biologic Drug Development 
No one single approach characterizes the development process for all biologics and each plan should be 
risk-based and consider the individual physico-chemical, biochemical and toxicological profile of the drug. 
There are however class-like properties of biologics that influence the regulatory requirements for many 
biologics in terms of advancing the drug from the preclinical stage to clinical, and onward to marketing 
authorization. Typically, small molecule drugs require toxicological assessment in a minimum of one rodent 
and one non-rodent species, substantial ADME (absorption, distribution, metabolism and excretion) 
characterization, genotoxicity evaluation and screening for drug-drug interaction potential. The safety 
profile of a biologic is typically influenced by the binding of the drug to a biological target and an 
exaggerated PD effect. Consequently, the safety of a biologic drug is to be evaluated in a relevant animal 
species. In many cases, only a single relevant species exists (e.g. non-human primate, NHP) and therefore a 
minimum of a single species is deemed necessary for toxicology testing for biologics. In part, due to the 
molecular size, restrictive biodistribution, and routes of catabolism, there is little need to extensively 
evaluate ADME properties of biologics. Exceptions of course exist, particularly for drugs with specific 
uptake into tissues such as with oligonucleotides and siRNA which demonstrate distribution into various 
organs (e.g. liver, kidney).(4) Also, due in part to the molecular size and similarity to native proteins, most 
biologics are assumed to not exhibit genotoxic potential, thus obviating the need for this evaluation in the 
drug development process. Lastly, biologic drugs have a lower potential for inhibiting drug metabolizing 
enzymes, and as these compounds are not typically metabolized to metabolites, are unlikely victims of PK 
drug interactions.(2)  
 
Clinical (human) development of a biologic is similar to small molecules in that initial testing in humans is 
typically focused on evaluating safety and PK, followed by confirmation of biological effect and therapeutic 
efficacy and safety in larger clinical trials. However, as with the nonclinical development plan, extensive 
studies on the ADME properties and drug-drug interaction potential for a biologic are often unwarranted. 
Instead, greater importance is placed on the relationship between drug exposure and PD response or receptor 
occupancy (RO).  
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1.3 Biosimilar Development 
An approach gaining popularity across the globe for reducing drug cost and improving access to otherwise 
out of reach therapeutic macromolecules is through the development of second entry biologic “copies” or 
biosimilars. The formal definition of a biosimilar may differ according to the regulatory jurisdiction or 
country; however it can be defined as a highly similar version of a previously approved therapeutic 
macromolecule.  There is a consistent fundamental appreciation that although a high degree of physico-
chemical characterization may be established between a biosimilar candidate and the reference innovative 
biologic (reference product), the two cannot be deemed identical.(5;6) This is in stark contrast to generic 
versions of small molecule drugs, where for the majority of compounds, when evidence of bioequivalence is 
presented, the two products are deemed interchangeable. For most orally absorbed drug products 
establishing bioequivalence is demonstrated through equivalence of systemic exposure, which is concluded 
when the 90% confidence interval for the geometric mean ratio of the pharmacokinetic parameters of 
interest (i.e. AUC and Cmax) for the test formulation over the reference formulation fall within the 
traditional bioequivalence margins of 80-125%.(7;8)  The caveat of course is that the drug can be quantified 
bioanalytically, with reasonable sensitivity. The basis of this approach originates from the longstanding 
view that the concentration in the blood is related to the concentration at the site of action and that two drugs 
with equivalent systemic exposure are expected to have the same efficacy and safety profile provided the 
relative exposure falls within a predefined acceptance range. Since most macromolecules are complex in 
structure and PK relative to smaller, synthetically derived drugs, the “generic” approach to establishing 
bioequivalence does not apply and hence additional nonclinical and clinical testing is required. 
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1.4 Biodistribution and Other Important Pharmacokinetic Properties of Therapeutic Macromolecules 
1.4.1 Biodistribution 
Intravenous (IV) administration of a drug provides immediate access of a drug directly into the systemic 
circulation. From the venous blood circulation, the drug is then transported throughout the body and enters 
the vasculature of various organs and tissues. Further transport across the membrane of blood capillaries into 
the interstitial fluid (ISF) of an organ is restricted based on the physico-chemical properties of the drug. The 
endothelial surface of a blood capillary restricts movement of large and non-lipophilic molecules. Channels 
that exist in the membrane do however allow the passage of fluid and smaller non-lipophilic molecules.(9)  
Convective transport of endogenous and exogenous macromolecules through large pores as well as 
vesicular transport of macromolecules has both been proposed as mechanisms of transport of large 
molecules across the endothelial layer.(10;11) Morphologic evidence of large pores is lacking in the 
literature and in a comprehensive review focused on endothelial pore sizes, Sarin (2010) argued that based 
on ultrastructure analysis, the existence of a specific large pore is unlikely.(12) Instead, Sarin suggests that 
the transport of large macromolecules (as large as 60 nm in diameter) distribute to the interstitial space via a 
phago-endocytic route. Examination of extravascular tissue concentrations after IV administration of iodine-
labeled human albumin confirms that macromolecules of high molecular weight (MW 69 kDa) and large 
spherical diameter (3.8 nm wide x 15 nm long) are indeed capable of crossing the endothelial membrane in 
humans into the interstitial space.(13;14)  In mice, lymphatic uptake of the monoclonal antibody (mAb) 
bevacizumab was negligible after IV administration, suggesting only a small fraction of the administered 
dose crossed the endothelial surface (see next Section: Role of the Lymphatic System in the 
Pharmacokinetics of Therapeutic Macromolecules). In lymph cannulated rats, IV administered trastuzumab, 
another mAb molecule, resulted in more substantial lymphatic recovery (approximately 44%).(15) Such 
varying results with respect to lymphatic uptake of large molecules observed in these studies may suggest an 
experimental or interspecies dependency in passage across the endothelium. However, regardless of the 
precise mechanism, macromolecules (endogenous or otherwise) appear capable of traversing the vascular 
endothelial barrier from the vascular system into the interstitial space, in a size and potentially, species-
dependent manner.  
 
Macromolecules have similarly been demonstrated to cross from the interstitial space directly into the 
vasculature in an apparent size dependent manner. Following subcutaneous (SC) administration, Supersaxo 
demonstrated that with increasing size, a greater proportion of the administered macromolecule was taken 
up by the lymph.(16;17) While this demonstrates a size dependency in terms of lymphatic uptake, the 
corollary to this observation is that as the molecular weight, and presumably hydrodynamic radius, 
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increases, the less likely a compound would transit to the vasculature from the interstitial space. Whether 
this is strictly a size limitation or a result of convective flow and pressure forcing drug against the path of 
least resistance (see next section) has not yet been conclusively determined. Despite the low resistance 
offered by the lymphatic-interstitial interface, macromolecules with MW less than 16 kDa have been found 
to diffuse passively across the blood capillary endothelium when administered subcutaneously.(18) Thus, it 
can be inferred that macromolecule molecular size is an influential determinant of lymphatic uptake 
potential. 
 
1.4.2 Clearance 
Clearance (CL), a PK parameter that describes the rate of drug removal from a biological system, is one of 
the most important parameters used in the prediction of human PK based on animal values. As summarized 
above in Table 1.1, the CL of macromolecules differs from small molecules.  
 
With small molecules, the majority of drug CL occurs via the hepatic (biotransformation or secretion into 
bile) or renal (filtration or active tubular secretion) routes, with a smaller portion of drugs being cleared by a 
variety of enzymes in plasma and other tissues. With macromolecules, CL mechanisms are likely highly 
compound  or class of compound dependent, with mechanisms ranging from protein catabolism, proteolytic 
degradation by soluble peptidases, target-mediated internalization and degradation within a cell and renal 
elimination of smaller protein components.(2;3)  Target-mediated internalization, termed target mediated 
drug disposition (TMDD), is of particular relevance with biologic macromolecules and interspecies scaling 
as animal models that do not express the target receptor may not process or clear the drug similar to those 
that do and consequently do not represent a reliable model for human prediction of PK. Moreover, the lack 
of target expression in a species does not allow for study of the PD response; an important parameter for 
safety assessment. Chapter 2 expands on these concepts and highlights the value of a single relevant NHP 
species in predicting the PK of therapeutic macromolecules based on animal data. 
1.4.3 Bioavailability 
When a drug is administered IV, the fraction of drug absorbed is equal to 100%. The relative bioavailability 
of an extravascularly administered drug is expressed as the fraction of the administered dose that is available 
for systemic action. As described in the section above, CL mechanisms of macromolecules include 
proteolytic degradation and cellular uptake. When these processes occur at a site of extravascular 
administration (e.g. following SC administration) there is the potential to reduce the bioavailability of the 
drug. Wang demonstrated that after SC injection of pegylated conjugates of erythropoietin in rats, CL 
occurred at the site of injection and by cells within the lymphatic fluid.(19) Similarly, Charman et. al. 
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observed that human growth hormone degraded prior to reaching the central lymphatics after SC 
administration.(20) Richter summarized the range of SC bioavailability’s for a number of therapeutic 
macromolecules across various animal species.(18) The review concluded there was no obvious trend 
between molecular weight of a macromolecule and the bioavailability across various species. However it 
should be noted that the between species bioavailability within any particular molecule was obtained in 
some cases from different studies, with varying study designs, anatomical sites of SC administration and 
doses and consequently should be interpreted with caution. As will be addressed in Chapter 3, appreciation 
of local CL processes and interspecies differences in said processes is an important factor when scaling PK 
from animal models to humans.  
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1.5 Role of the Lymphatic System in the Pharmacokinetics of Therapeutic Macromolecules 
As described in the previous section, lymphatic uptake of macromolecules from the interstitial space 
represents an important biodistribution process of said molecules, and an appreciation of lymphatic anatomy 
and function is an important consideration when employing in silico techniques to predict the PK of 
therapeutic macromolecules. Chapters 5 and 6, detail the development of PBPK models incorporating 
lymphatic distribution to improve the prediction of a new chemical entity (NCE) pegylated peptide 
conjugate’s (PPC) PK properties based on a single NHP species. As such a brief overview of the lymphatic 
system as it pertains to macromolecule distribution is presented herein. 
 
The lymphatic system is a parallel circulatory network consisting of capillaries, collecting vessels, lymph 
nodes, trunks and ducts, which vary in size and act as a one-way circuit for the transport of fluid, protein 
molecules and immune cells, draining from the interstitial space, eventually emptying into the venous 
circulation. (21) Lymph vessels do not possess tight junctions and therefore pose little resistance to 
macromolecule transport. As stated in the previous section, while in the interstitial space, macromolecules 
may undergo proteolytic degradation and phagocytic uptake prior to draining into the venous blood.(19;22) 
Transport of macromolecules within the lymph is facilitated by the unidirectional flow of lymphatic fluid, 
which is estimated to be 100 to 500 times slower than blood flow and influenced by ambient temperature, 
movement and massage.(21;23;24) In a comprehensive in silico PK analysis of SC administered mAbs, 
Zhao identified that lymph flow was an important determinant of the time to maximum concentration 
(Tmax). This finding is consistent with the research outlined in Chapters 3 and 5 of the current thesis, where 
lymph flow rate was an important determinant of the shape of the concentration vs. time profile (CPT), and 
interspecies differences may influence the potential to predict the shape of the CPT in humans. 
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1.6 Pegylated Therapeutic Peptides and Proteins 
Pegylation is introduced at this point as the therapeutic macromolecule employed in the primary aims (as 
will be described later in this chapter) is a pegylated cyclic peptide with a molecular weight of 
approximately 44 kDa. To better appreciate subsequent Chapters, which describe the in silico methods used 
in the prediction of this model compound, a brief summary on pegylation of drugs is provided herein. 
 
Pegylation of a compound involves conjugation of the drug portion to varying forms and chain lengths of 
polyethylene glycol (PEG).(25) PEG conjugation increases the drugs circulating half-life by reducing renal 
filtration and non-renal clearance routes of elimination, allowing for reduced dosing frequency of otherwise 
rapidly cleared peptides and proteins.(26) To date several pegylated versions of peptides have been 
approved and marketed in major regulatory jurisdictions (e.g. USA, Canada, and Europe). Conjugation of 
the granulocyte colony stimulating factor (G-CSF) prolonged the Tmax after SC administration 7-fold and 
more than doubled the circulating half-life relative to the unconjugated protein. (27) For cancer patients 
receiving myelosuppressive chemotherapy, pegylation of G-CSF allows for a single SC injection once per 
cycle as opposed to daily injections for the unconjugated version.(28;29) Similarly, pegylation of interferon 
α-2a for chronic hepatitis C infection requires once weekly dosing as opposed to the unconjugated form that 
was previously prescribed on a thrice weekly schedule. (30;31)  
 
In addition to slowing systemic CL, pegylation can potentially alter the biodistribution of a peptide or 
protein beyond what would be predicted by the compounds molecular weight. Due to the propensity to 
randomly conform water molecules, pegylation may increase the hydrodynamic volume of a protein thus 
affecting its biodistribution to a greater extent than what the molecular weight would suggest.(32) The 
relevance of pegylation on the biodistribution and prediction of PK for a pegylated compound will be 
further explored in Chapters 5 and 6. 
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1.7 Subcutaneous Route as an Important Route for New Drug Development  
The importance of the SC route to the drug development industry is evident in the growing number of drug 
products available for SC administration. In 2014, the U.S. Food & Drug Administration approved 41 new 
molecular entities and biological licensing applications, four of which had first approvals for SC 
administration(33). The industry has also witnessed conversion of IV to SC routes for a number of therapies 
where treatment that was previously relegated to a hospital can now largely be addressed in an ambulatory 
setting (e.g. IV heparin to SC low molecular weight heparins for treatment of deep vein thrombosis). With a 
growing emphasis on SC administration as the primary route for development, reliance on reliable PK 
scaling methods (nonclinical animal species to human) is correspondingly increasing. 
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1.8 Skin Anatomy and Physiology as it Pertains to Subcutaneous Drug Delivery 
An important organ as a physical barrier against the environment, skin represents approximately 15% of 
total body mass and covers an average adult surface area of 2.2 m
2
.(34;35) The skin also plays a vital role in 
sensory and touch, thermoregulation and biosynthetic regulation (e.g. vitamin D synthesis).(35) 
 
An illustration of the various layers and structures of the skin can be found in Figure 2.1. The epidermis, 
which is the most superficial skin layer, is composed of various cell types including keratinocytes, dendritic 
cells, melanocytes, Langerhans and Merkel cells. Beneath the epidermis is the dermis layer that is a highly 
innervated and vascularized segment responsible for the elasticity and tensile strength of skin. The dermis is 
abundant in proteins such as collagen, hyaluronic acid and glucosoaminoglycans.  At the interface of the 
dermis, lying between the dermis and the muscle tissue is the fatty subcutis, which is principally composed 
of adipocytes. 
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Figure 1.1: Cellular layers of the skin  (Reprinted with 
permission for thesis purposes from Frost 2007)(36);  drug 
administered by injection either via the subcutaneous or 
intramuscular (region) is taken up either via capillaries (red 
vessels) or the lymphatics (green vessels) based on size of the 
compound. 
 
 
SC administration entails injecting a drug product into the subcutis layer of the skin (Figure 2.1).There is 
little blood flow in the fatty tissue layer of the skin and thus the injected medication is generally absorbed 
more slowly than the IV route. 
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Figure 2.1: Illustration of a subcutaneous injection (graphic 
obtained from the United States National Institutes of Health 
patient information leaflet on administration of subcutaneous 
injections) 
 
Common sites of injection include the back region, abdomen and thigh. Section 1.5 of this Chapter notes 
that physical movement can potentially influence lymphatic uptake of drugs due to altered lymph flow.(23). 
In a comparative bioequivalence study evaluating two formulations of a SC administered human growth 
hormone (hGH) inconsistent PK was observed.(37) In this initial study, the injection site was allowed to be 
rotated within the thigh region within and across subjects. Upon repeating the investigation, with stringent 
controls in terms of injection site consistency, within-subject variability in PK was reduced and the two 
formulations were concluded to be bioequivalent. 
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1.9 Extrapolating the Pharmacokinetics of Therapeutic Macromolecules from Preclinical Animal 
Species to Humans 
A review of methods employed in scaling PK from animals to humans is addressed in part in Chapter 2: 
Contrasting toxicokinetic (TK) evaluations and interspecies pharmacokinetic scaling approaches for small 
molecules and biologics: applicability to biosimilar development. A brief introduction to this topic and a 
summary of the methods addressed in this thesis are described herein. 
Scaling of PK from animals to humans serves several purposes in the overall drug development of a NCE. 
Perhaps the most important benefit is that it provides a method of relating toxicology findings in the animals 
species studies as part of the preclinical program, to humans. As per ICH and other relevant guidelines for 
drug development, selection of the maximum recommended safe starting dose for both small molecules and 
biologics requires at least some consideration of the systemic exposure in animal toxicology studies.(38)  
Nonclinical TK, which involved estimating systemic exposure parameters associated with toxicological 
observations in the tested animals, provides drug developers with some indication of the NCEs PK 
characteristics. In turn, this data informs future study designs. For example, in a first-in-human (FIH) 
investigation, blood is collected for bioanalytical quantitation and subsequent PK characterization following 
a range of doses administered to humans. The placement and temporal relationship of blood sampling 
related to the dosing time can be informed by observations in animals. Nonclinical TK assessments for 
NCEs typically include characterizing the PK in a rodent (e.g. mouse or rat) and non-rodent species (e.g. 
dog, monkey). In smaller mammals where blood samples are limited to 1-2 samples per animal, PK 
evaluation is often limited to systemic exposure based on the average (mean) concentration time profile 
from all animals in the study. Average data are of limited value in comparing treatments as they provide 
little information on the variability in the PK response. A method of obtaining full PK profiles in each 
animal, particularly when smaller mammals are used, is by limiting the number of samples being drawn per 
animal but employing a consistent sampling schedule among all animals tested. This approach however has 
limited utility, particularly for therapeutic macromolecules in the IgG-type monoclonal antibody class of 
compounds where the half-life is typically extended (e.g. ~20 days).(39). A long half-life coupled with a 
sparse sampling scheme is unlikely to allow for appropriate characterization of the concentration-time 
profile to an extent sufficient to be considered a thorough evaluation of PK.  For larger mammals, although 
more blood samples over an extended duration may be possible, the total number of blood samples drawn 
may still be insufficient for adequately characterizing the PK of drugs with a prolonged absorption phase 
and/or a long terminal elimination half-life. Moreover, the number of animals in nonclinical investigations is 
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typically limited to 3-6 per treatment and in such cases, small sample sizes (n=3-6 per treatment) may be  
too low to estimate the PK parameters with any reasonable level of precision. The sample size and precise 
estimation of PK becomes especially important where detection of relatively small differences in PK (i.e. 
systemic exposure) is a primary objective (i.e. in the case of biosimilars). 
 
1.9.1 Compartmental Pharmacokinetic Modeling  
Information sourced for this section is influenced by Gabrielson and Weiner (2000).(40) In silico modeling 
methods have the potential to overcome some of the sparse data issues associated with nonclinical TK 
studies. One such method, employed in Chapter 4, is population-based compartmental modeling. Sometimes 
referred to as a “top down” approach, compartmental modeling condenses the biological system into a 
simplified mathematical representation of a biological system with a central or vascular compartment and 
one or more peripheral compartments. Each compartment in the model is associated with a volume that is 
either fitted or fixed at a theoretical value. Movement between compartments is represented by either micro 
rate constants or a distributional CL parameter. Similarly, CL of drug from the system is also parameterized 
as either a micro rate constant or CL, and typically for a typical small molecule CL occurs from the central 
compartment. Input into the system is either instantaneous into the central compartment for IV 
administration, or for extravascular administration, parameterized using a variety of different mathematical 
expressions, some of which are described in Chapter 4. 
 
In compartmental modeling, observed data is simultaneously fit to a model with various parameters, and 
model parameters that best describe the data are optimized using an algorithm intended to minimize the 
difference between the observed and predicted data. In traditional compartmental PK modeling, the 
observed data are measured concentrations of drug in some biological matrix (e.g. blood, plasma, urine, 
tissue, etc.…)  
 
With respect to therapeutic macromolecules, models can be adapted with receptor binding expressions to 
address TMDD and CL. Compartmental models with TMDD components have been demonstrated to 
describe the PK and PD response of interferon β-1a in both NHP and humans. (41;42)Receptor-mediated 
binding is a practical means of quantifying the non-linear nature of macromolecule CL where binding is 
saturable within the studied range. Models used for scaling macromolecules across species have also been 
parameterized with Michaelis-Menten expressions to characterize the non-linear nature of 
macromolecules.(43) 
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Population-based non-linear mixed-effect compartmental pharmacokinetic modeling, referred to in this 
thesis as popPK, is a sophisticated modification to compartmental modeling that allows for simultaneous 
estimation of a fixed-effect parameter (e.g. systemic CL), between-subject variability (random-effects), and 
residual or unexplained error. (44)This methodology also lends itself to quantification of factors that may 
explain the between-subject variability by way of covariates such as body weight, gender, age, 
concomitantly administered medications, to name a few.(44) 
 
Once a popPK model is considered adequately qualified, the model inputs such as dose and frequency of 
dose can be varied and used to simulate future events. In the context of interspecies scaling from animal to 
human, as will be explored in Chapter 4, incorporation of species body weights in the form of an allometric 
scaling factor can be used to scale the model to predict PK parameter values and concentration values in 
humans for clinical study planning. Chapter 4 further explores the utility of employing empirically selected 
scaling factors incorporated into a popPK model in the prediction of PK and CPT of a novel therapeutic 
macromolecule after SC administration. 
 
1.9.2 Physiological Based Pharmacokinetic Modeling 
Similar to compartmental PK models, PBPK models include a series of differential equations describing the 
mass transfer of drug between compartments. PBPK models however are parameterized with values that 
represent the size of the overall and sub-compartments within each anatomical organ being represented. 
Movement of drug throughout the model is governed by flow rates that have physiologic meaning such as 
blood (or plasma) flow and in the case of macromolecules, lymph flow. Drug specific parameters such as 
molecular size, molecular weight, lipophilicity and pKa influence are incorporated into the structural model 
to describe biodistribution of a drug. Biochemical process such as in-vitro experimentally obtained CL can 
also be incorporated to address CL processes in the model. Several publications have demonstrated the 
value of PBPK models in terms of small molecule PK, however the predictive capacity was dependent on 
the methods and quality of the data used to inform the biodistribution and CL of the molecules studied.(45) 
Since the non-TMDD CL processes of therapeutic macromolecules are thought to be conserved across 
species(46), PBPK may offer advantages over single-species allometric and popPK approaches as PBPK 
facilitates the scaling across species by adjusting the anatomical and physiologic parameters in a species-
dependent manner, independent of the drug’s physical properties. For macromolecules, the scaling potential 
of the model is predicated on whether the animal species expresses the target with similar homology to 
humans. PBPK literature reports describing the prediction of human PK of therapeutic macromolecules 
from TK data are not as common as allometric approaches, however where it has been reported, PBPK has 
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demonstrated some promise. (47-51) Most of the available PBPK literature centres on mAbs, and following 
IV administration.  Chapter 5 represents one of the few published PBPK models considering extravascular 
administration of a macromolecule and, at the time of publishing, was one of if not the first to propose a 
method of addressing SC administration of a therapeutic macromolecule. Moreover Chapter 6 extended the 
models capabilities to include simulations in a population on individuals. Since both chapters publishing as 
manuscripts, Gill has proposed a mechanistic PBPK approach for SC administration using the commercial 
platform, SimCyp®, however unlike the work addressed in Chapter 5, Gill and colleagues did not address 
the predictive capacity in terms of scaling to human based on animal data, nor predictions in a 
population.(52)  
 
1.9.3 Interspecies Scaling Methods 
In spite of the limitations of average animal TK, a commonly employed approach which utilizes this data for 
prediction of human PK is simple allometry and adaptations to the simple allometric technique. Simple 
allometry in drug development entails plotting the log of weight of multiple mammalian species vs. the log 
of a PK parameter of interest (e.g. CL) where the predicted human equivalent of the PK parameter is 
extrapolated based on Equation (1.1) (53;54): 
 
log y = log a + b • log W  (1.1) 
y = PK parameter of interest (usually CL, volume of distribution or half − life) 
b = allometric exponent for the PK parameter (slope) 
W = Weight of the mammalian species 
a = allometric coefficient (y − intercept) 
 
 
While used extensively for small molecules prediction of human PK parameters from animal data, methods 
based on simple allometry, including correction for species brain weight  or maximum lifespan potential 
(53), have performed inconsistently in terms of prediction accuracy when employed in therapeutic 
macromolecule predictions.(55-58) This may be a reflection of simple allometry requiring ≥3 different 
mammalian species(58)  and as described earlier in this chapter (see 1.4.2 Clearance), not all of the species 
tested may be appropriate animal models for assessing the PK of macromolecules. Although mammals share 
common anatomy and physiological processes there are differences among mammalian species, particularly 
with respect to the skin and will be explored in more detail in Chapters 4 and 5. Given that therapeutic 
macromolecules contain human elements (i.e. humanized) or are fully human proteins, these compounds 
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may not bind with the same affinity, or at all, with the nonclinical species target. Since CL of proteins can 
occur through target mediated processes, it stands to reason that the greater the difference in sequence 
homology between the nonclinical and human species, the lower the utility (i.e. predictive potential) that 
species will display. Another consequence of the differences among species is that the more humanized the 
protein is, the more immunogenic the protein may be in a nonclinical species. (59) This is not to suggest that 
immunogenicity of a humanized protein does not occur in humans from humanized proteins, but rather the 
potential is greater with greater difference between the therapeutic macromolecule and the species’ 
endogenous proteins. Should an immunogenic response be elicited in the animal species, altered systemic 
CL or biologic activity of the macromolecule in the nonclinical species may be observed and thus data 
obtained in this is species is consequently limited in terms of PK predictive capacity. (2) As such, there have 
been several investigations into the use of single-species allometric approaches, particularly employing 
NHP, for predicting PK of macromolecules in humans. (60-64)  
 
The SC route offers a convenient means of administering parenteral solutions or suspensions of therapeutic 
macromolecules. However, predicting the PK in humans from animal data is challenged by interspecies 
differences in skin anatomy and CL mechanisms. This thesis proposes several single species methods for 
scaling the PK from a NHP to human following SC administration in an effort to de-risk biologic and 
biosimilar drug development. Chapter 2 represents a published article written by the PhD candidate which 
summarizes the prediction accuracy of methods using empiric scaling factors based on average PK 
parameters values.(55) In Chapter 3, applicable single-species model-independent scaling methods 
described in Chapter 2 are applied to prediction of human PK for a novel pegylated peptide conjugate (PPC) 
discussed earlier in this chapter. In Chapter 4, a representation of another published manuscript describes a 
popPK model based approach for predicting the human time course of the same PPC following SC 
administration to NHP.(65) Chapters 5 and 6 (both published manuscripts) propose novel modifications to a 
whole body PBPK approach, incorporating lymphatic uptake and local drainage from the SC injection space 
for predicting the SC time course of the same PPC described earlier, in a virtual human individual and 
human population.(66;67) In Chapter 7, the gamut of methods addressed in this thesis are contrasted and 
compared with recommendations as to which methods may provide the most useful a priori information in 
the context of predicting the human PK of a SC administered therapeutic macromolecule.  
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1.10  Research Topic 
The principle objective of this thesis project was to develop a workflow for employing in silico approaches 
for de-risking the development of biologic and biosimilar therapeutic macromolecules through prediction of 
human PK after SC administration to nonclinical species.  In the context of this proposal, de-risking implies 
concentration data obtained from nonclinical animal species can be employed to predict the PK in a human 
(or population of humans) with greater accuracy than previously reported methods, which rely principally 
on model-independent approaches and do not address interspecies differences in the absorption process of 
macromolecules following SC administration.  
 
1.11 Objective 
The research objective of this thesis was to develop a model-based workflow, and compare to model-
independent methods, for translating macromolecule concentration data obtained from a single, non-human 
animal species, and use this data and workflow to predict the concentration vs. time course as well as 
important PK parameters, in humans. 
  
1.12 Hypothesis 
Model-based methods are superior in terms of predicting the time course and important PK parameters of a 
SC administered macromolecule, in humans, relative to traditional model-independent methods. 
 
Aim 1: Comparison of existing empiric allometric and model-independent methods for predicting human 
pharmacokinetics based on preclinical animal evaluation 
 
Addressed in Chapter 2, this research aim was intended to evaluate single-species allometric scaling 
methods which are commonly used with the additional intent of evaluating influence of a particular scaling 
factor exponent to yield the greatest accuracy in prediction of CL and volume of distribution (Vd) for 
therapeutic macromolecules. Single-species methods for predicting the PK of a therapeutic macromolecule 
in NHP were subsequently applied to the measured concentrations or non-compartmental analysis-derived 
PK parameters for a novel PPC in Chapter 3.  
 
Aim 2: Evaluation of population pharmacokinetic models incorporating empiric scaling factors for 
predicting the subcutaneous pharmacokinetics of a therapeutic macromolecule in humans  
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As detailed in Chapter 4, population-based compartmental modeling was used to describe PK data obtained 
from a single NHP species for a novel PPC. Empiric and fitted scaling factors were then integrated into the 
model and used to predict the concentrations in a population of humans and compared to observed data in 
humans. 
 
 
Aim 3: Development and evaluation of a PBPK model for subcutaneous administration of a therapeutic 
macromolecule 
 
As detailed in Chapter 5, a whole body PBPK model with lymphatic and vascular flow integrated in the 
model was developed integrating a novel means of parameterizing the SC depot to predict the SC time 
course of a SC administered novel PPC in NHP with subsequent scale up and prediction of the PK in 
humans. 
 
 
Aim 4: Incorporation of lymphatic biodistribution into a population PBPK model for a therapeutic 
macromolecule 
 
Chapter 6 expands on the model developed in Chapter 5. The PBPK model was refined to incorporate 
interindividual variability elements with the intent of evaluating which model parameters exert the greatest 
influence on the variability of prediction of SC administered macromolecules in a human population.  
  
Aim 5: Compare prediction capacity of published methods with methods developed in this thesis 
 
The intention of this research aim is collate the results obtained across the various methodologies tested and 
compare and contrast the utility of each method as it pertains to the compound in question (Chapter 7). 
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CHAPTER 2: CONTRASTING TOXICOKINETIC EVALUATIONS AND INTERSPECIES 
PHARMACOKINETIC SCALING APPROACHES FOR SMALL MOLECULES AND BIOLOGICS: 
APPLICABILITY TO BIOSIMILAR DEVELOPMENT 
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The contents of Chapter 2 were initially published as an original contribution manuscript by the PhD. 
candidate (Elliot Offman). The original manuscript has been edited and formatted according to thesis 
publication requirements. For reference purposes, the original publication is as follows: 
Offman E, Edginton AN. Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling 
approaches for small molecules and biologics: applicability to biosimilar development. Xenobiotic; 43(6): 
561-569. 
 
The PhD candidate conducted all the pertinent research, conducted the analysis where applicable and wrote 
the manuscript. 
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2.1 Introduction 
Global sales for biotechnologically-derived (biologic) drugs are increasing dramatically with an estimated 
one in eight prescriptions written globally at an annual treatment cost of more than USD$16,000.(1) By 
2015, approximately USD$60 billion in global sales are [Note: original version of this manuscript was 
published in 2012] set to lose patent protection opening the market to competition and with it an opportunity 
to reduce drug cost and improve access to otherwise out of reach medicines.(68) 
  
The formal definition of a biosimilar may differ according to the regulatory jurisdiction; however, it can be 
defined as a highly similar version of a previously approved therapeutic macromolecule. Regulatory bodies, 
such as the European Medicines Agency (EMA), have been proactive in developing a framework for the 
approval of biosimilar products. There is a consistent fundamental appreciation that although a high degree 
of physico-chemical characterization may be established between a biosimilar candidate and the reference 
innovative biologic, the two cannot be deemed identical. This is in stark contrast to small molecules where, 
for the majority of compounds, when evidence of bioequivalence is presented, the two products are deemed 
interchangeable.  
 
At the time of writing, the EMA had issued guidelines for industry sponsors for the non-clinical and clinical 
development of several biosimilar compounds or classes such as recombinant human erythropoietin, human 
growth factor and monoclonal antibodies (mAbs).(69) Recently, the US Food and Drug Administration 
(FDA) issued a series of draft guidance documents outlining a pathway for submitting a biosimilar product 
through a 351 (k) application. This framework differs somewhat from the EMA and a review of the draft 
guidelines is available for review.(5)  
 
Based on existing published guidelines, there is a high burden of evidence in the non-clinical phase to 
establish similarity between the biosimilar candidate and the reference biologic from a physico-chemical 
and biological characterization perspective.(70) This comparative characterization is usually performed 
through in-vitro methods comparing biological activity as well as through in-vivo methods such as pre-
clinical toxicology and toxicokinetic (TK) studies. Following this characterization, development moves to 
the clinical phase typically requiring a combination of Phase 1 and comparative efficacy and safety studies. 
These comparative Phase 1 studies offer further opportunity to screen the candidate biosimilar product for 
similarity prior to proceeding to the larger, more expensive and time consuming Phase 3 trial(s). 
 
The toxicity profile of some macromolecules, particularly in the mAbs class , may prohibit administration to 
healthy volunteers and the sponsor must consider whether to proceed directly to a Phase 3 study or to 
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conduct a smaller preliminary PK study in a relevant patient population.(71) Conducting such small 
“patient” PK studies are typically challenging to recruit, given that patients are not likely to derive clinical 
benefit from participating in a biosimilar PK/PD type trial, especially under a single-dose design. Moreover, 
these populations are not usually homogeneous in terms of co-morbidities and concomitant medications, 
further challenging the interpretation of results. Lastly there are ethical concerns with subjecting “sick” 
patients to intensive blood sampling when there is potentially no direct benefit. The alternative though 
entails proceeding directly to a comparative safety and efficacy trial without any comparative human data. 
This approach adds considerable risk to the overall clinical development for biosimilars should a difference 
in PK, or more importantly, a difference in the safety or efficacy profile which may be related to a 
difference in PK, wasn’t identified during the in-vitro or animal comparability assessment.  
 
Unlike with small molecules, small differences in manufacturing between the biosimilar and reference 
biologic may impart undetected differences that must be ruled out for the potential to result in significant 
safety and efficacy differences.(72;73) One potential means of overcoming the uncertainly of whether the 
test and reference biologic exhibit similar PK is to conduct robust comparative TK evaluations in a 
relevant animal species (if one exists).  TK studies offer an initial picture of the potential for comparable 
human PK and particularly systemic clearance (CL). The PK for the biosimilar product can then be 
compared to PK reported in the public domain for the reference biologic in humans as well as to the data 
for the reference biologic generated in the comparative TK study. This provides additional confidence 
that the biosimilar will be comparable to the reference biologic in human trials. Limitations, however, in 
the number of blood samples which can be drawn from any one animal for PK evaluation and the cost per 
animal may limit the interpretation of the pharmacokinetic comparison.  
 
2.2 Case Scenario 
A biosimilar sponsor developed a product intended to be similar to the reference biologic, a recombinant 
therapeutic protein <25 kDA. As part of the toxicological evaluation both the test and reference biologic 
were assessed for comparative pharmacokinetics in 4 male and 4 female rhesus monkeys and serum 
samples for PK analysis of the protein were collected over 24-hours following a single dose.  Based 
strictly on the mean derived pharmacokinetic parameters from standard non-compartmental analysis 
(NCA), the test values (e.g AUC, Cmax) were approximately 60% of the reference product. This was 
considered sufficiently similar in terms of PK similarity, given the entirety of the physico-chemical 
comparability package, to proceed to the phase 1 comparative human PK trial.  The human trial was 
performed as a randomized, single-blind, 2-sequence, 2-period, crossover study in 126 healthy adult 
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subjects. The geometric mean ratio expressed as % for the Test/Reference overall exposure parameter was 
approximately 85% with the lower tail of the 90% confidence limit falling below 80%, the traditional 
regulatory threshold for establishing bioequivalence of comparable formulations.(7) 
What this case illustrates is that basing the decision to proceed to human comparative PK studies on 
results from relatively small toxicokinetic evaluations can be a high risk venture because (1) the precision 
of the parameter estimate is low due to small sample size and (2) the criteria for scaling animal to human 
data may require a tighter threshold when the intention is to compare two formulations as the traditional 
2-fold difference may not be sufficiently discriminating.  
The purpose of this contribution is to address the second point above and consider the interspecies scaling 
approaches employed in predicting human PK and specifically CL for macromolecules and to determine 
which of those approaches may be most appropriate for guiding development of biosimilar compounds.   
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2.3 Methods 
As CL is a key driver of systemic exposure, literature evaluating the relative prediction success of one or 
more methods of interspecies CL scaling was reviewed.  PubMed was used to identify literature references 
for review from September 2011 through March 2012. Search terms used included: allometry/allometric, 
clearance, fusion protein, interspecies scaling, macromolecules, monoclonal antibodies, physiologic based 
pharmacokinetic modeling, therapeutic protein.  
 
For each method, an explanation of the method is followed by an assessment of prediction accuracy for 
small and large molecules. We deliberately omitted methods that considered physico-chemical properties or 
correction factors not likely to be of use in macromolecules (e.g. in-vitro metabolism data, protein binding), 
despite these approaches potentially having merit in predicting human PK with reasonable accuracy in small 
molecules.(74-77) Also omitted were literature comparisons where oral CL was assessed since all currently 
available biologics are available only in parenteral forms. To ensure a robust assessment of the utility of any 
one particular method, only those literature reports comparing predictive approaches with greater than 5 
compounds were included. The primary methods of interest for this review are listed in Table 2.1 including 
some caveats or instructions for use.  
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 Table 2.1: Methods for the prediction of human clearance 
Interspecies Method Formula Notes 
Simple Allometry  
≥3 Species log y = log a + b • log W W represents weight. Use ≥50-fold weight range 
for species(58)  
Maximum Lifespan Potential (MLP) 
Correction 
CLcorrected for MLP= CLspecies • MLPspecies 
MLP (years) = 185.4(BW)
0.636
(W)
-0.225
 
 
Plot the log of the product of CL x MLP for each 
species on y-axis as in simply allometry; BW and 
W are in kg(53) 
Brain Weight (BW) Correction 
 
CLcorrected for BW =  CLspecies • BWspecies 
 Plot as per MLP(53) 
 Rule of Exponents (ROE) When 0.55<b<0.7 use simple allometry; 
0.71<b<0.99 use MLP; b≥1 use BW 
Prediction error may not be acceptable when b<0.5 
or >1.3; MLP not recommended; macromolecules; 
use BW when b≥1 (57) 
Species-Invariant Time Techniques 
Kallynochrons (Elementary Dedrick) y-axis = concentration/(Dose/W);                x-
axis = time/W
1-b
 
b and c are the exponents derived from ≥3 species 
using simple allometry for CL and V (53) 
Apolysichrons (Complex Dedrick) y-axis = concentration/(Dose/W
c
);                       See notes on Kallynochrons  
x-axis = time/W
c-b
 
"Simplified" Allometry 
 Single Species Fixed Exponent CLhuman=CLanimal (Whuman/Wanimal)
b 
See Ling(61) 
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Two-Species Allometric Techniques 
  
Two-species fixed coefficient 
with optimized or fixed 
exponent 
 
CLhuman=atwo-species (Whuman)
b
 atwo-species is the coefficient obtained from 
conventional allometric scaling of the two-species 
data and b fixed is a fixed optimized value (78) 
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2.3.1 Evaluation of Interspecies Scaling Methods 
Several approaches for evaluating the success of a particular method have been employed in the literature; 
(75) however, one of the more intuitive measures of evaluating the success of any single prediction is the 
fold-error (FE) criteria (Equation 2.1). 
 
FE = (ypredicted)/(yobserved)  (2.1) 
 
To compare two or more methods for prediction success across a group of compounds either the average 
fold-error (AFE) (Equation 2.2) or the absolute average fold-error (AAFE) (Equation 2.3) can be used.(75) 
 
AFE = 10[∑log fold-error/n]  (2.2)                                                                                                                                                                      
  
        
 
AAFE = 10[∑|log fold-error|/n]  (2.3)                                                                                                                                                      
 
The advantage of AAFE is that it does not allow for an over-prediction to balance or cancel out an under-
prediction and comparison of AFE to AAFE for the same dataset suggests that the AAFE results in a more 
conservative estimate of prediction success.(78) Comparison of prediction accuracy has also been based on 
the proportion of observations falling within 2-fold.(60;78) This 2-fold threshold is considered acceptable 
when used to estimate the starting dose for first-in-human (FIH) trials on new compounds. For this purpose 
a 2-fold threshold may be reasonable, as FIH safe starting doses also consider the no observed adverse effect 
level (NOAEL) where only a small fraction (e.g. 1/10) of the human equivalent dose (HED) is administered 
initially. However, more stringent criteria for success is warranted since accepting a 2-fold difference could 
potentially result in up to a 300%
1
 difference between the PK parameters of two formulations. This would 
not provide sufficient confidence of equivalence according to the traditional regulatory threshold of the 90% 
confidence interval for the mean ratio of the PK parameter being within 80-125%. Given the low number of 
animals and sampling points in a TK study, it may be unrealistic to predict human CL within 20%. A more 
realistic range of acceptable error may be 30-50%.(79) Unlike recent reports that seek to assess the 
prediction accuracy for methods ultimately employed in predicting the human CL of macromolecules within 
2-fold(60), this review seeks to examine which methods previously applied for small molecules and 
                                                     
1 This was calculated by taking the % difference between predicted values of 200% and 50% (200-50/50)x100%. 
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macromolecules alike have the greatest potential to predict human CL within a tighter range of fold-error i.e. 
0.7-1.3-fold. 
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2.4 Results 
The following will provide a historical overview of each approach listed in Table 2.1 and provide 
comparative data on the strength of the approach to predict human CL. Since the methods were first 
employed in predicting CL of small molecules, brief reference to their relative prediction accuracy with 
small molecules is described. 
 
2.4.1 Allometry 
Allometry was first termed by Huxley and Tessier in 1936 where they agreed upon the algebraic formula 
:(54) 
y = bx
a   
(2.4) 
Where:  
y = some biological quantity 
b = biological constant 
x = mass of the animal 
a = allometric exponent 
 
This formula was initially used for describing the relationship between changes in relative dimension of 
parts of an organism and changes in overall size of the organism. This relationship has been reported for a 
number of biological functions, most notably by Kleiber where basal metabolic rate was related to species 
mass for mammals and birds with an allometric exponent of 0.74, and later by West and Brown who 
reported this relationship could be extended from mammalian cells, mitochondria and unicellular organisms 
through to whole mammalian species.(80;81) 
 
2.4.2 Simple Allometry With and Without Correction Factors for Small Molecules 
Plotting the weight of >1 mammalian species vs. PK parameters of interest is termed conventional or simple 
allometry and CL of the animal species of interest is derived from the double log plot of Equation (2.4). The 
naming convention for the parameters is typically reported as Equation 2.5:  
 
log 𝑦 = log a + 𝑏•log (W)  (2.5) 
 
Where a is the allometric coefficient; 𝑏 the allometric exponent or slope and W is body weight.  
 
Following a linearized power function: 
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When 𝑏<0, 𝑦 decreases as Weight (W) increases 
When 0<𝑏<1, 𝑦 increases as the species becomes larger 
When 𝑏=1, 𝑦 increases proportionally with W 
When 𝑏>1, 𝑦 increases greater than proportionally with W 
 
A frequently employed approach relying on relatively easily obtainable data, simple allometry, has been 
shown to be inconsistent in terms of its prediction accuracy for small molecules.(75) Incorporating 
correction factors such as Maximum Lifespan Potential (MLP) or Brain Weight (BW) has demonstrated 
improved prediction accuracy relative to simple allometry when applied according to the rule of exponents 
(ROE) originally proposed by Mahmood and Balian(82)(see Tables 2.1-2.3 for formulas and average values 
for MLP and BW correction). Employing ≥3 mammalian species for predicting human CL appears to be the 
prevailing approach.(79) An alternative to simplified allometric approaches, where one- or two-species are 
used with a fixed coefficient and/or exponent has also been employed.(78) When we compared the 
prediction accuracy of the ROE and one- and two-species methods for small molecules administered via the 
IV route, only the ROE resulted in a prediction accuracy within the currently proposed AAFE range of 0.7-
1.3 (Table 2.4), supporting the notion that simple allometry employing the ROE is a reasonable approach for 
human CL prediction of small molecules.  
 35 
 
 Table 2.2: Maximum Lifespan Potential (MLP) for species commonly used in 
 allometric scaling  
Species MLP (Years) 
Mouse 2.7 
Rat 4.7 
Rabbit 8.0 
Monkey 20 
Dog 20 
Human 93 
Adapted from Obach et al.(74) 
 
 Table 2.3: Brain weight as a percent of overall body weight for species commonly used in 
 allometric scaling  
Species % Body Weight 
Mouse 1.45 
Rat 0.75 
Rabbit 0.39 
Monkey 1.14 
Dog 0.531 
Human 2.19 
Adapted from Boxenbaum and Fertig(83) 
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* Fixed exponent was derived from a training set as described by Tang et al. (78) 
 
 
2.4.3 Species-Invariant Methods for Small Molecules 
Where classic allometric techniques predict human PK parameters, methods exist where plasma 
concentration time-profiles can potentially be predicted based on animal species. The concept of 
“pharmacokinetic” time, as opposed to chronologic time, has been described in the literature (e.g. by 
Boxenbaum)(84) as a means of evaluating the interspecies similarities across species. The principle is based 
on the observation that chronologic time is arbitrary and that different species clear drugs at rates relative to 
their lifespan. By normalizing the timescale, plasma concentrations from different species could be 
approximately superimposable. Dedrick (85) observed that the half-life of methotrexate could be scaled 
across mammalian species with an exponent of 0.25 and that by normalizing the chronologic time to 
physiologic time specific to a particular species would result in superimposable plasma-concentration time 
profiles. A composite best-fit plasma-concentration time profile could then be converted back to a human 
time scale and the curve could be integrated to derive pharmacokinetic parameters of interest using either 
compartmental or non-compartmental approaches. Boxenbaum(86) extended this approach to clearance and 
volume parameters and assuming fixed exponents of 0.75 and 1 for clearance and volume, respectively, and 
proposed a new time scale “kallynochron” where species have cleared the same volume of plasma per 
kilogram of body weight. The resultant plot is referred to as an Elementary Dedrick Plot (see Table 2.1). 
Similar approaches, including Complex Dedrick plots (using Apolysichrons) where a species clears the 
same fraction of drug per kg of body weight, have been applied in the literature but does not necessarily 
improve prediction of human PK parameters relative to simple allometry for small molecules.(87) Other 
time scales considering MLP (Dienitichrons) and MLP with BW (syndesichrons) exist as well, however 
Table 2.4: Absolute Average Fold-Error (AAFE) and proportion of small molecules within 0.7-
1.3 fold-error (79) 
Interspecies Scaling Approach Number of Compounds 
Included in the Analysis 
(N) 
AAFE Number within 
0.7-1.3 fold-
error (N) 
ROE 24 1.26 20 
Single species Rat 24 1.85 9 
Single species Dog 22 1.77 5 
Single species Monkey 16 1.86 6 
Rat-Dog (fixed exponent*) 10 2.12 2 
Rat-Monkey (fixed exponent*) 10 2.29 3 
Rat-Dog (allometry) 10 2.78 2 
Rat-Monkey (allometry) 10 2.31 3 
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these approaches have been infrequently reported in the literature in large scale comparisons of methods and 
are therefore not discussed here. 
 
2.4.4 Simple Allometry and ROE for Macromolecules 
Whereas many small molecules are extensively metabolized through processes which can vary across 
species, macromolecules are rapidly degraded in biological fluids via proteolysis, cleared through receptor 
mediated processes and, depending on the size of the molecule, filtered renally. These catabolic mechanisms 
are similar across mammalian species relative to humans and more so in those species sharing close genetic 
similarity (i.e. non-human primates). 
 
The simple allometric relationship between body weight and CL for small molecules across multiple 
mammalian species typically results in an allometric exponent of approximately 0.75. (88) Mordenti et al. 
demonstrated that similar relationships exist with proteins with molecular weights ranging from 
approximately 6 to 60 kDa and with various mechanisms of CL.(58) Derived exponents for clearance 
ranged from 0.65-0.84 when log-log plots of CL vs. weight were regressed. It should be noted, that these 
exponents included observed human data in addition to pre-clinical species. When the regression was 
repeated, excluding the human observations to test the prediction accuracy, the resultant fold-error ranged 
from 0.7-1.04 with an AAFE of 1.16 suggesting that simple allometry can be employed with reasonable 
prediction error for macromolecules similar to small molecule application (Table 2.5). Similar allometric 
exponents and prediction accuracy have been observed with coagulation factors and tissue-type 
plasminogen activators (Table 2.5).(56) 
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 Table 2.5: Comparison of interspecies scaling approach AAFE for clearance of 
 macromolecules 
 
Reference Therapeutic 
Classification 
Interspecies Scaling 
Approach 
Number of 
Compounds 
(N) 
AAF
E 
Number 
within 0.7-
1.3 fold-
error (N) 
Mordenti et al. 
(58) 
Various 
Therapeutic 
Proteins 
Simple allometry
a
  5 1.16 
 
5 
 
Mahmood (79) Various 
Therapeutic 
Proteins 
Simple allometry  6 2.05 2 
Maximum Lifespan 
Potential (MLP) 
6 3 1 
Brain weight (BW) 6 4.6 1 
Single species mouse, 
fixed exponent 0.75 
6 1.77 1 
Single species rat, fixed 
exponent 0.75 
5 1.77 1 
Mahmood (56) Coagulation 
Factors; 
Tissue-type 
plasminogen 
activators 
Simple allometry  5 1.25 5 
2-Species Rat-Dog 5 1.40 3 
    2-Species Rat-Monkey 4 1.98 2 
                  Dong et al.(64) mAb Single species Monkey, 
fixed exponent 0.75 
10 1.56 4 
Ling et al. (61) mAb Single species Monkey, 
fixed exponent 0.75 
13 1.54 3 
Single species Monkey, 
fixed exponent 0.80 
13 1.38 8 
Single species Monkey, 
fixed exponent 0.85 
13 1.26 11 
Single species Monkey, 
fixed exponent 0.90 
13 1.18 11 
Single species Monkey, 
fixed exponent 0.95 
13 1.23 11 
Single species Monkey, 
Dedrick, fixed exponent 
0.8 
6 1.36 4 
Single species Monkey, 
Dedrick, fixed exponent 
0.85 
6 1.29 5 
Single species Monkey, 
Dedrick, fixed exponent 
0.90 
6 1.24 4 
Oitate et al. (89) Mab Soluble 
target 
Single species Monkey, 
Dedrick, fixed exponent 
6 1.55 2 
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0.79 
 Mab 
Membrane-
bound target 
Single species Monkey, 
Dedrick, fixed exponent 
0.96 
6 1.45 3 
Deng et al. (63) mAb Simple allometry  11 1.91 1 
Rule of Exponents 8 1.64 0 
Single species Monkey, 
fixed exponent 0.85 
13 1.18 11 
 
     
a SA= simple allometry with ≥ 3 species not including human 
SS=single species 
MLP= Clearance X Maximum Life-Span Potential 
BW= Clearance X Brain Weight 
mAb=Monoclonal Antibody 
ROE=Rule of Exponents 
AAFE=Absolute Average Fold-Error 
 
 
Mahmood also reviewed the performance of simple allometry for monoclonal antibodies with and without 
correction for MLP and BW. MLP correction did not improve prediction of human CL where the exponent 
was <1.(57) Mahmood did observe that BW correction improves the prediction error when the exponent ≥1, 
however the recommendation for BW correction when the exponent is >1 is based on a single compound’s 
prediction accuracy upon BW correction and therefore the recommendation for BW correction when the 
exponent is >1 should be taken with caution.(57) A single-species approach using a fixed exponent of 0.75 
for CL was also evaluated, however only 1 species (mouse) was reported for all 6 compounds and the fold-
error was 0.37-2.15, with only one compound within ± 30% (Table 2.5).  
 
When data from only 2-species is available, scaling for small molecules as well as therapeutic 
macromolecules has shown inconsistent results however this approach is infrequently reported in the 
literature. Mahmood examined the prediction accuracy of the 2-species approach previously described for 
small molecules as applied to macromolecules however this dataset only included 5 compounds 
(coagulation factors and tissue-type plasminogen activators, Table 2.5).(56) One of the major criticisms of 
the two-species approach for macromolecules is that different species have varying propensities for eliciting 
antibody generation. If relying on 2 species for biosimilar comparison, the approach should only be used 
when both the test and reference biologic have been demonstrated to have similar immunogenic potential in 
the animals employed, and as with simple allometry, the mechanism of CL should be conserved across the 
species. 
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2.4.5 Single-Species “Simplified” Allometry for Macromolecules 
Examination of the proportion of compounds falling within the proposed fold error of 0.7-1.3 for single-
species approaches for small molecules (Table 2.4)  or for macromolecules (Table 2.5)(57) might lead one 
to assume that such an approach would not yield sufficiently reasonable CL prediction accuracy to 
confidently move forward in one’s development plan. Although not included in Table 2.5, as it did not meet 
the minimum threshold of 5 compounds, Mahmood reported single-species monkey data for 3 compounds 2 
of which fell within ± 20% (data not shown).(57) Larger scale comparisons of prediction accuracy from 
monkeys as a single-species model have more recently been published. Using a similar approach to that 
reported by Mahmood (i.e. single-species with a fixed exponent of 0.75) Dong et al. predicted CL within 2-
fold for 8/10 antibodies exhibiting linear PK with 4 compounds within ± 30% in terms of fold-error (Table 
2.5).(64) This supports the observation that monkey as a single-species results in overall reasonable 
prediction accuracy.  
 
On the other hand there were a relatively large proportion of the compounds falling outside the 0.7-1.3 
currently proposed threshold for prediction accuracy, which may have been improved by modifying the 
exponent value. The exponent used by Dong et al. was based on the assumed ¾ power rule, and has been 
shown to not work well for all types of therapeutic macromolecules, particularly coagulation factors .(56) 
Dong et al. reported that using an exponent of 0.85 (Table 2.5) did not consistently improve predictions for 
all 10 compounds exhibiting linear PK.(64) However when we calculated the AAFE (Table 2.5) of 13 
monoclonal antibodies from a report by Deng et al.(63) with a fixed exponent of 0.85, the resultant AAFE 
was near unity with a majority of compounds falling with 0.7-1.3. The antibodies in the Deng et al. report 
consisted of humanized, human and chimeric IgG and 4 of the antibodies are marketed and include 
antibodies with soluble receptors (e.g. trastuzumab).(63) When we compared the single-species approach to 
conventional simple allometry and ROE in terms of fold-error within 0.7-1.3 the single species with fixed 
exponent of 0.85 was far superior (Table 2.5). Wang and and Prueksaritanont further explored the influence 
of the exponent in terms of prediction accuracy of a single-species (combination of mouse, rat, rabbit, 
monkey and dog) whereby they considering fixed exponents ranging from 0.7 to 0.9 with increments of 0.05 
and confirmed that for 34 compounds, including monoclonal antibodies and fusion proteins, a fixed 
exponent of 0.8 provided the best overall prediction with 92% of compounds within 2-fold.(62) The authors 
did not report an overall prediction accuracy as the objective was to determine whether the predictions were 
reasonable for FIH dosing, however what is clear is that single species monkey can predict macromolecule 
CL for a reasonably diverse set of macromolecules and that the fixed exponent needed to achieve 
appropriate prediction accuracy, if used in biosimilar development, should be nearer to 0.8 or 0.85 as 
opposed to the previously assumed 0.75. 
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2.4.6 Species-Invariant Approaches for Macromolecules 
In addition to comparing simplified allometric approaches using a single-species and fixed exponents, Ling 
et al. found that a fixed exponent closer to 0.85 improved prediction accuracy of CL when using the Dedrick 
plot approach (Table 2.5).(61) Oitate et al. however similarly considered the single species monkey 
employing both Elementary and Complex Dedrick Plot approaches for both soluble and membrane-bound 
target mAbs and found that although both Elementary and Complex Dedrick plots resulted in similar 
predicted CL values neither resulted in an AAFE within 0.7-1.3 for a group of 12 mAbs (6 soluble and 6 
membrane-bound target) (Table 2.5 for Elementary Dedrick).(89) One explanation for the discrepancy 
between the two publications may be the method in which the CL values were estimated following 
normalization of the concentration time profiles.  Ling et al. employed a non-compartmental analysis 
approach for deriving the human PK parameters whereas Oitate et al. employed compartmental analysis. 
The non-compartmental approach may not be as accurate when using TK data where sampling tends to be 
sparse. Further exploration of species-invariant approaches is warranted prior to suggesting this approach 
ahead of simplified allometry using non-human primates. 
  
 42 
 
2.5 Discussion 
If the mechanism of CL varies widely across species then using a single species which is different from 
humans may over- or under-predict. This may explain why simple allometry performs better in some cases 
than single-species, even when non-human primates are used as the single-species. In cases where the 
pharmacokinetics are linear and the mechanism of CL is thought or known to be conserved across the 
species based on the reference biologic compound, a single species, such as non-human primates may be the 
most efficient and appropriate model to scale the PK from animals to humans. Where the mechanism of CL 
is known to differ among the species, obtaining CL values from ≥ 3 species for both the biosimilar candidate 
and the reference biologic compound seems warranted however as previously stated, species selection must 
consider whether the degree of immunogenicity is similar across species. Where simple allometry is used 
with ≥ 3 species, the evidence suggests utilizing species with over a 50-fold or greater weight range as data 
clustered around a narrow range of species can affect the prediction.(58) 
 
Single-species allometry has not been particularly useful for predicting CL in humans for small molecules, 
particularly when the compounds have been administered orally. Although monkeys have demonstrated 
reasonable predictive capacity for small molecules administered by IV, there is evidence to suggest that 
factors affecting oral bioavailability such a P-glycoprotein efflux and intestinal metabolism differ 
sufficiently between humans and monkeys such that the monkey is an insensitive model for predicting the 
oral CL of small molecules.(90) In contrast, for macromolecules, single-species, and particularly monkeys, 
have demonstrated reasonably good prediction of human CL across a variety of compounds including 
monoclonal antibodies and fusion proteins. There is less data available to support a universal application of 
single-species allometry for drugs exhibiting non-linear pharmacokinetics or for those administered via the 
subcutaneous route. 
 
A limitation of the current evaluation, as well as other reports of this nature, is that prediction accuracy is 
based on a mean value for the exponent tested. With the exception a few report (e.g. Oitate 2011), the range 
of exponents are rarely reported.(89) A prediction interval (i.e. a range of prediction accuracies by product 
and method) is rarer, and this adds to the uncertainty, and limits the interpretation of the results. Inclusion of 
prediction intervals in future evaluations may allow for better discrimination between the different fixed 
exponent values as opposed to basing decisions on mean predicted values.  
Another limitation of the current evaluation is that the compounds included in the simplified allometric 
approaches with fixed exponents tended to reside within the broader class of Mabs and thus the results may 
not be directly applicable to other therapeutic proteins such as fusion proteins and oligonucleotides. This is a 
consequence of the availability of literature reports which have been published to date evaluating single-
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species interspecies scaling techniques with fixed exponents and likely reflects the reality that Mabs 
represent a significant proportion of therapeutic compounds either in development or on the market. 
Additional research is required to determine whether the prediction accuracy of the single-species allometric 
approaches in monkeys with fixed exponents can be extrapolated to a broader range of therapeutic 
compounds outside the Mab class. 
 
The majority of the therapeutic macromolecules in the present review were administered IV for both 
animals and humans. Consideration of the subcutaneous route however is becoming increasingly important 
and many therapeutic macromolecules are available or are being tested currently for subcutaneous 
administration. This presents additional challenges for prediction of human pharmacokinetics from animal 
species as subcutaneous absorption of macromolecules such as mAbs follows uptake via the lymphatic 
pathway potentially imparting non-linearity in the subcutaneous absorption phase (through saturation of the 
proteolytic capacity or lymphatic transport).(72) There may also be interspecies differences in the 
mechanism of uptake of macromolecules from the subcutaneous compartment. Few literature reports are 
available on the interspecies scaling of macromolecules with subcutaneous administration. Dong et al. 
included data from macromolecules following subcutaneous administration where non-linearity in the 
pharmacokinetics has been observed.(64)  For these compounds, derivation of the PK parameters was done 
following fitting data empirically to a pharmacokinetic model with parallel linear and non-linear 
elimination. A similar approach has been applied previously by Woo and Jusko in an interspecies 
comparison of the PK and PD of recombinant human erythropoietin.(91) When predictions of 
macromolecules known to exhibit non-linearity in the absorption phase are to be made as biosimilars, fitting 
the data to an appropriate PK model may be beneficial rather than utilizing the traditional non-
compartmental approach, particularly when the animal data is derived from subcutaneous dosing. It should 
be noted that in some cases the comparison of human and animal PK was performed at saturating doses and, 
from a biosimilar perspective, it may be beneficial to include more than one dose level for each biosimilar 
candidate and the reference biologic to ensure the degree of non-linearity is similar between the two 
products.(62) Appropriate model development for a biosimilar may require the inclusion of factors such as 
the presence of soluble receptor targets, target-mediated clearance and neutralizing antibodies in the pre-
clinical species (especially in the case of multiple-dose PK data). 
 
Allometric approaches traditionally rely on either non-compartmental or some semi-mechanistic approach 
to assess CL and V, as such they are limited in their ability to extrapolate beyond the data being explained.  
There may be value in considering alternative approaches for scaling the PK of biosimilars. In contrast to 
allometric approaches, PBPK models consider anatomical spaces, physiologic processes as well as drug 
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specific characteristics to describe the PK of a given compound.(92;93) As PBPK models rely on well 
characterized physiologic processes and anatomy which are common across mammalian species, PBPK 
may offer advantages over traditional allometric approaches through limiting the number of different animal 
species for which in-vivo PK data is required for scaling up to human values. More work is required in this 
area as the literature supporting the use of PBPK in predicting human PK of macromolecules, and 
specifically application in biosimilars, is in its infancy. 
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2.6 Summary 
Biosimilars have enormous potential for both generating revenue for industry and saving expenditures for 
payers of drug therapies. The development of a biosimilar candidate, although abridged relative to an 
innovative compound, is still fraught with risk particularly when the toxicity profile limits comparative 
testing in Phase I necessitating sponsors to make decisions to proceed to large scale patient trials based on 
pre-clinical testing. Access to methodologies for better prediction of PK equivalence based on pre-clinical 
data, and in particular animal TK data, may prove helpful to sponsors in making such decisions. Allometric 
techniques, which have had mixed success in the prediction of human PK for small molecules, may actually 
have better predictive success for macromolecules with greater promise for single species approaches using 
non-human primates than that previously observed with small molecules. Whole-body PBPK modeling may 
offer an alternative approach for both interspecies scaling of macromolecules for biosimilar purposes as well 
as incorporation of disease processes simulating the conditions used in comparative efficacy and safety 
trials. The 2-fold threshold, traditionally employed as a measure of prediction accuracy for interspecies 
scaling may be too liberal if such approached for the purpose of de-risking candidate selection in biosimilar 
development. A tighter threshold of 0.7-1.3 may be more discriminating in identifying biosimilar candidates 
which would be less likely to exhibit similar PK to the reference biologic in humans. 
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CHAPTER 3: MODEL-INDEPENDENT SINGLE-SPECIES ALLOMETRIC SCALING METHODS 
FOR A PEGYLATED PEPTIDE CONJUGATE 
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This chapter consists of unpublished works. The PhD candidate conducted all the pertinent research, 
conducted all described analyses, created all tables, plots and figures and wrote the entire chapter. 
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3.1 Introduction and Objectives 
Simplified allometry as introduced and discussed in Chapters 1 and 2 provide for a means of extrapolating 
the systemic exposure from animals to humans to predict the dose required in humans corresponding to an 
exposure threshold below what is considered safe in animals. Pharmacokinetic (PK) parameters can be 
estimated via a number of computational methods and can be crudely divided into model-based and model-
independent methods. Model-based methods can be further partitioned into mechanistic, semi-mechanistic 
models and empiric compartmental models, all of which employ a series of mass transfer equations to 
describe drug movement between compartments, with mechanistic models being more anatomically and 
physiologically representative relative to empirical models.   Model-independent methods however, are far 
less computationally intensive, and potentially offer utility in the prediction of human PK following 
administration of a drug to a preclinical species early in drug development. 
 
Model-independent methods rely on non-compartmental analysis (NCA) to estimate important PK 
parameters and exposure to drugs. Gabrielsson and Weiner (40) provide a detailed explanation of the 
principles of NCA, however a brief explanation is provided herein. The parameters of greatest interest 
following a single dose of a drug are defined in Table 3.1. The maximum observed concentration (Cmax) is 
the peak of the concentration vs. time profile (CPT), and literally involves identifying the highest observed 
concentration. The area under the curve (AUC) represents the overall extent of drug which is available for 
systemic action and is derived based on integral calculus theory. The CPT is partitioned into smaller areas 
and then the cumulative areas are summed to obtain a single value.(94)  The linear trapezoidal method, 
involves dividing the CPT into discrete trapezoids and calculating the area of each trapezoid and summing 
the trapezoids to obtain a single AUC value. Another variation is the log-linear version which assumes a log 
scale for the CPT after the peak concentration, during the descending portion of the curve, which is assumed 
to mitigate the risk of overestimation of systemic exposure during the exponential decline in the 
concentrations over time. Regardless, both methods share underlying assumptions, being: (a) applicable to 
any typical route of administration (intravenous [IV], subcutaneous [SC], oral, etc.); (b) no specific 
biodistribution (i.e. compartmental) pattern is assumed and (c) clearance of the drug occurs from the 
sampling compartment.  
 
The rate of disappearance of the drug from the sampling compartment is also an important PK parameter as 
it reflects how quick the body is clearing the drug. The term half-life (T1/2) refers to the time the 
concentration in the sampling compartment divided by a factor of 2. In NCA, the T1/2 is derived from the 
regression of the log-linear terminal (β) portion of the CPT, which describes the elimination phases of the 
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drug and is calculated as the natural log (Ln) of 2 divided by the apparent terminal elimination rate constant 
(λ), which is derived from the regression of the β portion of the CPT.(40) 
 
Clearance (CL) and volume of distribution (Vd), as introduced in Chapter 1 are important PK parameters of 
a drug which inform key decision points related to drug, dose and regimen and. Said parameters can be 
estimated using NCA, or more computationally intensive methods that will be described in more detail in 
later chapters. 
 
Formally, CL is the volume of plasma cleared of drug per unit of time. From a physiologic perspective, 
estimating CL following different dose levels or following different routes of administration helps inform 
whether the drug is cleared in a linear fashion or exhibits some degree of capacity-limited absorption or 
elimination. Based on a drug’s physical and chemical properties, there is either a propensity or restriction on 
the tissue penetration of a drug after administration. The Vd is a parameter which is intended to quantify the 
volume required to explain the observed concentration in the sampling compartment after administration, 
and may not necessarily have an anatomic or physiologic basis.(95)  The Vd is a parameter which attempts 
to describe the extent of distribution of a drug in the body,  however depending on the analyst and data 
available, can potentially be expressed as: (1) Vc which relates that mass of drug in the blood immediately 
after instantaneous administration (i.e. IV administration); (2) Vss which is the volume of distribution when 
equilibrium of the drug has been achieved between the blood and tissue compartments; (3) Vz, which is a 
proportionality constant which relates the distribution of a drug in the blood and tissue compartments at 
pseudo-equilibrium.  
 
Following IV administration, CL and volume parameters can be estimated by NCA, however for 
extravascular administration, where the bioavailability (F) is unknown, these parameters are divided by “F” 
which is the fraction of drug dose that appears in systemic circulation. With NCA methodology, when the 
time interval between two data points is large, there is greater risk in over- or under-estimating the area of 
the trapezoid.  In Chapter 1 and again in Chapter 2, limitations of PK evaluation in animal studies were 
raised, with one major limitation being frequency and duration of blood sampling from the animal. Thus, 
employing animal pharmacokinetic (referred to as toxicokinetics or TK in preclinical development) studies 
to obtain estimates of exposure can be fraught with considerable uncertainty.  
 
Another model-independent approach to scaling PK based on allometric theory is the Elementary Dedrick 
plot (Dedrick plot for short). The theory underlying this approach is addressed in additional detail later in 
this chapter, however the principle of a Dedrick plot is to normalize the x-axis of a CPT such that time is 
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relative to the species size and the resultant x-axis is a dimensionless time scale referred to as 
kallynochrons.(53;86) An added benefit over traditional allometry that scales only the mean PK parameter 
value, Dedrick plots allow for visualization of the entire CPT. This approach has been employed for small 
and large molecule scaling with varying success, and has typically been used following IV 
administration.(87;89;96)  
 
This chapter seeks to evaluate the prediction accuracy of single-species allometric scaling of model-
independent derived PK parameters for a subcutaneously administered large molecule. The exemplary 
molecule is the same pegylated peptide conjugate (PPC) which is also the subject of Chapters 4-6. As this is 
the first chapter in this thesis for which computational analysis was performed on the data obtained for this 
molecule, some additional background is provided.  Data for an investigation PPC was provided 
confidentially by a benefactor (pharmaceutical industry sponsor) wishing to remain anonymous for 
proprietary reasons. The unconjugated molecule is conjugated to a linear polyethylene glycol (PEG)-40 
chain. Out of respect and wishes of the Sponsor, the investigational drug will be referred to as PPC 
throughout the chapters which are not versions of already published material (where the compound is 
referred to as a pegylated peptide conjugate). 
  
PPC has currently just completed the initial phase of human development. Concentration vs. time data as 
well as some important study conduct information was provided for a first-in-human (FIH) dose escalation 
study as well as for preclinical exposure evaluation in a single, non-human primate (NHP) species. As such, 
the objective of this chapter was to test the prediction accuracy of single-species interspecies scaling 
methods for later comparison to the more computationally intensive, model-dependent methods described in 
Chapters 4-6.  
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3.2 Methods 
3.2.1 Data 
Drug concentration data for PPC was provided following IV and SC administration to a NHP cynomologus 
monkey species. Additionally, concentration data was provided for the same PPC following SC 
administration to humans by the Sponsor specifically for the purpose of this thesis research project. Nine 
non-naïve (previous exposure to other experimental treatments) female NHP (mean weight 3.4 kg) were 
evaluated for single- and repeat-dose exposure of PPC. Three NHPs each received a single 7 mg/kg IV dose 
and three received a single 7 mg/kg SC dose to the back region. Blood samples were obtained for PK 
evaluation at 0.083, 0.5, 1, 4, 8, 24, 48, 72, 120, 144, 168, 192 and 336 hours after the dose. An additional 
three NHPs received seven, daily, consecutive 7 mg/kg SC doses with an identical PK sampling schedule 
with the single-dose group (i.e. 0.083, 0.5, 1, 4, 8, 24, 48, 72, 120, 144, 168, 192 and 336 hours after the first 
dose). 
 
The human data was obtained as part of the FIH dose escalation study where four healthy male subjects   in 
each cohort (weight range 60-80 kg) received a single SC dose of either 45 mg, 90 mg, 180 mg, 360 mg or 
720 mg to the abdominal region. Blood samples were obtained for PK evaluation immediately prior to the 
dose and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 240, 336, 408, 504, 576 and 672 hours after the dose, 
with an additional sample drawn 1008 hours after the dose for the 720 mg dose cohort.  
 
The human study was conducted under good clinical practice and according the ethical principles outlined in 
the Declaration of Helsinki. Plasma was analyzed from both species employing an LC-MS/MS method with 
a limit of quantitation of 1 μg/mL for both NHP and human matrices. 
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3.2.2 PK parameter Estimation 
For NHPs and humans, each individual’s concentration data was subject to NCA to obtain estimates for 
those parameters listed in Table 3.1. Regression of λ was based on a minimum of three concentration 
observations and could not include the Cmax value. Regressions were only considered acceptable where 
there was an apparent terminal phase and where the coefficient of determination (R
2
) value was >70%. 
Where an R
2
 was not calculable, parameters dependent on λ were set to missing. 
 
Table 3.1: Pharmacokinetic parameters derived in the current evaluation obtained by non-
compartmental analysis using Phoenix WinNonlin (version 6.4, Certara) 
Parameter Definition Calculation 
AUC0-t 
 
Area under the concentration vs. 
time profile from dose time (0) to the 
last quantifiable time point 
Measured by the linear 
trapezoidal method 
AUC0-inf Area under the concentration vs. 
time profile from dose time (0) 
extrapolated to infinity 
AUC0-t + the ratio of the last 
measureable concentration/λ 
Cmax Highest observed concentration Taken directly from the 
observed data 
Tmax Time of Cmax Taken from time of Cmax 
CL/F Clearance after extravascular 
administration 
Calculated as Dose/AUC0-inf 
Vz/F Volume of distribution based on the 
terminal phase after extravascular 
administration 
Calculated as Dose/λ•AUC0-inf 
λ Apparent terminal elimination rate 
constant 
Determined by the slope of the 
log-linear portion of the 
concentration vs. time profile 
T1/2 Apparent terminal elimination half-
life 
Calculated by dividing 
Ln(2)/λ 
For parameters divided by F, F is equal to 1 for intravenous administration and may be less than 1 for extravascular administration. 
 
Individual parameters were then summarized descriptively to obtain an arithmetic mean value for each of 
the two species. 
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NCA and descriptive statistics were performed using Phoenix ® 1.4 WinNonlin version 6.4® (Certara) and 
Excel (Microsoft). Prior to NCA, concentration values below the limit of quantitation (BLQ) were set to 
zero prior to Tmax and missing for any BLQ values afterwards. 
 
As the observed human dataset consisted of 5 unique subject cohorts across 5 dose levels, linear regression 
of the log value of AUC and log value of Cmax, respectively vs. log of dose administered was performed. If 
the 95% confidence interval for the slope of the regression did not include zero, then a linear proportional 
relationship between PK parameters of interest with dose would be assumed. In such a case CL/F, Vz/F and 
T1/2 would be assumed to be independent of dose and the mean PK parameters across all 5 dose levels would 
be calculated. Otherwise, comparison of the predicted PK parameters would be compared to the mean PK 
parameter by cohort/dose level. 
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3.2.3 Interspecies scaling methods 
3.2.3.1 Fixed-exponent single-species scaling of clearance and volume 
For single-species CL/F,  Vz/F and T1/2 scaling, the PK parameter value for humans (Phuman) was obtained by 
multiplying the corresponding parameter obtained from NHPs (Pmonkey ) with a body weight ratio raised to a 
scaling factor exponent as per Equation 3.1. Body weight ratios assumed the arithmetic average of the NHPs 
(i.e. 3.4 kg) and the median of the per protocol range of humans (i.e. 70 kg). 
 
Phuman  = Pmonkey •(Weighthuman/Weightmonkey)
exponent
   (3.1) 
 
Generally, and as described in greater detail in Chapter 2, volume of distribution parameters are assumed to 
scale proportionally with body weight and thus an exponent of 1 was assumed. Similarly, an exponent of 
0.85 was assumed for clearance parameters. Consistent with the proposal by Boxenbaum and Ronfeld, T1/2 
can similarly be scaled across species according to Equation 3.1, where the exponent is the difference 
between the exponents for volume and clearance parameters(86); in our case 0.15. 
As a sensitivity evaluation, the theoretical value was varied by ± 0.05 exponent increments.  
 
Prediction accuracy for each predicted vs. observed value was performed by dividing the predicted by the 
observed value and reported as fold-error (FE). Consistent with the proposal in Chapter 2 (Equation 2.1), a 
prediction was determined reasonable where the FE, which is the ratio of a predicted parameter (P) over the 
observed parameter, falls between 0.7-1.3. 
 
3.2.3.2 Elementary Dedrick Plot 
Scaling of NHP to humans was performed by normalization of the CPT whereby plasma concentration and 
time scales following a single SC dose for NHPs were normalized to a human time scale and plotted as 
Elementary Dedrick plots similarly to the concentration-time transformations used by Lave et al.(46;89)
 
Normalization of time and concentration were performed as per Equations 3.2 and 3.3 assuming empiric 
exponent values for c and b of 1 and 0.85 respectively, for apparent extravascular volume (Vz/F) and 
clearance (CL/F), respectively. 
 
Timehuman,predicted = Timemonkey•(Weighthuman/Weightmonkey)
c-b
   (3.2) 
 
Concentrationhuman, predicted  = 
Concentrationmonkey,observed • (Dosehuman/Dosemonkey) •(Weightmonkey/Weighthuman)
  
                           (3.3) 
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As NHPs were dosed on a 7 mg/kg basis, doses were multiplied by the mean body weight to obtain an 
absolute dose prior to scaling. Following normalization, scaled concentrations obtained from NHPs were 
descriptively summarized to obtain an arithmetic mean concentration at each nominal time point and 
overlaid with the observed, concentration data obtained from humans. If the PK was determined to be linear 
across all dose levels, human observed concentration values were to be normalized to the lowest dose level 
(i.e. 45 mg). NCA was then performed on the mean observed human data and compared to the mean 
predicted human concentrations as scaled from NHPs.  
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3.3 Results 
Although the methodology in this chapter is focused on the prediction accuracy methods following a single 
SC dose, for transparency and to provide a clear illustration of the PK of the test compound in NHPs, the 
CPT following single-dose IV administration as well as following single- and repeat-dose SC administration 
are provided. Figures 3.1a and 3.1b illustrate the linear and log scale CPT for in NHPs following the 7 
mg/kg IV and SC doses. Figures 3.2a and 3.2b illustrate the same scales for 20 human male subjects over 5 
SC dose levels. Single 7 mg/kg SC administered doses in NHPs achieved similar concentrations (1-100 
μ/ml) observed in humans when considering the range of doses administered in the human population.  
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Figure 3.1: Concentration vs. time profiles (linear scale – 
3.1a; log x vs. log y scale – 3.1b) of a pegylated peptide 
conjugate following a single 7 mg/kg IV administration (open 
circle), a single 7 mg/kg SC administration (open diamond) 
and a day-7 profile following seven repeat daily 7 mg/kg SC 
administrations (closed triangle) in cynomologus monkeys 
(n=3 monkeys per group). 
Figure 3.1a 
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Figure 3.1b 
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Figure 3.2: Concentration vs. time profile (linear scale – 3.2a; 
log x vs. log y scale – 3.2b) of a pegylated peptide conjugate 
following single-dose SC administration to healthy male 
subjects (n=4 per dose cohort) participating in a first-in-
human single-ascending dose study.  
Figure 3.2a 
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Figure 3.2b 
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3.3.1 Fixed Exponent Scaling 
Results of fixed-exponent scaling of PK parameters are presented in Table 3.2.  An empiric scaling factor of 
0.85 was assumed for CL/F, which resulted in an FE of only 0.67. This was outside of the ±30% pre-
specified acceptance margin. In contrast, scaling factors closer to 1 resulted in a FE closer to unity, implying 
a proportional relationship of CL/F with body weight across species. With respect to volume, a scaling 
factor of 1 resulted in FE values well within the ±30% region suggesting Vd is proportional to body weight. 
An empiric allometric scaling factor of 0.15 somewhat over-estimated the observed T1/2 with an exponent 
closer to 0.05 providing the FE closest to unity.  
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Table 3.2: Prediction accuracy of single-species simplified allometric scaling of extravascular 
clearance, extravascular volume of distribution and half-life from cynomologus compared to 
humans for a single, subcutaneous dose of a pegylated peptide conjugate 
 
Parameter Observed 
NHP 
NHP 
body 
weight 
Human 
body 
weight 
Equation 
3.1 
Exponent 
Predicted  
(Human) 
Observed 
(Human) 
Fold 
error 
Criteria 
Achieved 
(between 
0.7-1.3) 
CL/F 0.20 3.4 70 0.7 5.62 13.16 0.43 No 
CL/F 0.20 3.4 70 0.75 6.54 13.16 0.50 No 
CL/F 0.20 3.4 70 0.8 7.61 13.16 0.58 No 
CL/F 0.20 3.4 70 0.85 8.85 13.16 0.67 No 
CL/F 0.20 3.4 70 0.9 10.29 13.16 0.78 Yes 
CL/F 0.20 3.4 70 0.95 11.97 13.16 0.91 Yes 
CL/F 0.20 3.4 70 1 13.93 13.16 1.10 Yes 
Vz/F 51.78 3.4 70 0.85 2302.42 4054.96 0.57 No 
Vz/F 51.78 3.4 70 0.9 2678.34 4054.96 0.66 No 
Vz/F 51.78 3.4 70 0.95 3115.63 4054.96 0.77 Yes 
Vz/F 51.78 3.4 70 1 3624.33 4054.96 0.89 Yes 
Vz/F 51.78 3.4 70 1.05 4216.08 4054.96 1.00 Yes 
Vz/F 51.78 3.4 70 1.1 4904.44 4054.96 1.20 Yes 
Vz/F 51.78 3.4 70 1.15 5705.19 4054.96 1.40 No 
T1/2 180.73 3.4 70 0 180.73 214.34 0.84 Yes 
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T1/2 180.73 3.4 70 0.05 210.23 214.34 0.98 Yes 
T1/2 180.73 3.4 70 0.1 244.56 214.34 1.10 Yes 
T1/2 180.73 3.4 70 0.15 284.49 214.34 1.30 Yes 
T1/2 180.73 3.4 70 0.2 330.94 214.34 1.50 No 
T1/2 180.73 3.4 70 0.25 384.97 214.34 1.80 No 
T1/2 180.73 3.4 70 0.3 447.82 214.34 2.10 No 
T1/2 180.73 3.4 70 0.35 520.94 214.34 2.40 No 
T1/2 180.73 3.4 70 0.4 605.99 214.34 2.80 No 
CL/F: Extravascular clearance in mL/h; Vz/F: Extravascular volume of distribution in mL; T1/2: Apparent terminal elimination half-
life in hr; NHP: Cynomologus monkey 
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3.3.2 Dedrick Plot  
As described in the methods section, if the human exposure was deemed proportional to dose, comparison 
of scaled concentrations from NHPs would be performed relative to the dose normalized CPT averaged 
across all five human dosing cohorts. Figures 3.3a and 3.3b demonstrate that exposure in humans, as 
measured by AUC and Cmax, increased proportionally with increasing dose with the 95% confidence 
interval for the slope including a value of one. Consequently, Dedrick plot prediction accuracy was based on 
human dose-normalized concentrations to the lowest (i.e. 45 mg) human dose cohort. Dedrick plots on the 
linear scale (Figure 3.4a) qualitatively suggest reasonable prediction of the human data, with slight over-
prediction of the peak concentration. Due to truncation of the NHP observed data, the terminal elimination 
phase is not comparable between the two species. When comparing log scale plots (Figure 3.4b), it becomes 
evident that the Dedrick plot scaling could not account for potential interspecies differences in the 
absorption phase of the CPT. This obvious over-prediction in the mean CPT however did not translate to 
significant differences in the main PK parameters of interest. Table 3.3 presents the results of the NCA 
performed on the average predicted vs. observed CPT where exposure parameter FE (AUC0-t
 
 and Cmax) 
and Vz/F were within ± 10%. In contrast, AUC0-inf
-
fell just outside; and CL/F fell just within the pre-
specified acceptance boundary.  
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Figure 3.3: Log of pegylated peptide conjugate dose 
administered to healthy male subjects in the first-in-human 
single-ascending dose study vs. log of AUC (3.3a) or Cmax 
(3.3b) (obtained by non-compartmental analysis) for the 
corresponding subject, to evaluate proportionality of dose vs. 
exposure. Closed circles represent the individual values. The 
blue line and grey shaded region represent the regression 
slope and corresponding 95% confidence interval of the slope. 
Where the 95% confidence interval includes a value of 1, 
proportionality cannot be rejected. 
Figure 3.3a 
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Figure 3.3b 
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Figure 3.4: Dedrick Plot (linear scale – 3.4 a; log x vs. log y – 
3.4b). Dashed line represents the dose-normalized (to a 45 mg 
dose) arithmetic mean observed concentration of a pegylated 
peptide conjugate vs. nominal time profile in healthy human 
subjects following escalating doses in a first-in-human single-
ascending dose study. The solid line represents the arithmetic 
mean concentration of pegylated peptide conjugate following 
a single, 7 mg/kg dose in cynomologus monkeys (n=3) scaled 
to human vs. nominal time from the cynomologus PK 
evaluation.  
Figure 3.4a 
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Figure 3.4b 
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Table 3.3: Prediction accuracy of non-compartmentally derived pharmacokinetic parameters 
obtained from Dedrick Plot scaling of the concentration vs. time profile in cynomologus monkeys 
to human scale for a single, subcutaneous dose of a pegylated peptide conjugate 
 
Parameter Units 
Predicted 
(Human) 
Observed 
(Human) FE 
Criteria 
Achieved 
Tmax hr 113.34 168.00 0.67 No 
Cmax μg/mL 9.61 8.65 1.10 Yes 
AUC0-t μg·hr/mL 3539.14 3458.54 1.00 Yes 
AUC0-inf μg·hr/mL 5099.09 3652.78 1.40 No 
Vz/F mL 3641.40 3916.80 0.93 Yes 
CL/F mL/hr 8.83 12.32 0.72 Yes 
AUC%Extrap % 
30.59 5.32 NC NA 
CL/F: Extravascular clearance; Vz/F: Extravascular volume of distribution;  AUC0-t: Area under the curve to the last measurable time 
point; AUC0-inf: Area under the curve extrapolated to infinity; AUC%Extrap: percent of the AUC extrapolated; Obs: Observed data; 
Pred: Predicted data; BW: Body weight; NC: Not calculated; NA: Not applicable 
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3.4 Discussion 
Perhaps the most limiting characteristic of NCA when using this method to calculate PK parameters for 
macromolecules is the assumption that CL occurs via the sampling compartment. As briefly mentioned in 
Chapter 1, macromolecules are generally catabolized into smaller building blocks as opposed to 
biotransformed like small molecules.This breakdown can potentially occur within the interstitial space, 
lymphatic system and vasculature and thus the assumption of CL via the sampling compartment may be 
violated. Although macromolecules can be eliminated renally, due to molecular size restrictions, this is 
thought to be a minor pathway for most intact proteins and peptides. Pegylated compounds, such as the one 
studied in this thesis project, have been reported to be eliminated renally at approximately 0.1% of the 
glomerular filtration rate.(25;97) However, as with other pegylated therapeutic compounds, the likely 
pathway for the current peptide is likely a mixture of renal and non-renal extrahepatic processes which 
include uptake and digestion by immune cells and proteolytic breakdown of the intact pegylated peptide. 
(26) These processes may be occurring outside of the sampling compartment (e.g. in the interstitial space). 
Although compartmental PK modeling approaches, as employed in Chapter 4, have been reported in the 
literature for assessing prediction accuracy of single-species allometry,(62;63)   Dong et al. employed NCA 
for estimating the PK parameters of macromolecules for the purpose of interspecies scaling of 
macromolecules with linear PK.(64) In spite of the obvious violation of a basic NCA assumption, such 
predictions yielded sufficiently reasonably accuracy for some of the tested compounds.  
 
Another limitation of scaling NCA-derived parameters is the assumption of linear PK, which was only 
confirmed for the current evaluation upon receipt of the concentration data across five dose levels in 
humans. In the current evaluation, there was an a priori assumption of linear and stationary (lack of time-
dependency) PK in NHPs prior to scaling. As only data following a single dose level (i.e. 7 mg/kg) in NHPs 
was available there was no way prove linearity a priori. However nonparametric superposition of the single 
SC dose was overlaid with the repeat-dose SC data and this suggested stationarity (superposition data not 
shown). Should evaluation of PK linearity yield a suggestion of non-linear CL/F, model-independent scaling 
of NCA-derived CL/F would not be reliable as clearance changes with exposure and no single clearance 
value could reliably be employed for translation from one species to another. 
 
While the current analysis supported the a priori assumption for Vd and species body weight, an a priori 
allometric scaling factor assumption of 0.85 for CL did not achieve a reasonable FE (Table 3.2). As 
described in Table 3.1, NCA-derived extravascular CL/F is the quotient of dose and AUC0-inf where AUC0-inf 
is dependent on the ratio of the last observed concentration divided by the apparent terminal rate constant. 
For the NHP concentration data, the extrapolated area, which is defined as 1-(AUC0-t/AUC0-inf) expressed as 
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a percentage, was approximately 30%. Large extrapolated areas can be associated with a poorly defined 
terminal elimination phase, and consequently greater uncertainty in the value for the λ and in any secondary 
parameters dependent on λ. As such, reliance on NCA-derived PK parameters for interspecies scaling may 
be limited by studies with different species and inconsistent or inequivalent sampling schedules used to 
define the PK. 
 
With respect to the Dedrick plot analysis, based solely on the prediction accuracy of the main PK 
parameters, this method may be reasonable for scaling macromolecule PK, despite clearance processes not 
necessarily occurring via the sampling compartment. Oitate et. al. evaluated prediction accuracy of Dedrick 
plots for a group of IV administered mAbs with soluble and membrane bound targets using allometric 
exponents of 0.79 and 0.96 for CL, respectively and 1 for Vss.(89;98) Of the twelve studied compounds, 
only five would have met the pre-defined ± 30% acceptance range of the current evaluation. It should be 
noted however that Oitate et al estimated CL and Vss using an empiric 2-compartment model and not NCA. 
In contrast, using Dedrick plots and compartmental modeling for a group mAbs, Deng demonstrated good 
prediction accuracy of CL and Vss when using exponents of 0.85 and 1 for CL and Vss, respectively. In the 
current evaluation, Vz/F was used and not Vss. NCA derived Vss assumes that equilibrium between the 
sampling compartment and tissue compartments is achieved, and also that bioavailability is essentially 
complete. With extravascular administration, equilibrium cannot be assumed and thus the Vz/F method is 
used, which represents pseudo-equilibrium. However, the Vz parameter, as stated in Table 3.1, is dependent 
on λ being reliably estimated. Therefore some of the limitations in scaling NCA-derived clearance apply 
similarly to Vz/F. 
 
In the current evaluation, upon graphical evaluation on the log scale (Figure 3.4b) there was an obvious 
difference between species in terms of the absorption profile which was further reflected by the FE in Tmax 
(Table 3.3). This observation however did not translate into a significant difference in the main exposure 
parameters. Although elimination or clearance of a drug can occur from the moment the drug enters the 
biological system, the duration of time from dosing to Tmax can be generally referred to as the absorption 
phase, where absorption processes predominate over elimination. For the scaled dataset, the time from 
dosing to Tmax represented approximately 21% or only 1/5
th
 of the total duration of sampling.  As such, the 
duration where the over-prediction was most evident did not account for sufficient circulating drug exposure 
to result in an obvious difference in FE. Perhaps with a drug exhibiting a shorter elimination T1/2, or a longer 
absorption phase relative to the elimination phase, where the absorption phase represents a larger proportion 
of the AUC, poorer prediction accuracy would be more evident. 
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Although the Tmax was under-predicted, Cmax was reasonably well predicted. This may be due to the fact 
that PPC has a similar Vd and F across the two evaluated species (i.e. monkeys and humans). The derived 
value for Vz/F was approximately 50 ml/kg regardless of species, which is consistent with plasma volume 
in mammals.(99)
 
  
The volume parameter derived was based on extravascular administration and thus Vz/F, meaning that the 
volume is dependent on the unknown bioavailability factor “F”. The bioavailability after SC administration 
for this same compound in NHPs was previously estimated at approximately 90%.(66) Data following IV 
administration in humans was not available, however PBPK simulations (detailed later in this thesis) of IV 
administration in humans predicted a similar bioavailability in humans.(66)  Thus the close agreement 
between predicted and observed exposure parameters may be partly a result of the similar bioavailability 
following SC administration across the two tested species. Bioavailability for SC administered 
macromolecules has been reported to vary widely across species.(18) As the SC bioavailability is unknown 
at the time of scaling from animals to humans for a FIH, the utility of empiric scaling methods are 
associated with a high degree of uncertainty.  
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3.5 Conclusion 
Pharmacokinetic parameters derived using model-independent approaches may be scaled from NHP to 
humans assuming weight-based allometric functions with empiric scaling factors. However, prediction of 
parameters dependent on reliable estimation of an apparent elimination rate constant is subject to 
uncertainty. Moreover, this method must assume linear PK across a wide range of concentrations and near 
complete bioavailability if employed for extravascular administration. If the objective of scaling is to predict 
the time course of the drug after administration, it is not possible when simply relying on the mean value of 
a PK parameter such as CL. Combined, these factors limit the a priori utility of these computational 
methods in predicting the PK of a SC administered macromolecule. Dedrick plots, which are capable of 
predicting the time course of a drug after IV administration, do not account for interspecies physiologic and 
anatomic factors that influence the absorption of drugs. Although overall exposure parameters may have 
been reasonably predicted in the current evaluation, poor prediction in the absorption phase of the drug may 
limit the utility of this approach for other compounds. Moreover the unknown differences in SC 
bioavailability may limit the utility of empiric methods relative to more mechanistic, model-based methods. 
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CHAPTER 4: PHARMACOKINETIC TIME COURSE SCALING OF A SUBCUTANEOUSLY 
ADMINISTERED PEGYLATED PEPTIDE CONJUGATE FOR A FIRST-IN-HUMAN 
INVESTIGATION 
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The contents of Chapter 4 were initially published as an original contribution manuscript by the PhD 
candidate (Elliot Offman). The original manuscript has been edited and formatted according to thesis 
publication requirements. For reference purposes, the original publication is as follows: 
Offman E, Edginton AN. Pharmacokinetic Time Course Scaling of a Subcutaneously Administered 
Pegylated Peptide Conjugate for a First-in-Human Investigation. Eur J Drug Metab Pharmacokinet. Feb. 
2016 (epub ahead of print). 
The PhD candidate conducted all the pertinent research, conducted all described analyses, created all tables, 
plots and figures and wrote the entire manuscript. 
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4.1 Introduction 
As drug development transitions from preclinical to human phases, exposure and toxicology results 
obtained from preclinical animal species are used, in part, to inform the design of the first-in-human (FIH) 
investigation. For subcutaneously (SC) administered drugs, the time course, peak or maximum 
concentration (Cmax) and overall exposure as measured by area under the curve (AUC) in humans are 
important parameters for both study design (e.g. temporal placement of blood samples) and risk 
evaluation. Accurate prediction of the human pharmacokinetic profile can also mitigate the risk of 
protocol amendments associated with inadequate pharmacokinetic characterization and reduce the burden 
of interim pharmacokinetic evaluations throughout the FIH investigation. 
Reports on the prediction of macromolecule pharmacokinetic in humans have largely focused on the 
monoclonal antibody (mAb) class and in particular, IgG type mAbs.(57;61-64;100) Moreover, many of 
these reports focus on prediction capacity of methods following intravenous administration (IV). 
Prediction methods rooted in allometric theory have demonstrated utility in predicting human clearance 
(CL) and volume of distribution (Vd) for mAbs as well as some other classes of macromolecules 
exhibiting linear pharmacokinetic. Whereas traditional allometric methods for scaling pharmacokinetic 
parameters suggest using data obtained from three or more species across a wide range of species body 
weight (82), single species methods employing non-human primates (NHP) have also yielded reasonable 
results for predicting drug exposure after IV administration of mAbs(63;63). These methods however rely 
on empirically selected scaling factors to explain the relationship between species body weight and a 
mean or averaged pharmacokinetic parameter value, obtained from a small number of animals. While 
scaling an averaged pharmacokinetic parameter such as CL may provide an estimation of overall systemic 
exposure of a drug, this method provides no information as to the time course after administration (e.g. 
temporal relationship between dose time and time to Cmax). Dedrick plots, which do allow for an 
evaluation of the time course have demonstrated reasonable prediction capacity for mAbs, however to 
date, the utility of this method following extravascular administration has not been reported, nor is 
expected, as this method does not consider absorption processes.(61)  
More mechanistic, physiologically-based pharmacokinetic (PBPK) models incorporating lymphatic 
biodistribution facilitate prediction of the concentration vs. time profile after dosing and several authors 
have demonstrated the prediction capacity of these in silico approaches.(48;50;50;51;101;102) In most 
cases, however these reports are confined to the mAb class of drugs and following IV administration. 
More recently we reported the time course scaling of a pegylated peptide conjugate from NHP to humans 
after SC administration using a PBPK approach.(66) 
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While mAbs represent an important therapeutic class in pharmacologic treatment of disease, there 
remains a substantial collection of non-mAb macromolecules that exhibit varying biodistribution and CL 
properties. Cytokines, clotting factors, oligonucleotide derivatives and pegylated peptides represent 
important macromolecule classes in development for administration via the SC route. Although some 
reports suggest CL can be empirically scaled for these classes (56;58;103), reliable methods for predicting 
the time course of SC administered macromolecules are lacking, particularly for the non-mAb classes.  
In order for empiric methods to be confidently employed in a priori extrapolation of pharmacokinetic 
following SC administration, the relationship between species size and drug absorption (if one indeed 
exists) requires further evaluation. Richter et. al. (18) highlighted challenges in predicting the SC 
absorption of macromolecules across species, noting interspecies differences in skin anatomy, local 
catabolism and bioavailability (F), which leads to difficulty in extrapolating across species.  Woo and 
Jusko identified an inverse relationship between species body weight and first-order absorption rate 
constants following SC administration of erythropoietin to rats, monkeys and humans.(91) Similarly, 
Jolling et al. reported an inverse relationship for first-order absorption rate and body weight across several 
preclinical species in terms of a pegylated erythropoietin.(104) As such, and in spite of anatomical skin 
interspecies differences, there remains some potential to explain the relationship between species weight 
and absorption processes by an empiric relationship. 
The objective of this work was to illustrate a model-based scaling workflow for a priori optimization of 
study design for a FIH trial of a SC administered macromolecule employing empiric scaling factors and a 
single non-clinical animal species.  
4.2 Methods  
4.2.1 Study Design 
The exemplary molecule is a freely water soluble, linear PEG-40 conjugated peptide currently under 
clinical development, with a molecular weight of approximately 44 kDa. Drug concentration data was 
provided by the Sponsor of the research (withheld for commercial and proprietary purposes) following 
intravenous and SC administration in NHPs in a study not intended to meet compliance with good 
laboratory practices. . Nine non-naïve (previous exposure to other experimental treatments) female 
cynomologus NHP (mean weight 3.4 kg) were equally divided into three groups where each received 
either (1) a single 7 mg/kg intravenous dose (2) seven daily repeat SC 7 mg/kg doses or (3) a single 7 
mg/kg SC dose.  For SC doses, administration was to the back region. 
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The same drug was subsequently administered to a group of healthy male subjects participating in a FIH 
dose escalation study. Twenty healthy male subjects  (weight range 60-80 kg) received a single SC dose 
of either 45 mg, 90 mg, 180 mg, 360 mg or 720 mg to the abdominal region (n=4 subjects per cohort). 
The human study was conducted under good clinical practice and according the ethical principles outlined 
in the Declaration of Helsinki.  
4.2.2 Pharmacokinetic Sampling and Bioanalysis 
The blood collection schedule for quantitation of the administered drug was identical for all 3 NHP 
groups with 0.5-1 mL collected from the femoral vein immediately prior to the dose and 0.25, 0.5, 1, 4, 8, 
48, 72, 96, 120, 144, 168, 192, 216 and 336 hours after the dose (or after the first dose for the 7-day 
repeat-dose group). Following administration to humans, blood samples were collected from each subject 
immediately prior to the dose and 1,4,8,12,24,48,72,96,120,144,168,240,336,408,504,576,672 hours after 
the dose. Subjects participating in the highest dose cohort (720 mg) had an additional sample collected at 
1008 hours post-dose. Serum was analyzed from both species employing an LC-MS/MS method with a 
limit of quantitation of 1 μg/mL for both NHP and human matrices.  
4.2.3 Data Analysis and Population Pharmacokinetic Modeling 
Prior to using the concentration data for model fitting and scaling, plotting of the raw data was performed 
followed by non-compartmental analysis (NCA) to obtain initial estimates of the relevant 
pharmacokinetic parameters.  NCA and descriptive statistics were performed using Phoenix v 1.3 
WinNonlin version 6.3® (Pharsight, a Certara Company) and Excel (Microsoft). Population 
pharmacokinetic model development was performed using Phoenix NLME version 1.2 (Pharsight, a 
Certara company) using the First-Order Conditional Estimation with Interaction algorithm. All plots 
presented in this manuscript were produced using R with ggplot2 package.(105;106) Concentrations 
below the limit of quantitation (BLQ) were set to missing in all instances.   
4.2.4 Model Development  
Prior to scaling to human exposure, concentration data obtained from NHPs was first fit to a compartmental 
pharmacokinetic model using population pharmacokinetic estimation methods. Between-subject (or inter-
subject) variability was modeled assuming a log-normally distributed model as in Equation 4.1:  
Pi= TVP* exp
ηp  (4.1) 
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Where Pi represents the pharmacokinetic structural parameter in the i
th
 individual and is equal to a typical 
value of the parameter (TVP, i.e. the population mean value) plus some deviation (η) from that population 
mean value. Each ηp was assumed to be log-normally distributed with a mean of 0 and a variance of ω
2
.   
 
Residual error was modeled as a proportional error model for the base model taking the form of Equation 
4.2: 
COBS=CPRED*(1+ε)   (4.2) 
 
Where COBS is the observed concentration, CPRED is the population predicted value and ε is the deviation 
from the population predicted value and is assumed to be normally distributed with a mean of 0 and 
variance of σ2.  
Initially the IV route was modeled alone to obtain estimates for the systemic parameters of CL and Vd. 
Data was fit to 1-, 2- and 3-compartmental models.  
4.2.5 Model Evaluation 
The final model was selected based on individual data fit from diagnostic plots as well as the Akaike 
information criterion (AIC). Estimates for systemic parameters (i.e. CL and Vd) were then fixed to 
facilitate estimation of the parameters describing the absorption process for the SC route. Absorption 
processes tested included a single first-order absorption rate, dual first-order (with and without lag time) 
and mixed (zero- and first-order, with and without a lag-time on the first-order process). Based on the 
AIC and diagnostic plots the final model was selected for simultaneously fitting all available IV and SC 
data. As one group of NHP received daily dosing for 7 consecutive days, an inter-occasion effect was also 
tested for inclusion and influence on model diagnostics. Qualitative model discrimination was performed 
using visual predictive checks (VPC) where the model predicted median and 95
th
 percentile of the 
simulations are overlaid with the observed data and whereby adequate fit is judged when the observed 
data points fall largely within the 95
th
 percentile of the model predicted concentrations. 
4.2.6 Model Based Scaling 
Following final model development, human exposure following a single SC dose of drug was simulated by 
incorporating allometric scaling factors directly into the model prior to simulation. Population predicted 
typical values of structural parameters estimated in the NHP were multiplied by the weight-based ratio of 
human: monkey, raised to an exponent using the form in Equation 4.3: 
 
TVPhuman  = TVPmonkey *(Weighthuman/Weightmonkey)
exponent  
(4.3) 
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Prior to simulating the scaled concentrations for the human population, a population of 1000 unique 
individual body weights for humans was first simulated assuming a range of body weights corresponding 
to the human study.  
 
Four scenarios were tested. The first scenario employed a fitting process, whereby the exponent was 
estimated in Phoenix NLME using the naïve pooled engine for the first dosing cohort (i.e. 45 mg) and 
then the estimated scaling factors were used to predict the concentrations for all 5 dosing cohorts 
simultaneously. Additional scenarios testing theoretical allometric scaling previously demonstrated to 
support allometric scaling of IV administered large molecules were applied to CL and Vd parameters. 
Scaling of the absorption processes assumed an inverse relationship with species body weight based on 
previous observations in SC administered macromolecules. 
 
4.3 Results 
4.3.1 Samples Included in the Analysis 
In the NHP dataset, 144 samples were included in the population analysis of which 22 (15.2%) were 
noted as BLQ. For the human dataset, 355 samples were collected, of which 44 (12.3%) were noted as 
BLQ and four samples with no result available. As the database was not finalized, a demographic 
summary of the human male subjects who participated in the trial was not available at the time of writing. 
4.3.2 Population Model Structure and Evaluation 
The overall structural model for the pegylated peptide conjugate in monkeys was best described by a 2-
compartment model with a single linear clearance process. The absorption aspect of the model, used to 
describe drug input into the body was best described with dual, parallel first-order processes, each rate 
associated with a fraction of the total absorbed dose and a lag-time associated with the slower of the two 
absorption processes (Figure 4.1). Initially a relative bioavailability term (Frel) was included; however the 
estimated Frel approached 1 suggesting essentially complete SC bioavailability, and therefore was 
dropped from the model with a corresponding improvement of the AIC. The amount of drug absorbed 
was then described as a fraction of the administered dose via each of the two first-order rate processes. 
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Figure 4.1: Structural population pharmacokinetic model for a 
pegylated peptide conjugate described as a 2-compartment 
model with parallel first-order absorption processes and linear 
elimination. Aa1 and Aa2 represent the mass of drug 
delivered to the SC tissue for absorption via the two 
independent absorption processes; Ka1, Ka2 are the first-order 
absorption rate constants; tlag represents the lag time 
associated with the first absorption compartment; F1 and 1-F1 
represent the fraction of the absorbed dose associated with the 
respective absorption compartments; Vd, CL, Vd2, CL2 are 
the volume and clearance associated with the central and 
distributional compartments.  Vd volume of distribution of the 
central compartment, Vd2 distributional compartment volume, 
CL clearance from the central compartment, CL2 
distributional clearance, Ka1 absorption rate constant 1, Ka2 
absorption rate constant 2, F1 and (1 - F1) are the relative 
proportions of absorbed dose via each of the absorption rates 
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Final model parameters were estimated with good precision (Table 4.1). Random effects were included 
for both the central volume and clearance process. Inclusion of an interoccassion variability parameter 
(IOV) on the bioavailability parameter did not improve the model diagnostics and therefore was removed 
from the model. The impact of IOV on CL or Vd was not assessed as it was deemed unlikely that either 
parameter was time-dependent based on a comparison of single vs. repeat daily doses at the 7 mg/kg dose 
level (data not shown). As data for only a single dose level was available to test, it was assumed that non-
linearity in either absorption or elimination processes could not be properly assessed. As the NHP were of 
similar age and body weight, no specific anthropometric covariates were tested in this analysis. 
Diagnostic plots and visual predictive checks (Figures 4.2 and 4.3) suggested reasonable model fit. 
Consequently the model was deemed appropriate for the model-based allometric scaling step. 
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Table 4.1: Population pharmacokinetic model derived parameter estimates for a pegylated peptide 
conjugate in cynomologus monkeys following simultaneous estimation of concentration data 
obtained after administration of   single 7 mg/kg intravenous and SC doses and daily SC doses for 
seven days.  
 
Parameter Estimate CV% 
Vd (L) 0.11 8.77 
CL (L/hr) 0.00059 7.84 
Vd2 (L/hr) 0.043 25.85 
CL2 (L/hr) 0.00092 46.70 
Ka1 (hr
-1
) 0.035 17.00 
F1 0.87 3.10 
Ka2 (hr
-1
) 0.23 26.31 
Lag-time (hr) 6.34 8.08 
Residual  
Error 
15 7.10 
 
SC subcutaneous, Vd volume of distribution of the central compartment, Vd2 distributional compartment volume, CL clearance from 
the central compartment, CL2 distributional clearance, Ka1 absorption rate constant 1, Ka2 absorption rate constant 2, F1 relative 
proportion of absorbed dose, CV% coefficient of variation/relative standard error of the parameter estimate 
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Figure 4.2a: Model diagnostic plots for the final population 
pharmacokinetic model describing a single 7 mg/kg dose 
administered intravenously and single and multiple 7 mg/kg 
doses administered subcutaneously to cynomologus monkeys. 
Closed circles represent the observed vs. population predicted 
concentrations and the dashed line is the line of identity.  
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Figure 4.2b: Model diagnostic plots for the final population 
pharmacokinetic model describing a single 7 mg/kg dose 
administered intravenously and single and multiple 7 mg/kg 
doses administered subcutaneously to cynomologus NHPs. 
Closed circles represent the conditional weighted residuals vs. 
predicted concentrations with solid line as the loess fit. 
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Figure 4.3: 5th, 50th and 95th percentile of simulated 
concentrations (solid lines) vs. observed concentrations (solid 
circles) in cynomologus monkeys following a single 
intravenous dose (top panel), seven daily repeated 
subcutaneous doses (middle panel) and a single subcutaneous 
dose (bottom panel). For single dose IV and SC groups, 
pharmacokinetic samples were drawn sequentially over a 336 
hour post-dose period. For the seven daily repeat dose group, 
pharmacokinetic samples were drawn at 1, 4 and 8 hours after 
the first dose, then every 24 hours from days 2-9 with an 
additional sample drawn on day 15.  IV intravenous, SC 
subcutaneous 
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4.3.3 Model Based Scaling  
Figures 4.4a and 4.4b graphically display the prediction accuracy of the four tested scenarios. Scenarios are 
presented in both linear-x/linear-y and log-x/log-y scales to allow for appreciation of prediction capacity in 
the various portions of the concentration vs. time profile. Specifically, in Figure 4.4a, the linear-x/linear-y 
scale allows the best appreciation of the prediction accuracy of the peak (Cmax), whereas in contrast, the 
log-x/log-y curve facilitates the best appreciation of prediction accuracy for the early time points critical in 
evaluating the full absorption phase. Overall, absorption, peak and elimination phases of the curve were best 
described in Scenario 3, which assumed empiric exponents of 1 on clearance and volume parameters and -
0.4 on absorption parameters. Estimation of the scaling factor exponents in the first dosing cohort (Scenario 
1) resulted in a reasonable prediction of the absorption phase across all 5 dosing cohorts with the exception 
of the initial 10-20 hours post-dose. Although not obvious from the log-log plot, linear scale plots suggest 
Cmax was under predicted in this case, which was particularly evident in the highest dose cohort. Assuming 
empiric scaling factors of 0.85, 1 and -0.4 (Scenario 2) for CL did not appreciably alter the absorption phase 
predictions however over-estimated the elimination phase of the curve, whereas assuming an exponent of 1 
resulted in a poor prediction of the absorption and peak phases of the profiles. 
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Figure 4.4a (linear-x/linear-y) and 4b (log-x/log-y): 
Experimentally obtained concentrations across 5 dose cohorts 
in humans (symbols) and  5th-95th model scaled simulated 
concentrations (shaded region) for each corresponding dose 
level. Scenario 1: Scaling factors fit on lowest dose cohort (45 
mg) and fitted exponents applied to simulations for all 
subsequent dosing cohorts; Scenario 2:exponent of 1 on Vd & 
Vd2; 0.85 on CL and CL2; -0.4 on Ka1 and Ka2; Scenario 
3:exponent of 1 on Vd & Vd2, CL and CL2; -0.4 on Ka1 and 
Ka2; Scenario 4: assumes an exponent of 1 on all model 
parameters. Vd volume of distribution of the central 
compartment, Vd2 distributional compartment volume, CL 
clearance from the central compartment, CL2 distributional 
clearance, Ka1 absorption rate constant 1, Ka2 absorption rate 
constant 2 
 
Figure 4.4a 
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Figure 4.4b 
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4.4 Discussion 
Model-based approaches to support extrapolation of pharmacokinetic exposure is an important element of 
ensuring appropriate dose selection for testing in early human trials. Population pharmacokinetic model-
based scaling may be  particularly useful in estimating the pharmacokinetic parameters in animal studies 
where sparse sampling and a small number of individual animals is studied. Incorporating allometric scaling 
factors into a population pharmacokinetic model is a fairly commonplace methodology for describing 
pharmacokinetic within-species size relationships in adults and children. (107;108) However these 
evaluations have tended to be retrospective and interpolative in nature, describing the relationship among 
data from a range of individuals.  
 
Although retrospective in nature, the current investigation considers an extrapolative workflow which has 
application in the prospective prediction of the pharmacokinetic time course of a SC administered 
macromolecule to guide study design for an FIH. We employed both fitted and empiric approaches for 
scaling exponents used to relate body weight to population model pharmacokinetic parameters to evaluate 
whether empiric exponents would have potential value in an a priori scenario. 
 
There are challenges in extrapolating the SC pharmacokinetic from animals to humans particularly due to 
interspecies difference in the skin anatomy and physiology and potential differences in SC bioavailability 
where the drug may be broken down at the site of administration and/or prior to the initial appearance in the 
venous circulation. Bioavailability following extravascular administration of macromolecules may be, in 
part, a function of the lymphatic transit time.(109) 
 
In the current investigation, the fraction of the absorbed dose (F), which is a surrogate for extravascular 
bioavailability, was assumed to scale directly across species. This assumption removed a significant level of 
complexity from the scaling step although, based on historical evaluation, this assumption would be unlikely 
to apply to all species and all macromolecules, (18) However for the current investigation, given that SC 
bioavailability in NHPs was essentially complete, human SC bioavailability was similarly assumed. 
Additional considerations in the model scaling step may be required to account for potential differences in 
SC bioavailability for different compounds where the bioavailability varies substantially across species. 
 
The present investigation supports previously published reports where single-species NHP-derived 
macromolecule clearance and volume parameters were scaled with reasonable error to human values based 
on body weight raised to some empiric scaling factor. Successful predictions for macromolecules tend to be 
positive, ranging from 0.75 to 1 for clearance and approximately proportional to body weight for volume 
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parameters.(61-64) In contrast, the rate of input into the systemic circulation suggests an inverse relationship 
between species body weight and ka. Although few reports have examined this relationship our observations 
are also consistent in direction and magnitude with the scaling factor estimate across rat, NHP and humans 
for erythropoietin.(91) Jolling et. al. observed a similar relationship for a pegylated erythropoietin, where the 
first-order absorption rate constant scaled across several preclinical species and humans with an exponent of 
-0.149.(104) Neither physiologic nor anatomic explanations were provided in previous reports for an inverse 
relationship between body weight and absorption rate following SC administration. Absorption of  large 
molecules from the SC space into the lymphatics is influenced by lymph flow.(18;109;110) Consequently, 
interspecies differences in lymph flow, particularly as it pertains to skin lymph flow, may underlie the 
slower absorption from the SC into the systemic circulation in humans relative to smaller mammalian 
species. Recently, using the same concentration data for both monkey and human as in the current 
manuscript, we developed a PBPK model in NHPs which was then demonstrated to scale the concentration 
vs. time profile to humans across a range of doses. In order to achieve line shape consistency with the 
simulated and observed data, a slower skin lymph flow was required in humans relative to NHPs.(66) A 
striated muscle, the panniculus carnosus, is located in the hypodermis of many preclinical animal species. 
This muscle is absent in humans and in higher order NHPs and has been suggested to at least in part, 
influence interspecies differences in drug absorption from the SC space.(18) Humans and furless animals 
also have fibrous bands that anchor the subcutaneous layer of skin and may reduce compliance and elasticity 
of the skin tissue, potentially resulting in slower transit from the SC space into the lymphatic transport 
system.(36) Although empiric in nature, an inverse mathematical expression relating absorption rate to 
species body weight seems to explain  the observations in the current investigation and explains similar 
observations by others.(91;104)  The precise numerical value for this inverse scaling factor may differ 
depending on the molecule and the number of different species included in the exponent estimation step. 
Pegylated and non-pegylated erythropoietin have molecular weights of 35 and 30 kDa, respectively, and yet 
estimated exponents  were  -0.149 and -0.349, respectively.(91;104;111) In these investigations however, 
several preclinical species including rat, rabbit, monkey and dog were included in the model parameter 
estimation process. Mager and colleagues independently fit recombinant human interferon β-1a to a target-
mediated drug disposition model with first-order absorption in both human and rhesus monkeys.(41;42) 
Slow first-order rate constants of 0.104 hr
-1
 and 0.0414 hr
-1
 were estimated in monkeys and humans, 
respectively. Based on Equation (1) in the current manuscript, and considering an average body weight of 
approximately 3 kg for the monkeys and 70 kg for humans, a scaling factor exponent of -0.3 can explain the 
observed relationship in that publication.(91)  
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It should also be noted that the scaling factor obtained by fitting the first dosing cohort (-0.49, Table 4.2) in 
the human study was very close to the empiric value of -0.4 with only a modest improvement in the 
objective function for the fitted value. For future prospective extrapolation, a precise negative exponent 
cannot yet be proposed which would apply to all macromolecules. However in the context of predicting the 
exposure vs. time profile in humans based on a single NHP species, an inverse relationship between body 
weight and first-order rate constants appear to scale reasonably well within a range of -0.3 to -0.5. This 
relationship may be rooted in anatomical and physiologic interspecies differences such as skin lymph flow. 
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 Table 4.2: Model-based scaling scenarios and corresponding prediction objective functions. 
 
Scenario Exponent Source Parameter Exponent 
Used in 
Simulation 
Objective 
Function 
  
(1) Fitted Scaling Exponent 
fit from 1
st
 human dose 
cohort 
CL, CL2 1.42 40.06   
  Vd, Vd2 1.28    
  Ka1, Ka2 -0.49    
(2) Empiric Scaling Exponent CL, CL2 0.85 74.12   
  Vd, Vd2 1    
  Ka1, Ka2 -0.4    
(3) Empiric Scaling Exponent CL, CL2 1 55.08   
  Vd, Vd2 1    
  Ka1, Ka2 -0.4    
(4)  Empiric Scaling Exponent CL, CL2 1 497.11   
  V, V2 1    
  Ka1, Ka2 1    
Vd volume of distribution of the central compartment, Vd2 distributional compartment volume, CL clearance from the central 
compartment, CL2 distributional clearance, Ka1 absorption rate constant 1, Ka2 absorption rate constant 2 
4.1 Conclusion 
 
In conclusion, predicting the full time course of a macromolecule following SC administration for a FIH 
trial first requires estimation of absorption processes in preclinical development. Simulations suggest that an 
inverse relationship exists between species body weight and first-order absorption processes. An a priori 
workflow integrating empirically selected scaling factors into a population pharmacokinetic model may 
provide for an adequate prediction of the time course for pegylated macromolecules exhibiting linear 
pharmacokinetic with essentially complete bioavailability. 
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CHAPTER 5: A PBPK WORKFLOW FOR FIRST-IN-HUMAN DOSE SELECTION OF A 
SUBCUTANEOUSLY ADMINISTERED PEGYLATED PEPTIDE 
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The contents of Chapter 5 were initially published as an original contribution manuscript by the PhD. 
candidate (Elliot Offman). The original manuscript has been edited and formatted according to thesis 
publication requirements. For reference purposes, the original publication is as follows: 
Offman E, Edginton AN. A PBPK workflow for first-in-human dose selection of a subcutaneously 
administered pegylated peptide. J Pharmacokinet Pharmacodyn. 2015; 42(2):135-50 
The PhD candidate conducted all the pertinent research, conducted all described analyses, created all tables, 
plots and figures and wrote the entire manuscript. 
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5.1 Background 
Predicting the time course of drugs in humans from animal species following subcutaneous (SC) 
administration has been challenging. No single method has been demonstrated to be superior or even 
consistent in terms of prediction accuracy. Furthermore, none appear to be influenced by whether the 
compound is a peptide/protein or a smaller synthetic compound. This is in contrast to the intravenous (IV) 
route of protein administration, where human pharmacokinetics (PK) can be reasonably predicted within <2-
fold based on single-species simplified allometric techniques using non-human primate data.(55;61;63) The 
PK following SC administration is complicated by the absorption into the systemic circulation via lymphatic 
and vascular pathways. Supersaxo et al (17) initially identified that interferon 2a appeared in significant 
mass when cannulating the efferent popliteal lymphatic duct in sheep following SC administration whereas 
lymphatic presence of drug was minimal when administered via the IV or intradermal route. Later, 
Supersaxo (16) reported that compounds with molecular weight (MW) less than 1 kDa exhibited little 
lymphatic absorption with increasing tendency for lymphatic transport as the  MW increased above 16 kDa. 
These findings can potentially be extended to larger proteins and other mammalian species. Recently it has 
been reported that trastuzumab (15) was preferentially absorbed via the lymphatic route following SC 
administration in rats and Wang (19) has reported pegylated erythropoetin and inteferon exhibited 
significant lymphatic uptake from the SC space in rats and dogs. Richter (18) more recently reported that 
molecules with diameters less than 10 nm are capable of diffusing from the SC space into vasculature. 
However, molecules with diameters greater than 10 nm have a preferential and progressively greater 
proportion of lymphatic uptake with increases in size. The latter observations are consistent with a 2-pore 
theory where molecules of a certain size threshold become too large to diffuse from the SC space into the 
vasculature.(10;112) 
 
There is value in developing mechanistic methods for not only predicting the time profile after SC 
administration, but also the SC bioavailability, for the purposes of scaling from animals to humans. 
Conventional allometric scaling of new chemical entities (NCE) has historically relied on evaluation of 
mean clearance (CL) values obtained in one or more preclinical species as a means of estimating exposure 
and dose selection for first-in-human (FIH)/single-ascending dose (SAD) studies. This approach provides 
little information on the time course of drug exposure after administration which may impact the safety and 
tolerability of the NCE. Moreover, allometric techniques employing clearance scaling are further 
confounded by non-linear PK and bioavailability (for extravascular administration). The SC exposure time 
course of therapeutic proteins has been particularly challenging to predict in light of the interspecies 
differences in skin anatomy and physiology as well as a general lack of understanding of factors impacting 
SC bioavailability differences. 
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Work by Zhao (109) and Kagan (113) have focused on the more mechanistic determinants of SC 
bioavailability, considering site of administration, volume of the injection site space and, in the case of 
mAbs, binding to the Brambell receptor (FcRN)  at the site of injection. Such reports have either used 
compartmental modeling to describe the absorption process or employed a hybrid compartmental-
physiologic model.  Although predictions of observed data may have been successful, these methods are 
largely top down approaches. Meaning, the models are predicated on the assumption of having data 
describing the drug absorption to obtain an absorption rate constant and bioavailability fraction  (113) which 
cannot be assumed to scale across species. 
 
In most cases, the ultimate goal of studying the PK of a macromolecule is to translate findings to humans. 
There is no agreement on which species represents the best model for projecting the SC time course of 
therapeutic macromolecules, if one even exists. For SC administration, investigators have argued that the 
subcutaneous tissue of monkeys is dissimilar to human and have proposed the use of the minipig.(114) 
However, given the impact of target mediated drug disposition (TMDD), it is questionable as to whether the 
benefit of an animal model being employed due to similarity in skin anatomy overrides the overall benefit of 
using a species more inclined to express the drugs intended target. Regardless, where monkeys are 
employed, typically small sample sizes are used, thus limiting the interpretation of PK data, especially when 
variable. 
 
Physiologically-based pharmacokinetic (PBPK) approaches have demonstrated utility in predicting the time-
course of therapeutic proteins when administered intravenously.(47;48;50;51) However there is little 
published data supporting its success with SC administration in any species, and less evidence for scaling of 
SC bioavailability from an animal species to human using this method.  Given the appetite for therapeutic 
macromolecules to be administered via the SC route there is particular utility in the application of PBPK 
modeling in the planning and conduct of FIH/SAD studies. This modeling technique allows for the results 
of non-clinical work to be extrapolated to humans based on interspecies differences in anatomy and 
physiology without necessarily testing an IV formulation in humans. Herein we present a workflow for 
translating single-dose IV and SC PK from a single non-human primate species to the human scale using a 
PBPK modeling approach for the purposes of planning and refining a FIH dose selection. 
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5.2 Methods 
 
The workflow is comprised of 4 stages: 
1) Simulation of the primate IV PK and optimization of the model parameters 
2) Simulation of the primate SC PK to verify the model can adequately predict concentrations 
following SC administration 
3) Scale up of the model to humans and simulation of the PK following SC administration under 
human clinical trial conditions 
4) Optimize human model and simulate future dose cohorts 
 
5.2.1 Observed Datasets 
Observed data was obtained for 3 non-naïve (previous exposure to other experimental treatments) female 
cynomolgus monkeys (mean weight 3.4 kg), each receiving a single 7 mg/kg intravenous dose of a 
proprietary (name and target withheld for commercial proprietary purposes) freely water soluble, linear 
PEG-40 conjugated peptide, with a molecular weight of approximately 44 kDa.  Drug was infused as a 
bolus in 5% dextrose in water. Serial blood samples were quantified for the pegylated conjugate at pre-dose 
and post-dose at 5, 15, 30 min, 1, 4, and 8 hours on Day 1; 0 hrs on Days 2-9 and Day 15 (360 hours post-
dose). An additional 3 cynomolgus monkeys were administered the same dose via the SC route to the back 
region with the same sampling schedule.  
 
As part of a single-dose escalation study in healthy volunteers, concentration data was provided by the 
Sponsor for the same peptide measured in 4 males (weight range 60-80 kg) receiving a single, SC fixed 45 
mg dose into the abdominal region with sampling up until approximately 504 hours. This initial dose level 
was used to test the human model assumptions and two subsequent dose levels (90 mg and 180 mg) were 
used to confirm prediction potential.  
 
A graphical depiction of a typical FIH combined SAD and multiple-ascending dose (MAD) and the 
overaching workflow in the context of a FIH program are presented in Figure 5.1.  
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Figure 5.1: Graphical depiction (top panel) of a first-in-human 
(FIH) combined single-ascending dose (SAD) /multiple-
ascending dose (MAD) program in healthy volunteers (HV). 
Proposed workflow (bottom panel) for incorporating the 
PBPK model process for a FIH study.  
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Non-compartmental analysis (NCA) was performed (Phoenix WinNonlin v 6.3, Pharsight) on the primate 
IV and SC data to obtain initial estimates of the PK parameters as well as to calculate absolute 
bioavailability of the SC route. 
 
5.2.2 Development of the Base PBPK Model for IV Administration in Cynomolgus Monkeys 
For ease of visualization of the simulated vs. observed IV & SC data, model building was performed using 
Berkeley Madonna (v8.3.1.8; http://www.berkeleymadonna.com). The model was then recoded in 
Pharsight Modeling Language (PML) for executing within the Phoenix NLME platform (v1.2, Certara). 
Select mass balance equations are presented in Appendix 5.1 and the full code for Berkley Madonna is 
provided in the Supplementary material section. All concentration vs. time profile figures were produced in 
R.(105) 
 
5.2.3 Model Structure 
The proposed overall and sub-compartment structures are based in part on the PBPK platform developed 
previously by Shah and Betts (50) and is depicted graphically in Figures 5.2a and 5.2b. The overall structure 
consists of a unique compartment for each of the venous and arterial circulation, a lymph node compartment 
and 15 individual organs where each organ consists of a vascular and interstitial sub-compartment. For IV 
administration, the drug is administered directly into the venous supply and is carried to the lung at a rate 
equal to hematocrit-corrected cardiac output. Once in the lung vasculature, a fraction of the drug is 
convectively transported from the plasma to the interstitial compartment; a process partially defined by a 
vascular reflection coefficient (σv). Drug in interstitium then transits into the lymphatic supply which is 
partially defined by a lymphatic reflection coefficient (σisf). The remaining drug is carried into the arterial 
supply for distribution into the remaining organs according to the plasma flow rate supplying each organ. 
Plasma flow from the intestines, pancreas and spleen empty into the liver. In each organ, convective 
transport from plasma to interstitial space and ultimately to lymph occurs, with lymph transit eventually 
returning drug to the venous system. The skin interstitial compartment is sub-divided further into a depot 
and residual space to account for SC administration. The volume of the depot interstitial compartment was 
set at the actual volume administered for each of the species tested, based on the assumption that as fluid is 
injected into the SC space expansion to accommodate the volume would occur due to the nature of the 
extracellular matrix components in the SC space. The proportion of lymph flow assigned to skin and depot 
interstitium was assumed to be proportional to the respective volumes relative to the total skin interstitial 
space. 
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Figure 5.2a: Structure of a whole-body PBPK platform 
(adapted from Shah & Betts 2012). Solid black arrows 
indicate plasma flow. Dark grey dashed arrows indicate 
lymphatic transport. S. Int. and L. Int. represent small and 
large intestines. Each organ compartment includes lymphatic 
flow emptying from the organ into the lymph node. For IV 
administration, drug is administered into the “Venous 
Supply”. For SC administration, drug is administered into the 
“Skin Compartment” interstitium (see Figure 5.2b) 
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Figure 5.2b: Structure of the proposed subcompartment 
model. Drug enters the organ plasma vascular space via the 
arterial circulation.  Q and L refer to blood flow and lymph 
flow. The symbol σ refers to a reflection coefficient, where σ 
v is the vascular reflection coefficient and σ isf is the 
interstitial reflection coefficient. For SC administration, drug 
is administered directly into a fraction of the skin interstitial 
space. 
 
 
 
Organ volumes and blood flow rates for both primates and humans were obtained from the BioDmet 
database (http://pdsl.research.ge.com/BioDMET/).(115) The fraction vascular (Fvv) and interstitial (Fvic) 
were obtained from Kawai et al (116) and hematocrit values from Davies and Morris.(99) A listing of the 
anatomical and physiological values can be found in Appendix 5.2. Lymphatic flow (L) was set at a fraction 
of blood flow (i.e. where blood flow was divided by 500 to obtain the lymph flow) to each organ as per 
Swartz.(21) The vascular reflection coefficients for each organ (σv) were taken from Shah and Betts (50) 
however, each organ σv was scaled to a single scaling factor (σv,sf) to reduce the number of organ σv 
parameters needed to be optimized to 1. Lymphatic reflection coefficients (σisf) were set at 0.2 based on 
Garg and Balthasar.(102) 
 
Although the clearance mechanism has not been formally evaluated for this pegylated conjugate, clearance 
is believed to occur via a renal and a non-renal pathway. A renal clearance process was incorporated into the 
kidney vascular compartment. Although the drug is considered a macromolecule, evidence suggests that 
high molecular weight pegylated compounds can be cleared renally at about 0.1%  of the glomerular 
filtration rate (GFR).(25;97) Consequently, the fraction of GFR (FGFR) responsible for renal clearance was 
set at 0.1% of GFR. The value of GFR in cynomolgus monkeys was taken as the midpoint of previously 
reported values i.e. 2.41-2.61 mL/min/kg.(117) A non-renal clearance was also included to account for 
opsonisation whereby the drug-target complex acts as a signal for phagocytosis by macrophages. A non-
specific, non-renal clearance (NRCL) was incorporated into the model within each organ vascular and 
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interstitial compartment. According to Gordon (118) macrophages do not enter efferent lymphatics or the 
thoracic duct and therefore the clearance process was not included in the lymphatic compartment. From the 
NCA of the primate IV bolus data, total clearance was estimated to be approximately 0.181 mL/hr/kg. 
Subtracting the renal component (i.e. 0.1 % of GFR, i.e. 0.12 mL/hr/kg) resulted in an initial estimated 
NRCL of 0.061 ml/hr/kg. NRCL was assumed to be uniform in each compartment where macrophagic-
mediated clearance occurs and the total NRCL was then partitioned in a manner proportional to the volume 
of the compartment.  
5.2.4 Primate IV model optimization 
Parameters associated with the greatest uncertainty were estimated by fitting the observed concentration of 
drug in plasma using NLME assuming a proportional residual error model (Equation 5.1): 
 
Cobserved=C•(1+ε)  (5.1) 
 
where Cobserved is the observed concentration, C is the fitted predicted value and ε is the deviation from the 
predicted value and is assumed to be normally distributed with a mean of 0 and variance of σ2. 
Due to the uncertainty in the parameters of L, σisf, σv,sf, and NRCL, these parameters were initially fit with 
all other parameters fixed at anatomical/physiological values. However due to the sparseness of the data and 
potential identifiability issues, precision could not be estimated for each of the four listed parameters. Of 
these four, the parameters assumed to have the greatest uncertainty that could be fitted with precision, (i.e. 
σv,sf and NRCL) were the only two parameters allowed to fit in the initial IV model development step with 
all other parameters being fixed at literature or experimentally obtained values as described in Appendix 5.2 
and Table 5.1. 
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Table 5.1: Parameter estimates following a single IV administration (7 mg/kg) to cynomologus 
monkeys and scaling of the model to humans for SC administration 
 
Parameter/Species 
(units) 
Definition Estimate Fitted CV% 
Cynomologus Monkey     
     
σv,sf Vascular reflection coefficient scaling factor 
 
0.96 Fitted 1.41 
NRCLcynomologus 
(ml/kg/hr) 
Non-renal/non-specific clearance mechanism in 
monkeys 
0.196 Fitted 17.91 
σisf Interstitial reflection coefficient 0.2 Fixed N/A 
FGFR Fraction of glomerular filtration rate 0.001 Fixed N/A 
L Numerical value blood flow was divided by to obtain 
lymph flow value  
 
500 Fixed N/A 
Residual Error / 0.13 Fitted 10.67 
     
Human     
     
Sigma_v_scaling 
factor 
/ 0.96 Fixed N/A 
NRCLhuman  (ml/kg) Non-renal/non-specific clearance mechanism in 
humans 
8.71 Scaled N/A 
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σisf / 0.2 Fixed N/A 
FGFR / 0.001 Fixed N/A 
L / 500 Fixed N/A 
LS Numerical value blood flow was divided by to obtain 
skin lymph flow value 
1000 Fitted 11.29 
N/A: Not applicable for fixed parameters 
Fixed parameters imply the parameter was fixed at the literature or experimentally obtained value 
Fitted implies the value was obtained through a minimization algorithm using Phoenix NLME  
NRCLhuman was allometrically scaled according to body weight to an empiric exponent of 0.85 
 
Sensitivity analysis was performed on the IV bolus model by perturbing the value of the parameters with the 
greatest uncertainty and re-simulating the concentration vs. time profile at each perturbation. For the 
parameters FGFR, NRCL and σisf, the null parameters were each perturbed by ± 10%. For  σv,sf the estimate 
could not be perturbed by more than 5% upwards as this would have increased the vascular reflection 
coefficient for the brain to >1.The parameter L was varied from 500 down to 100 as this is the range of 
reported values for this parameter.(21) Individual plasma concentration vs. time profiles for each of the 3 
monkeys who received IV drug was simulated for each of the perturbed conditions. The mean area under the 
curve (AUC) calculated by NCA for each of the perturbed datasets (AUCperterbed) was compared to the mean 
of the null (AUCnull) using % change [(AUCperterbed –AUCnull)/AUCnull]. 
 
5.2.5 SC Administration in Monkeys and Humans 
For SC administration in monkeys, all systemic parameters defined or optimized in the IV model were held 
constant. The simulated bioavailability was calculated and compared to the observed bioavailability.  
For translation to humans, the model was adapted to include human organ volumes, GFR, cardiac output, 
hematocrit and relative flow of blood to each organ. Fvv and Fvic were assumed to be constant across 
species. The non-renal clearance (NRCL) was scaled assuming the principles of simplified allometry with a 
fixed exponent of 0.85 which has been demonstrated to be a reasonable scaling factor from primates to 
humans in previous reports.(55;62-64)  
 
At the time of this writing, the randomization scheme for the human study was still in a blinded stage and 
therefore the precise body weights of the subjects included was unknown and therefore an assumption of 70 
kg (midpoint of the inclusion weight range for the study) was used for human simulations.   
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After comparison of the first human cohort observed data to the simulated profile, optimization was 
performed whereby skin lymph flow as a fraction of skin blood flow (LS) was fitted as a parameter rather 
than fixed to the previous value of 500.  The optimized model was used to re-simulate the first dosing cohort 
(i.e. 45 mg single SC dose) as well as two subsequent dosing cohorts (90 mg and 180 mg) for which data 
was available at the time of this writing. 
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5.3 Results 
5.3.1 IV Model Structure and Optimization 
Prior to optimization, the model demonstrated reasonable fit with the observed data. However, through the 
fitting process, the NRCL was estimated with precision at a considerably higher value than initially 
estimated (Table 5.1). Goodness of fit plots (Figure 5.3) including an overlay of the observed and simulated 
profiles (Figure 5.4) demonstrate high agreement between simulated and observed IV data in all three 
cynomolgus monkeys included in this analysis.   
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Figure 5.3: Diagnostic plots for the IV model fit. Left panel 
illustrates the relationship between individual predicted 
concentrations (IPRED) obtained from a single-dose 7 mg/kg 
IV administration to 3 cynomologus monkeys. Closed 
symbols represent observed vs. predicted concentrations and 
dashed line represents the line of identity. Right panel 
illustrates the distribution of weighted residuals vs. IPRED 
(closed symbols) from the IV model in cynomologus 
monkeys. 
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Figure 5.4: Plasma concentrations of a linear PEG-40 
conjugated peptide versus time in 3 cynomolgus monkeys 
following a single 7 mg/kg IV dose, displaying a linear (top 
panel) and semi-log (bottom panel) scale for concentration .  
Closed symbols are measured values and lines are model 
simulations 
 
5.3.2 Sensitivity Analysis 
The sensitivity analysis suggested that AUC was sensitive to each of the parameters tested, with the greatest 
sensitivity associated with σv,sf (Table 5.2).  Lymph flow as a fraction of blood flow (L), which when varied 
by 5-fold, changed the AUC by 4% demonstrating that for IV administration, lymph flow, which is 
uncertain, was not influential in describing overall exposure via the IV route in monkeys. Taken together, 
these results suggest that the most influential factor in the drugs overall exposure appears to be the 
convective transport across the vascular endothelium into the interstitial space.  
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Table5.2: Change in AUC as a result of parameter perturbation within the IV cynomologus monkey PBPK 
model. 
Parameter & % 
Perturbation 
Definition AUClast 
(ug/mL*hr) 
% Change 
from Null 
Null/Base Model Base human model without optimization 28550 - 
FGFR +10% Fraction of glomerular filtration rate 27612 3.3 
FGFR -10% / 29540 -3.5 
NRCL +10% Non-renal/non-specific clearance mechanism 28143 1.4 
NRCL -10% / 28955 -1.4 
L100 Numerical value blood flow was divided by to 
obtain lymph flow value 
27407 4.0 
σisf +10% Interstitial reflection coefficient 28409 0.5 
σisf -10% / 28687 -0.5 
σv,sf +5% Vascular reflection coefficient scaling factor 31690 -11.0 
σv,sf -10% / 23846 16.5 
 
5.3.3 SC Administration in Monkeys and Humans 
Simulating the concentration vs. time profile when the dose was administered into the SC depot also showed 
agreement with the observed data in monkeys (Figure 5.5). No optimization was performed in the 
generation of the SC monkey simulations. The absorption phase was well described by the model. 
Comparison of the simulated SC AUC relative to the simulated IV time course resulted in a similar 
bioavailability to that estimated by comparing the NCA-derived AUCs of the observed data (90% for 
simulated vs. 89% for observed). Therefore the model was considered adequate to scale to human by 
substituting organ size, blood flow rates, GFR and NRCL. 
 
 
Figure 5.5: Plasma concentrations of a linear PEG-40 
conjugated peptide versus time in 3 cynomolgus monkeys 
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following a single 7 mg/kg SC dose, displaying a linear (top 
panel) and semi-log (bottom panel) scale for concentration .  
Closed symbols are measured values and lines are model 
predictions.  
 
 
Figure 5.6 (solid line) presents the simulated human profile when administering a fixed 45 mg dose of the 
PEG-40 conjugated peptide to the SC depot compartment relative to the observed data from four healthy 
male participants in the first cohort of a FIH dose escalation study.  
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Figure 5.6: Model simulated and observed plasma 
concentrations of a linear PEG-40 conjugated peptide versus 
time in humans.  The solid line represents the simulated 
concentrations from the null human model after scaling (as 
described in the methods section). The dashed line represents 
the simulated concentrations after adjustment for lymph flow 
from the skin (LS). Closed geometric symbols represent 
unique individual subjects in the first single-ascending dose 
cohort, receiving a single 45 mg SC dose to the abdominal 
region. 
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Although the observed data had a slower input than what was predicted from the model, the peak (Cmax) 
and overall exposure (AUC) as estimated by NCA, were within 24% and 30% of the mean observed data 
(Table 5.3), respectively, indicating that the time course was relatively well predicted. In line with the 
graphical comparison, the time to Cmax (Tmax) was somewhat earlier than what was observed, however the 
observed median value was influenced by one of the four subjects who had a distinguishably different 
profile than the other three subjects. Optimization of the parameter LS resulted in a value of 1000 with high 
precision (Table 5.1) and produced a simulation which described the observed data more closely than the 
null model (Figure 5.6 – dashed line). The simulated Cmax and AUC values differed by only 11% and 25%, 
respectively, from the observed values. 
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Table 5.3: Key NCA-derived pharmacokinetic parameter comparisons of observed human subjects 
receiving a single SC (45 mg) dose compared to simulated data obtained from the null human 
model and after optimization of skin lymphatic flow (LS)  
 
 
 
 
 
 
 
 
  
Parameter 
(units) 
Sample 
Size  
Observed  
Dataset 
 
Simulated 
Dataset 
Simulated 
After 
Optimization 
of LS 
%Difference  
Observed 
vs. 
Predicted 
%Difference 
Observed vs 
Optimized 
 N Mean CV%     
AUC 
(ug/mL*hr) 4 2035 22.1 2888 2714 30 25 
Cmax  
(ug/mL) 4 6.64 8.34 8.78 7.50 24 11 
Tmax*  
(hr) 
4 156* 72.0-
336* 
72.0 120  
*Median (Min-Max reported for Tmax) 
LS: Numerical value blood flow was divided by to obtain skin lymph flow value 
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Applying the same mechanistic principles as for estimating the monkey absolute bioavailability, human SC 
absolute bioavailability was simulated to be 94% and 88% based on the null and optimized models, 
respectively.  As the LS optimized model appeared to better describe the absorption profile and overall time 
course of the SC administration, this version was used to simulate the next two dose cohorts (90 mg and 180 
mg) which successfully predicted the proportionally higher dose levels in terms of the time course and peak 
concentration (Figure 5.7).  
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Figure 5.7: Model predicted (solid line) and observed 
(symbols) plasma concentrations of a linear PEG-40 
conjugated peptide versus time in humans for subsequent 
cohorts at 2x and 4x the initial SC dose of 45 mg. Closed 
geometric symbols correspond to unique individual subjects in 
each cohort. 
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5.4 Discussion 
We undertook this effort to further understand the mechanistic influences of SC bioavailability and 
interspecies differences in the context of scaling PK data obtained in the preclinical stages to predict the 
human time course and to support optimal study design of a FIH trial. The goal of this exercise was to 
develop a workflow to reduce the burden of preclinical development. An additional objective was to reduce 
the early human clinical work required to optimize the human dose through model-based drug development. 
The workflow entailed developing a fully body PBPK model with flexibility to incorporate 
mechanistic/semi-mechanistic elements to predicting the concentration vs. time profile for a broad range of 
SC administered therapeutics.  
 
Prediction of the human PK profile after SC administration based on modeling of data from preclinical 
species has been challenging and inconsistent when allometry is employed in an a priori manner.(55)  No 
single method is currently recommended for scaling the SC exposure from animals to humans as a result of 
the perceived lack of similarity in skin architecture across species.  Anatomical differences in the skin 
architecture is hypothesized to be partially responsible  for the inconsistency in interspecies SC 
bioavailability.(18) Although some work has demonstrated that the minipig may be a good model for 
scaling PK to humans for protein therapeutics administered SC (114), use of a minipig in protein 
therapeutics is questionable due to the potential difference in target expression and affinity.  
 
A full body PBPK model was selected for scaling preclinical PK to human PK for several reasons. First, 
interspecies anatomical and physiological differences hypothesized to affect SC absorption are included as 
model components.(115) This allows for a biologically rational extrapolation to occur. Second, a full body 
PBPK model, as opposed to a reduced or lumped model, allows for the customization of clearance 
mechanisms based on a compound’s therapeutic classification. Outside of mAbs, there exists a wide variety 
of therapeutic macromolecules which have entirely different clearance mechanisms from mAbs, and where 
SC administration is a desirable route of administration. The PEG conjugate in the current investigation 
could only be appropriately characterized by including a renal and non-renal component. Other classes of 
therapeutic macromolecules such as micro-RNA have been demonstrated to exhibit a differential uptake 
amongst the various tissue compartments.(119) In such cases a lumped model would not provide a true 
physiologic and anatomic representation of the drug’s biodistribution. Furthermore, a PBPK approach has 
the advantage of overcoming limitations in sparse sampling and a low number of animals as it does not rely 
on the frequency or placement of the concentration samples to be useful in qualifying a model. 
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We hypothesized, prior to initiating this workflow that a PBPK model that could simulate the IV disposition 
of a therapeutic macromolecule would similarly result in a reasonable prediction of the time course 
following SC administration. Since the physiological factors driving drug distribution and CL were expected 
to scale across species, the SC time course and bioavailability would be influenced by the residence time of 
the drug within the SC space. Our hypothesis was further predicated on the assumption that since 
macromolecules are subject to lymphatic uptake from the interstitial space, any reduced bioavailability 
following SC administration would be a result of a longer duration of exposure to the non-renal clearance 
mechanisms in the SC milieu. 
 
In the current model, the time course in plasma was sensitive to the parameter values for convective 
transport from the organ vasculature into the interstitium, and subsequent transit to the lymph. Parameter 
values for σv,organ and σisf were adapted from previous reports by Shah and Betts (50) and Garg and Balthasar 
.(102) In the former, the values were based on a platform PBPK model which was demonstrated to have 
broad application across a range of monoclonal antibodies (mAbs) when tested in several preclinical species 
and humans. The latter obtained from Garg and Balthasar (10) was based on an assumption that transit to the 
lymphatics would not encounter substantial resistance. It should be noted that these values were evaluated 
with mAbs and that smaller macromolecules could exhibit a lower reflection coefficient of which more 
research is necessary to more precisely estimate. With respect to lymphatic transit, the current pegylated 
peptide with a molecular weight of approximately 44 kDa is considerably smaller than an IgG mAb. Due to 
the propensity to randomly conform water molecules, pegylation may increase hydrodynamic volume of a 
protein thus affecting its biodistribution to a greater extent than what the molecular weight would suggest 
.(26) To achieve slower lymphatic uptake than what our model produced, the σisf would have to be >0.5 
(data not shown). A higher interstitial viscosity could also be responsible for the interspecies difference in 
the lymphatic uptake. Although we were unable to identify data describing differences in proteoglycan 
content differences between cynomolgus monkeys and humans, the density of the various skin layers is 
reported to be similar.(115) To account for a potential higher viscosity and thus slower transit of a 
macromolecule through the interstitium, we adjusted downward the lymph flow by increasing the LS in the 
human model and allowed it to fit through estimation. This adjustment allowed for better agreement 
between the observed and simulated data suggesting that perhaps a higher viscosity or lower skin lymph 
flow may be responsible for slower absorption into the systemic circulation in humans as compared to 
monkeys.  
 
Supersaxo reported that  compounds greater than  16 kDa tend to drain into the lymphatics from the 
application site.(16) The size, shape and charge of the molecule however, rather than the absolute molecule 
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weight, may exert a greater influence on the proportion of diffusive versus convective transport of the 
molecule with molecular diameters of 10 nm and greater having little to no diffusive capacity.(18)  Sarin 
(12) reported that capillary pores range from 5-12 nm in most tissues. Considering that the hydrodynamic 
radii of a PEG-40 conjugated macromolecule would exceed the 10 nm diameter threshold for bi-directional 
flow across the capillary endothelium (32), it was assumed that the drug would follow a one-way circuit 
between the interstitium and organ vasculature. The hydrodynamic diameter for the pegylayted conjugate is 
similar to the approximately 9.3 nm diameter of IgG mAbs lending credibility to the observed scaling factor 
applied to the vascular reflection coefficients being similar to that employed in mAb PBPK models. 
(120;121)  
 
For a mAb, Zhao (109) identified that bioavailability from the SC and intramuscular route was most 
sensitive to the lymphatic transit time followed by lymphatic flow rates and endosomal uptake. This 
publication also noted that the bioavailability increased with a reduction in the duration of transit through 
the lymph. This mechanistic observation is similar to our observations, where the absolute bioavailability 
appears to be driven by the lymph flow rate from the SC site of administration to the lymphatic space. In the 
current manuscript, the transit time from the SC space to the lymph node was influenced by the skin lymph 
flow rate which is derived as a fraction of skin blood flow. Reducing the lymph flow was necessary to slow 
the transit time from the SC space to the venous circulation in order to appropriately characterize the 
absorption phase and maximum concentration. 
 
While the lymph flow from the SC space appeared to have an appreciable effect on PK of the drug, the site 
of injection cannot be ruled out as a source of variability in the current study. For the cynomologus studies, 
drug was injected SC into the back region while for humans the abdominal region was selected. Work by 
Kagan and Mager (113) have demonstrated, at least for rats administered a mAb, that there is a differential 
absolute bioavailability when administering to the back vs. abdomen with the abdominal region exhibiting a 
larger absorption rate constant (corresponding to a shorter duration of absorption). It is difficult to draw a 
comparison between the two reports due to different species and drug products having been administered, 
however if site of administration differences followed the observations of Kagan and Mager, one would 
expect that the absorption to be more rapid than what we observed in the human data.   
 
Subjects participating in the human study were considered healthy and fell within a very narrow weight 
range (60-80 kg), consequently it is not expected that subcutaneous fat composition would be contributing 
to the observed differences between species. The body size alone of the species may account for the 
difference where the absorption may be slower in larger animals as has been observed by Woo and Jusko for 
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erythropoietin.(91) Further research into the interspecies mechanistic determinants of drug absorption from 
the SC space is warranted to improve our understanding of this observation. 
 
Although the lymph flow to skin differed by 2-fold relative to the null human model once optimized, an 
informal analysis revealed that the model was not sensitive to lymph flow to the remaining organs when all 
organ L values including skin LS were adjusted in the human model upwards to 1000. Consequently, this 
affirms that skin lymph flow is a primary driver of both absolute SC bioavailability as well as the shape of 
the concentration vs. time profile. The fact that skin lymph flow was much slower than lymph flow to other 
organs is not a unique finding when considering Baxter’s seminal PBPK evaluation of macromolecules 
where mouse skin lymph flow as a percentage of plasma flow was much slower than lymph flow for other 
organs.(47) 
 
Zhao(109) also reported that the volume at the site of administration did not influence the shape of the 
concentration vs. time profile. In the current evaluation, the volume of the SC space was set at the injection 
volume. We hypothesized that the degree of spreading would be limited by the SC skin structure and would 
not exceed the volume that was administered, however in an informal analysis (data not shown) 
demonstrated that increasing the volume (whilst maintaining the same mass of drug) by 10-fold and 100-
fold did not influence the shape of the profile in line with the observations by Zhao.(109)   
 
Absolute bioavailability in monkeys was estimated from observed data using NCA. Although an underlying 
assumption of NCA is that clearance occurs via the central compartment and that macromolecules may not 
meet this assumption, employing NCA in the current scenario for estimation is justified when applying the 
same computation method to estimate relative exposure between two dosing conditions. In primates, 
exposure to the non-renal clearance mechanisms within the depot compartment accurately accounted for the 
reduced bioavailability. The simulated bioavailability was estimated at 90% and observed to 89% (obtained 
via NCA).  It is expected therefore that for drugs exhibiting less than 100% absolute bioavailability, the 
residence time in the depot compartment is indirectly proportional to bioavailability. Confirmation of this 
hypothesis in humans would require IV data however this data is not forthcoming due to the desire to 
develop the drug for SC administration in the clinic.  
 
PBPK model platforms as proposed by Shah and Betts (50) were principally developed for mAbs, 
incorporating recycling of the IgG mAb in the endosomal space, back to the plasma. In addition, these 
models incorporate elements such as pinocytosis and exocytosis mechanisms resulting in uptake and return 
from the interstitium to the endosomal and vascular spaces. Although pegylated therapeutics are reported to 
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be subject to pinocytosis and release from the cell either as intact or de-conjugated molecules (25), inclusion 
of an endosomal space with pinocytosis and exocytosis did not improve the disposition of the current 
molecule. This is not unexpected as the drug is not a mAb and not subject to binding by FcRn.  
 
CL processes were defined as both renal and non-renal. Renal CL has been previously suggested to occur at 
a rate of approximately 0.1% of GFR for similar molecular weight pegylated drug molecules.(25;97). As 
pore size in renal glomeruli are reported to be approximately 15 nm (12) and the fact that PEG exhibits as 
high water solubility, a degree of renal filtration was not unexpected. 
 
Renal elimination alone however was unable to account for the total body CL after IV administration. As 
the compound is a peptide, a degree of NRCL was also anticipated. However, identifying more than one 
route of CL when concentration data is only available in one biological matrix is challenging. As described 
in the results section, FGFR could not be estimated with precision during the optimization process and was 
fixed where the difference between total CL and renal CL was then attributed to the non-specific process. 
Through the sensitivity analysis, FGFR did not have an appreciable effect on the AUC when varied by 10% 
of the nominal value. The fact that the fitted NRCL value was nearly 4-fold greater than the initial estimated 
value may be a factor of using NCA to obtain the initial value and that the sampling interval did not 
adequately characterize the terminal phase of the profile for the monkey data.  
 
An important distinction between the current proposed model and other PBPK models for therapeutic 
macromolecules is that the current model did not incorporate target binding and saturable clearance. While 
saturable binding is a hallmark of many mAbs and fusion proteins it is not necessarily applicable in all 
macromolecule models. For the current model, as previously mentioned, target binding data was not 
available for either species where the amount of target could be readily quantified, however based on initial 
toxicokinetic evaluations in primates, it was not assumed to be saturable. Consequently it was decided that 
the non-specific clearance, which was intended to account for a variety of potential clearance mechanisms 
(proteolytic degradation, macrophagic opsonisation) was the best choice for parameterizing the model in an 
a priori manner. This approach would have limitations where saturable CL is involved however evaluation 
of the preclinical data under single and repeat dosing suggested linear pharmacokinetics. For other 
compounds, the model is flexible in that where saturable binding data is available, it can be incorporated. At 
the time of this writing, three human cohorts covering a 4-fold difference in dose have been evaluated 
confirming approximately linear pharmacokinetics (Figures 5.6 & 5.7) supporting the assumptions of linear 
clearance in the animal model. 
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NRCL was scaled-up to human employing simplified allometric theory. An allometric method was selected 
based on the rationale that a mechanistically obtained value was not obtainable. In previous reports, a fixed 
exponent of 0.85 has been reasonably reproducible in scaling monkey CL to humans for therapeutic 
macromolecule. (55;62-64) Our own informal analysis (data not shown) suggests that an exponent ranging 
from 0.75-0.9 would have produced a similarly shaped curve, whereas exponents greater than 1 would result 
in an unacceptable level of under-prediction. This method of scaling accurately addressed the non-renal 
clearance component and resulted in a human SC bioavailability that was similar to that in primates.  
However, the preferable method, where possible, would be to include a mechanistic means of addressing all 
clearance processes. 
 
It should be emphasized that the weight range in the human study was 60-80 kg and that the simulations 
were based on a 70 kg body weight. Adjusting the body weight for the simulations to the upper end of the 
range did result in slightly better fit with the observed dataset (data not shown) without adjusting the 
lymphatic flow to the skin. In the current workflow, and in the context of applying this workflow in 
predicting dose and exposure for a FIH study, actual body weight would not be obtainable without breaking 
the blind of these typically blinded studies. The workflow is intended to provide a reasonable estimation of 
the exposure and time course of a projected starting dose in humans and consequently an exact match of the 
simulation with the observed data is not an objective in the initial human data evaluation. Pauses in the 
availability of human data during the dose escalation provided an opportunity however to optimize the 
model and allowed for accurate prediction of the next cohort’s concentration vs. time profile.  
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5.5 Conclusion 
The workflow described above was developed specifically to address a process for selecting doses and 
regimens for SC administered therapeutic proteins in a FIH environment. We have demonstrated that 
through employing a PBPK model development process the SC absorption can be simulated with good 
precision in a commonly used preclinical species with particular relevance in biologic drug development. 
The model, which was developed for a pegylated peptide may be readily adapted to other non-mAb protein 
therapeutics exhibiting renal and non-specific linear CL with a similar high MW and a high degree of 
lymphatic uptake from the SC site. Scale-up to human demonstrated reasonable overlap with the first human 
dose cohort with peak and overall exposure within <30% of the observed data, and provided an opportunity 
to further optimize the model for more precise estimation of the time course for subsequent dose levels. 
 
  
 124 
 
 
5.6 Chapter 5 supplementary material 
Berkeley Madonna code for a macromolecule PBPK Model with Renal and Non-Specific Clearance in Each 
Organ Compartment 
{Physiological Parameters} 
 
{Constants to be set for average weight of the species being simulated} 
 
{Body Weight} 
BW = ___;enter per species (use average body weight) 
  
{Hematocrit} 
hct==___;enter per species 
 
{Human Cardiac Output mL/hr} 
CO==___;enter per species 
 
{Total plasma volume} 
PV=____*BW   ; = plasma volume per kg per species 
 
{Glomerular Filtration Rate} 
GFR=___;enter per species  
;NOTE that units for GFR should be confirmed and if the GFR is entered in per body weight, then clearance 
must be multiplied by the body weight in the kidney plasma compartment. 
  
{Organ Volumes} 
Vheart=___;enter per species 
Vlung=___;enter per species 
Vmuscle=___;enter per species 
Vskin=___;enter per species  
Vadipose=___;enter per species 
Vbone=___;enter per species  
Vbrain=___;enter per species 
Vkidney=___;enter per species 
Vliver=___;enter per species  
Vsmallintestines=___;enter per species 
Vlargeintestines=___;enter per species 
Vpancreas=___;enter per species 
Vthymus=___;enter per species 
Vspleen=___;enter per species 
Vother=___;enter per species 
 
{Organ Vascular Volume Fraction (Fvv)} 
Fvvheart=___;enter per species 
Fvvlung=___;enter per species  
Fvvmuscle=___;enter per species Fvvskin=0.019 
Fvvadipose=___;enter per species 
Fvvbone=___;enter per species 
Fvvbrain=___;enter per species  
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Fvvkidney=___;enter per species 
Fvvliver=___;enter per species 
Fvvsmallintestines=___;enter per species 
Fvvlargeintestines=___;enter per species  
Fvvpancreas=___;enter per species 
Fvvthymus=___;enter per species 
Fvvspleen=___;enter per species 
Fvvother=___;enter per species 
 
{Organ Volume of Interstitial Compartment Fraction (Fvic)} 
Fvicheart=___;enter per species 
Fviclung=___;enter per species  
Fvicmuscle=___;enter per species  
Fvicskin=___;enter per species  
Fvicadipose=___;enter per species  
Fvicbone=___;enter per species  
Fvicbrain=___;enter per species  
Fvickidney=___;enter per species  
Fvicliver=___;enter per species  
Fvicsmallintestines=___;enter per species  
Fviclargeintestines=___;enter per species  
Fvicpancreas=___;enter per species  
Fvicthymus=___;enter per species 
Fvicspleen=___;enter per species  
Fvicother=___;enter per species  
 
 
{Plasma Volume by organ (total organ volume * fraction vascular volume*1-hematocrit, mL)} 
 
Vheart_pla= Vheart*Fvvheart*(1-hct) 
Vlung_pla=Vlung*Fvvlung*(1-hct) 
Vmuscle_pla=Vmuscle*Fvvmuscle*(1-hct) 
Vskin_pla=Vskin*Fvvskin*(1-hct) 
Vadipose_pla=Vadipose*Fvvadipose*(1-hct) 
Vbone_pla=Vbone*Fvvbone*(1-hct) 
Vbrain_pla=Vbrain*Fvvbrain*(1-hct) 
Vkidney_pla=Vkidney*Fvvkidney*(1-hct) 
Vliver_pla=Vliver*Fvvliver*(1-hct)  
Vsmallintestines_pla=Vsmallintestines*Fvvsmallintestines*(1-hct) 
Vlargeintestines_pla=Vlargeintestines*Fvvlargeintestines*(1-hct) 
Vpancreas_pla=Vpancreas*Fvvpancreas*(1-hct) 
Vthymus_pla=Vthymus*Fvvthymus*(1-hct) 
Vspleen_pla=Vspleen*Fvvspleen*(1-hct) 
Vother_pla=Vother*Fvvother*(1-hct) 
 
{Venous Plasma Volume (mL)} 
Vven_pla=(2/3)*(PV-
(Vheart_pla+Vlung_pla+Vmuscle_pla+Vskin_pla+Vadipose_pla+Vbone_pla+Vbrain_pla+Vkidney_pla+V
liver_pla+Vsmallintestines_pla+Vlargeintestines_pla+Vpancreas_pla+Vthymus_pla+Vspleen_pla+Vother_
pla)) 
;adapted from the assumptions in Peters(122) 
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{Arterial Plasma Volume (mL)} 
Vart_pla=(1/3)*(PV-
(Vheart_pla+Vlung_pla+Vmuscle_pla+Vskin_pla+Vadipose_pla+Vbone_pla+Vbrain_pla+Vkidney_pla+V
liver_pla+Vsmallintestines_pla+Vlargeintestines_pla+Vpancreas_pla+Vthymus_pla+Vspleen_pla+Vother_
pla)) 
; adapted from the assumptions in Peters(122) 
 
{Interstitial Volume by Organ, mL} 
Vheart_isf = Vheart*Fvicheart 
Vlung_isf=Vlung*Fviclung 
Vmuscle_isf=Vmuscle*Fvicmuscle 
Vskin_isf=(Vskin*Fvicskin)-Vdepot 
Vdepot=____; define either based on injection volume or approximately 1 mL 
Vadipose_isf=Vadipose*Fvicadipose 
Vbone_isf=Vbone*Fvicbone 
Vbrain_isf=Vbrain*Fvicbrain 
Vkidney_isf=Vkidney*Fvickidney 
Vliver_isf=Vliver*Fvicliver 
Vsmallintestines_isf=Vsmallintestines*Fvicsmallintestines 
Vlargeintestines_isf=Vlargeintestines*Fviclargeintestines 
Vpancreas_isf=Vpancreas*Fvicpancreas 
Vthymus_isf=Vthymus*Fvicthymus 
Vspleen_isf=Vspleen*Fvicspleen 
Vother_isf=Vother*Fvicother 
 
{Human Volume of Lymph Node Compartment (mL)} 
Vlymph=____;enter per species 
 
{Blood Flow scaling factor (fraction of CO)} 
QBheart= ___;enter per species 
QBlung=___;enter per species 
QBmuscle=___;enter per species 
QBskin=___;enter per species  
Qbadipose=___;enter per species 
Qbbone=___;enter per species 
Qbbrain=___;enter per species 
Qbkidney=___;enter per species 
Qbliver=___;enter per species 
Qbsmallintestines=___;enter per species 
Qblargeintestines=___;enter per species 
Qbpancreas=___;enter per species 
Qbthymus=___;enter per species  
Qbspleen=___;enter per species 
Qbother=___;enter per species 
 
{Plasma Flow to Organs mL/hr} 
{other than lung, each blood flow is defined as a fraction of lymph-flow reduced lung plasma flow so no 
need to include hematocrit} 
 
Qlung=(1-hct)*CO 
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Qheart= QBheart*(Qlung-Llung) 
Qmuscle=QBmuscle*(Qlung-Llung) 
Qskin= QBskin*(Qlung-Llung) 
Qadipose= QBadipose*(Qlung-Llung) 
Qbone= QBbone*(Qlung-Llung) 
Qbrain= QBbrain*(Qlung-Llung) 
Qkidney= QBkidney*(Qlung-Llung) 
Qliver= QBliver*(Qlung-Llung) 
Qsmallintestines=QBsmallintestines*(Qlung-Llung) 
Qlargeintestines=QBlargeintestines*(Qlung-Llung) 
Qpancreas=QBpancreas*(Qlung-Llung) 
Qthymus= QBthymus*(Qlung-Llung) 
Qspleen= QBspleen*(Qlung-Llung) 
Qother= QBother*(Qlung-Llung) 
 
 
{Lymph flow from organs expressed in mL/hr} 
L=500; lymph fraction of blood flow 
Llung=QBlung*CO/L; except for lung which is defined as the fraction of the cardiac output divided by the 
lymph fraction 
Lheart= (QBheart*(CO-Llung))/L 
Lmuscle=(QBmuscle*(CO-Llung))/L 
Lskin=((QBskin*(CO-Llung))/L)*0.99903 
Lskin_depot=((QBskin*(CO-Llung))/L)* 0.00097 
Ladipose=(QBadipose*(CO-Llung))/L 
Lbone=(QBbone*(CO-Llung))/L 
Lbrain=(QBbrain*(CO-Llung))/L 
Lkidney=(QBkidney*(CO-Llung))/L 
Lliver=(QBliver*(CO-Llung))/L 
Lsmallintestines=(QBsmallintestines*(CO-Llung))/L 
Llargeintestines=(QBlargeintestines*(CO-Llung))/L 
Lpancreas=(QBpancreas*(CO-Llung))/L 
Lthymus=(QBthymus*(CO-Llung))/L 
Lspleen=(QBspleen*(CO-Llung))/L 
Lother=(QBother*(CO-Llung))/L 
Llymph=Lheart+Llung+Lmuscle+Lskin+Lskin_depot+Ladipose+Lbone+Lbrain+Lkidney+Lliver+Lsmallin
testines+Llargeintestines+Lpancreas+Lthymus+Lspleen+Lother 
 
{Vascular Reflection Coefficients}  
Sigma_v_scalingfactor= 1; Can be optimized for each tissue or optimized as a scaling factor  
Sigma_v_lung=0.95 
Sigma_v_heart=0.95 
Sigma_v_adipose=0.95 
Sigma_v_muscle=0.95 
Sigma_v_kidney=0.9 
Sigma_v_bone=0.85 
Sigma_v_thymus=0.9 
Sigma_v_skin=0.95 
Sigma_v_brain=0.99 
Sigma_v_other=0.95 
Sigma_v_smallintestines=0.9 
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Sigma_v_largeintestines=0.95 
Sigma_v_spleen=0.85 
Sigma_v_pancreas=0.9 
Sigma_v_liver=0.85 
 
 
{Lymphatic Reflection Coefficients}  
Sigma_isf=0.2;  
 
{Non-renal Clearance Code} 
{Define the total volume where non-renal clearance occurs} 
Vvascular_total= Vven_pla + Vart_pla + Vheart_pla+ Vlung_pla + Vmuscle_pla + Vskin_pla + 
Vadipose_pla + Vbone_pla + Vbrain_pla + Vkidney_pla + Vliver_pla + Vsmallintestines_pla + 
Vlargeintestines_pla + Vpancreas_pla + Vthymus_pla + Vspleen_pla +Vother_pla 
Visf_total=Vheart_isf + Vlung_isf + Vmuscle_isf + Vskin_isf + Vadipose_isf + Vbone_isf + Vbrain_isf + 
Vkidney_isf + Vliver_isf +Vsmallintestines_isf + Vlargeintestines_isf + Vpancreas_isf + Vthymus_isf + 
Vspleen_isf + Vother_isf+Vdepot 
 
Vtotal=Vvascular_total + Visf_total 
 
 
{Define each volume space clearance occurs in as a fraction of the overall volume the total clearance occurs 
in} 
VNRCL_ven_pla=Vven_pla/Vtotal 
VNRCL_art_pla=Vart_pla/Vtotal 
VNRCL_heart_pla=Vheart_pla/Vtotal 
VNRCL_lung_pla=Vlung_pla/Vtotal 
VNRCL_muscle_pla=Vmuscle_pla/Vtotal 
VNRCL_skin_pla=Vskin_pla/Vtotal 
VNRCL_adipose_pla=Vadipose_pla/Vtotal 
VNRCL_bone_pla=Vbone_pla/Vtotal 
VNRCL_brain_pla=Vbrain_pla/Vtotal 
VNRCL_kidney_pla=Vkidney_pla/Vtotal 
VNRCL_liver_pla=Vliver_pla/Vtotal 
VNRCL_smallintestines_pla=Vsmallintestines_pla/Vtotal 
VNRCL_largeintestines_pla=Vlargeintestines_pla/Vtotal 
VNRCL_pancreas_pla=Vpancreas_pla/Vtotal 
VNRCL_thymus_pla=Vthymus_pla/Vtotal 
VNRCL_spleen_pla=Vspleen_pla/Vtotal 
VNRCL_other_pla=Vother_pla/Vtotal 
 
 
VNRCL_heart_isf=Vheart_isf/Vtotal 
VNRCL_lung_isf=Vlung_isf/Vtotal 
VNRCL_muscle_isf=Vmuscle_isf/Vtotal 
VNRCL_skin_isf=Vskin_isf/Vtotal 
VNRCL_adipose_isf=Vadipose_isf/Vtotal 
VNRCL_bone_isf=Vbone_isf/Vtotal 
VNRCL_brain_isf=Vbrain_isf/Vtotal 
VNRCL_kidney_isf=Vkidney_isf/Vtotal 
VNRCL_liver_isf=Vliver_isf/Vtotal 
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VNRCL_smallintestines_isf=Vsmallintestines_isf/Vtotal 
VNRCL_largeintestines_isf=Vlargeintestines_isf/Vtotal 
VNRCL_pancreas_isf=Vpancreas_isf/Vtotal 
VNRCL_thymus_isf=Vthymus_isf/Vtotal 
VNRCL_spleen_isf=Vspleen_isf/Vtotal 
VNRCL_other_isf=Vother_isf/Vtotal 
VNRCL_skin_depot=Vdepot/Vtotal 
 
 
{Non-renal clearance value} 
NRCL=_____; mL/kg 
 
{Exposure Conditions} 
AdminDose = _____; Enter Administered Dose 
F=____; Relative Bioavailability Term if applicable (otherwise =1) 
DOSE=AdminDose*F 
 
 
 
{Mass Balance Equations} 
 
{Venous Plasma Circulation} 
;Aven_pla=amount in venous plasma circulation (ug); Aven_pla'=dAven_pla/dt 
;Amount coming from each of the organs (difference between plasma and lymph flow) summed;with 
amount coming from lymph minus amount going to lungs 
Aven_pla'= ((Qheart - Lheart)* Cheart_pla) + (((Qliver-Lliver) + (Qsmallintestines-Lsmallintestines) + 
(Qlargeintestines-Llargeintestines) + (Qspleen-Lspleen) + (Qpancreas-Lpancreas))*Cliver_pla) + 
((Qadipose-Ladipose)* Cadipose_pla) + ((Qmuscle-Lmuscle)* Cmuscle_pla) + ((Qkidney-Lkidney)* 
Ckidney_pla) + ((Qbone-Lbone)* Cbone_pla) + ((Qthymus-Lthymus)* Cthymus_pla) + ((Qskin-
(Lskin+Lskin_depot))* Cskin_pla) + ((Qother-Lother)* Cother_pla) +  
((Qbrain-Lbrain)*Cbrain_pla)+ (Llymph*Clymph) - (Qlung*Cven_pla) - ANRCL_ven' 
Cven_pla=Aven_pla/Vven_pla; relating concentration in the venous system to the amount and volume of 
the venous system. 
INIT Aven_pla=0 
ANRCL_ven'=NRCL*Cven_pla*VNRCL_ven_pla 
INIT ANRCL_ven=0 
 
 
{Arterial Plasma Circulation} 
;Aart_pla=amount in arterial plasma circulation (ug); Aart_pla'=dAart_pla/dt 
Aart_pla'= ((Qlung-Llung)*Clung_pla) - (Qheart*Cart_pla) - (Qadipose * Cart_pla) - (Qmuscle * Cart_pla) 
- (Qkidney * Cart_pla) - (Qbone * Cart_pla) - (Qthymus * Cart_pla) - (Qskin* Cart_pla) - (Qbrain * 
Cart_pla) - (Qliver* Cart_pla) - (Qsmallintestines* Cart_pla) - (Qlargeintestines* Cart_pla) -  (Qspleen * 
Cart_pla) - (Qpancreas* Cart_pla)- (Qother*Cart_pla)-ANRCL_art' 
Cart_pla=Aart_pla/Vart_pla; relating concentration of arterial plasma to volume of the arterial plasma. 
INIT Aart_pla=0;  
ANRCL_art'=NRCL*Cart_pla*VNRCL_art_pla 
INIT ANRCL_art=0 
 
{Lymph} 
;Alymph=amount in Lymph (ug) ; Alymph'=dAlymph/dt 
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;isf = interstitial fluid 
;Sigma_isf= interstitial reflection coefficient 
Alymph'= (Llung*(1-Sigma_isf)*Clung_isf) + (Lheart*(1-Sigma_isf)* Cheart_isf) + (Ladipose*(1-
Sigma_isf)* Cadipose_isf) + (Lmuscle*(1-Sigma_isf)* Cmuscle_isf) + (Lkidney*(1-Sigma_isf)* 
Ckidney_isf)  + (Lbone*(1-Sigma_isf)* Cbone_isf) + (Lthymus*(1-Sigma_isf)* Cthymus_isf) + (Lskin*(1-
Sigma_isf)* Cskin_isf) + (Lbrain*(1-Sigma_isf)* Cbrain_isf) + (Lliver*(1-Sigma_isf)* Cliver_isf) + 
(Lsmallintestines*(1-Sigma_isf)* Csmallintestines_isf) + (Llargeintestines*(1-Sigma_isf)* 
Clargeintestines_isf) +  (Lspleen*(1-Sigma_isf)* Cspleen_isf) + (Lpancreas*(1-Sigma_isf)* Cpancreas_isf) 
+ (Lother*(1-Sigma_isf)*Cother_isf)- (Llymph*Clymph) +(Lskin_depot*(1-Sigma_isf)* Cskin_depot)  
INIT Alymph=0 
Clymph=Alymph/Vlymph 
 
{Lung} 
;Alung=amount in lung (ug) ; Alung'=dAlung/dt 
Alung'= (Qlung*Cven_pla) - (Llung*( 1-(Sigma_v_scalingfactor*Sigma_v_lung))*Clung_pla) - ((Qlung-
Llung)*Clung_pla)-ANRCL_lung_pla' 
Alung_isf'= (Llung*(1-(Sigma_v_scalingfactor*Sigma_v_lung))* Clung_pla) - (Llung*(1-
Sigma_isf)*Clung_isf)-ANRCL_lung_isf' 
Clung_isf=Alung_isf/Vlung_isf 
Clung_pla=Alung/Vlung_pla 
INIT Alung=0 
INIT Alung_isf=0 
ANRCL_lung_pla'=NRCL*Clung_pla*VNRCL_lung_pla 
INIT ANRCL_lung_pla=0 
ANRCL_lung_isf'=NRCL*Clung_isf*VNRCL_lung_isf 
INIT ANRCL_lung_isf=0 
 
 
{Heart} 
Aheart'= (Qheart* Cart_pla) - (Lheart*(1-(Sigma_v_scalingfactor*Sigma_v_heart))* Cheart_pla) - 
((Qheart-Lheart)*Cheart_pla) -ANRCL_heart_pla' 
Aheart_isf'= (Lheart*(1-(Sigma_v_scalingfactor*Sigma_v_heart))* (Cheart_pla)) -(Lheart*(1-
Sigma_isf)*Cheart_isf)-ANRCL_heart_isf' 
Cheart_pla=Aheart/Vheart_pla 
INIT Aheart=0 
Cheart_isf=Aheart_isf/Vheart_isf 
INIT Aheart_isf= 0 
ANRCL_heart_pla'=NRCL*Cheart_pla*VNRCL_heart_pla 
INIT ANRCL_heart_pla=0 
ANRCL_heart_isf'=NRCL*Cheart_isf*VNRCL_heart_isf 
INIT ANRCL_heart_isf=0 
 
{Adipose} 
Aadipose'= (Qadipose* Cart_pla) - (Ladipose*(1-(Sigma_v_scalingfactor*Sigma_v_adipose))* 
Cadipose_pla) - ((Qadipose-Ladipose)*Cadipose_pla) -ANRCL_adipose_pla' 
Aadipose_isf'= (Ladipose*(1-(Sigma_v_scalingfactor*Sigma_v_adipose))* (Cadipose_pla)) -(Ladipose*(1-
Sigma_isf)*Cadipose_isf)-ANRCL_adipose_isf' 
 
Cadipose_pla=Aadipose/Vadipose_pla 
INIT Aadipose=0 
Cadipose_isf=Aadipose_isf/Vadipose_isf 
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INIT Aadipose_isf= 0 
ANRCL_adipose_pla'=NRCL*Cadipose_pla*VNRCL_adipose_pla 
INIT ANRCL_adipose_pla=0 
ANRCL_adipose_isf'=NRCL*Cadipose_isf*VNRCL_adipose_isf 
INIT ANRCL_adipose_isf=0 
 
 
 
{Muscle} 
Amuscle'= (Qmuscle* Cart_pla) - (Lmuscle*(1-(Sigma_v_scalingfactor*Sigma_v_muscle))* Cmuscle_pla) 
- ((Qmuscle-Lmuscle)*Cmuscle_pla) -ANRCL_muscle_pla' 
Amuscle_isf'= (Lmuscle*(1-(Sigma_v_scalingfactor*Sigma_v_muscle))* (Cmuscle_pla)) -(Lmuscle*(1-
Sigma_isf)*Cmuscle_isf)-ANRCL_muscle_isf' 
Cmuscle_pla=Amuscle/Vmuscle_pla 
INIT Amuscle=0 
Cmuscle_isf=Amuscle_isf/Vmuscle_isf 
INIT Amuscle_isf= 0 
ANRCL_muscle_pla'=NRCL*Cmuscle_pla*VNRCL_muscle_pla 
INIT ANRCL_muscle_pla=0 
ANRCL_muscle_isf'=NRCL*Cmuscle_isf*VNRCL_muscle_isf 
INIT ANRCL_muscle_isf=0 
 
{Kidney} 
Akidney'= (Qkidney* Cart_pla) - (Lkidney*(1-(Sigma_v_scalingfactor*Sigma_v_kidney))* Ckidney_pla) - 
((Qkidney-Lkidney)*Ckidney_pla) -(ACLR')-(ANRCL_kidney_pla') 
Akidney_isf'= (Lkidney*(1-(Sigma_v_scalingfactor*Sigma_v_kidney))* (Ckidney_pla)) -(Lkidney*(1-
Sigma_isf)*Ckidney_isf)-(ANRCL_kidney_isf') 
Ckidney_pla=Akidney/Vkidney_pla 
INIT Akidney=0 
Ckidney_isf=Akidney_isf/Vkidney_isf 
INIT Akidney_isf= 0 
ACLR'=CLR*Ckidney_pla 
CLR=(GFR*FGFR); renal clearance rate of a pegylated protein 
INIT ACLR=0 
FGFR=0.001; fraction of GFR at which a pegylated protein is renally excreted 
ANRCL_kidney_pla'=NRCL*Ckidney_pla*VNRCL_kidney_pla 
INIT ANRCL_kidney_pla=0 
ANRCL_kidney_isf'=NRCL*Ckidney_isf*VNRCL_kidney_isf 
INIT ANRCL_kidney_isf=0 
  
 
 
 
 
{Bone} 
Abone'= (Qbone* Cart_pla) - (Lbone*(1-(Sigma_v_scalingfactor*Sigma_v_bone))* Cbone_pla) - ((Qbone-
Lbone)*Cbone_pla) -ANRCL_bone_pla' 
Abone_isf'= (Lbone*(1-(Sigma_v_scalingfactor*Sigma_v_bone))* (Cbone_pla)) -(Lbone*(1-
Sigma_isf)*Cbone_isf)-ANRCL_bone_isf' 
Cbone_pla=Abone/Vbone_pla 
INIT Abone=0 
 132 
 
Cbone_isf=Abone_isf/Vbone_isf 
INIT Abone_isf= 0 
ANRCL_bone_pla'=NRCL*Cbone_pla*VNRCL_bone_pla 
INIT ANRCL_bone_pla=0 
ANRCL_bone_isf'=NRCL*Cbone_isf*VNRCL_bone_isf 
INIT ANRCL_bone_isf=0 
 
{Thymus} 
Athymus'= (Qthymus* Cart_pla) - (Lthymus*(1-(Sigma_v_scalingfactor*Sigma_v_thymus))* 
Cthymus_pla) - ((Qthymus-Lthymus)*Cthymus_pla) -ANRCL_thymus_pla' 
Athymus_isf'= (Lthymus*(1-(Sigma_v_scalingfactor*Sigma_v_thymus))* (Cthymus_pla)) -(Lthymus*(1-
Sigma_isf)*Cthymus_isf)-ANRCL_thymus_isf' 
Cthymus_pla=Athymus/Vthymus_pla 
INIT Athymus=0 
Cthymus_isf=Athymus_isf/Vthymus_isf 
INIT Athymus_isf= 0 
ANRCL_thymus_pla'=NRCL*Cthymus_pla*VNRCL_thymus_pla 
INIT ANRCL_thymus_pla=0 
ANRCL_thymus_isf'=NRCL*Cthymus_isf*VNRCL_thymus_isf 
INIT ANRCL_thymus_isf=0 
 
{Skin} 
Askin'= (Qskin* Cart_pla) - ((Lskin+Lskin_depot)*(1-(Sigma_v_scalingfactor*Sigma_v_skin))* 
Cskin_pla) - ((Qskin-(Lskin+Lskin_depot))*Cskin_pla) -ANRCL_skin_pla' 
Askin_isf'= (Lskin*(1-(Sigma_v_scalingfactor*Sigma_v_skin))* (Cskin_pla)) -(Lskin*(1-
Sigma_isf)*Cskin_isf)-ANRCL_skin_isf' 
Askin_depot'= (Lskin_depot*(1-(Sigma_v_scalingfactor*Sigma_v_skin))* Cskin_pla) - (Lskin_depot*(1-
Sigma_isf)*Cskin_depot) - ANRCL_skin_depot' 
 
 
Cskin_pla=Askin/Vskin_pla 
INIT Askin=0 
Cskin_isf=Askin_isf/Vskin_isf 
INIT Askin_isf= 0 
Cskin_depot=Askin_depot/Vdepot 
INIT Askin_depot=DOSE 
ANRCL_skin_pla'=NRCL*Cskin_pla*VNRCL_skin_pla 
INIT ANRCL_skin_pla=0 
ANRCL_skin_isf'=NRCL*Cskin_isf*VNRCL_skin_isf 
INIT ANRCL_skin_isf=0 
ANRCL_skin_depot'=NRCL*Cskin_depot*VNRCL_skin_depot 
INIT ANRCL_skin_depot=0 
 
 
 
{Brain} 
Abrain'= (Qbrain* Cart_pla) - (Lbrain*(1-(Sigma_v_scalingfactor*Sigma_v_brain))* Cbrain_pla) - 
((Qbrain-Lbrain)*Cbrain_pla) -ANRCL_brain_pla' 
Abrain_isf'= (Lbrain*(1-(Sigma_v_scalingfactor*Sigma_v_brain))* (Cbrain_pla)) -(Lbrain*(1-
Sigma_isf)*Cbrain_isf)-ANRCL_brain_isf' 
Cbrain_pla=Abrain/Vbrain_pla 
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INIT Abrain=0 
Cbrain_isf=Abrain_isf/Vbrain_isf 
INIT Abrain_isf= 0 
ANRCL_brain_pla'=NRCL*Cbrain_pla*VNRCL_brain_pla 
INIT ANRCL_brain_pla=0 
ANRCL_brain_isf'=NRCL*Cbrain_isf*VNRCL_brain_isf 
INIT ANRCL_brain_isf=0 
 
{Other} 
Aother'= (Qother* Cart_pla) - (Lother*(1-(Sigma_v_scalingfactor*Sigma_v_other))* Cother_pla) - 
((Qother-Lother)*Cother_pla) -ANRCL_other_pla' 
Aother_isf'= (Lother*(1-(Sigma_v_scalingfactor*Sigma_v_other))* (Cother_pla)) -(Lother*(1-
Sigma_isf)*Cother_isf)-ANRCL_other_isf' 
Cother_pla=Aother/Vother_pla 
INIT Aother=0 
Cother_isf=Aother_isf/Vother_isf 
INIT Aother_isf= 0 
ANRCL_other_pla'=NRCL*Cother_pla*VNRCL_other_pla 
INIT ANRCL_other_pla=0 
ANRCL_other_isf'=NRCL*Cother_isf*VNRCL_other_isf 
INIT ANRCL_other_isf=0 
 
{Small intestines} 
Asmallintestines'= (Qsmallintestines* Cart_pla) - (Lsmallintestines*(1-
(Sigma_v_scalingfactor*Sigma_v_smallintestines))* Csmallintestines_pla) - ((Qsmallintestines-
Lsmallintestines)*Csmallintestines_pla) -ANRCL_smallintestines_pla' 
Asmallintestines_isf'= (Lsmallintestines*(1-(Sigma_v_scalingfactor*Sigma_v_smallintestines))* 
(Csmallintestines_pla)) -(Lsmallintestines*(1-Sigma_isf)*Csmallintestines_isf)-
ANRCL_smallintestines_isf' 
Csmallintestines_pla=Asmallintestines/Vsmallintestines_pla 
INIT Asmallintestines=0 
Csmallintestines_isf=Asmallintestines_isf/Vsmallintestines_isf 
INIT Asmallintestines_isf= 0 
ANRCL_smallintestines_pla'=NRCL*Csmallintestines_pla*VNRCL_smallintestines_pla 
INIT ANRCL_smallintestines_pla=0 
ANRCL_smallintestines_isf'=NRCL*Csmallintestines_isf*VNRCL_smallintestines_isf 
INIT ANRCL_smallintestines_isf=0 
 
 
{Large Intestines} 
Alargeintestines'= (Qlargeintestines* Cart_pla) - (Llargeintestines*(1-
(Sigma_v_scalingfactor*Sigma_v_largeintestines))* Clargeintestines_pla) - ((Qlargeintestines-
Llargeintestines)*Clargeintestines_pla) -ANRCL_largeintestines_pla' 
Alargeintestines_isf'= (Llargeintestines*(1-(Sigma_v_scalingfactor*Sigma_v_largeintestines))* 
(Clargeintestines_pla)) -(Llargeintestines*(1-Sigma_isf)*Clargeintestines_isf)-ANRCL_largeintestines_isf' 
Clargeintestines_pla=Alargeintestines/Vlargeintestines_pla 
INIT Alargeintestines=0 
Clargeintestines_isf=Alargeintestines_isf/Vlargeintestines_isf 
INIT Alargeintestines_isf= 0 
ANRCL_largeintestines_pla'=NRCL*Clargeintestines_pla*VNRCL_largeintestines_pla 
INIT ANRCL_largeintestines_pla=0 
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ANRCL_largeintestines_isf'=NRCL*Clargeintestines_isf*VNRCL_largeintestines_isf 
INIT ANRCL_largeintestines_isf=0 
 
{Spleen} 
Aspleen'= (Qspleen* Cart_pla) - (Lspleen*(1-(Sigma_v_scalingfactor*Sigma_v_spleen))* Cspleen_pla) - 
((Qspleen-Lspleen)*Cspleen_pla) -ANRCL_spleen_pla' 
Aspleen_isf'= (Lspleen*(1-(Sigma_v_scalingfactor*Sigma_v_spleen))* (Cspleen_pla)) -(Lspleen*(1-
Sigma_isf)*Cspleen_isf)-ANRCL_spleen_isf' 
Cspleen_pla=Aspleen/Vspleen_pla 
INIT Aspleen=0 
Cspleen_isf=Aspleen_isf/Vspleen_isf 
INIT Aspleen_isf= 0 
ANRCL_spleen_pla'=NRCL*Cspleen_pla*VNRCL_spleen_pla 
INIT ANRCL_spleen_pla=0 
ANRCL_spleen_isf'=NRCL*Cspleen_isf*VNRCL_spleen_isf 
INIT ANRCL_spleen_isf=0 
 
{Pancreas} 
Apancreas'= (Qpancreas* Cart_pla) - (Lpancreas*(1-(Sigma_v_scalingfactor*Sigma_v_pancreas))* 
Cpancreas_pla) - ((Qpancreas-Lpancreas)*Cpancreas_pla) -ANRCL_pancreas_pla' 
Apancreas_isf'= (Lpancreas*(1-(Sigma_v_scalingfactor*Sigma_v_pancreas))* (Cpancreas_pla)) -
(Lpancreas*(1-Sigma_isf)*Cpancreas_isf)-ANRCL_pancreas_isf' 
Cpancreas_pla=Apancreas/Vpancreas_pla 
INIT Apancreas=0 
Cpancreas_isf=Apancreas_isf/Vpancreas_isf 
INIT Apancreas_isf= 0 
ANRCL_pancreas_pla'=NRCL*Cpancreas_pla*VNRCL_pancreas_pla 
INIT ANRCL_pancreas_pla=0 
ANRCL_pancreas_isf'=NRCL*Cpancreas_isf*VNRCL_pancreas_isf 
INIT ANRCL_pancreas_isf=0 
 
 
{Liver} 
Aliver'= (Qliver* Cart_pla) + ((Qsmallintestines-Lsmallintestines)*Csmallintestines_pla) + 
((Qlargeintestines-Llargeintestines)*Clargeintestines_pla) + ((Qspleen-Lspleen) * Cspleen_pla) +  
((Qpancreas-Lpancreas)*Cpancreas_pla) - (Lliver*(1-(Sigma_v_scalingfactor*Sigma_v_liver))* 
(Cliver_pla)) - (((Qliver-Lliver) + (Qsmallintestines-Lsmallintestines) + (Qlargeintestines-Llargeintestines) 
+ (Qspleen-Lspleen) + (Qpancreas-Lpancreas))*Cliver_pla)- ANRCL_liver_pla' 
 
 
Aliver_isf'= (Lliver*(1-(Sigma_v_scalingfactor*Sigma_v_liver))* Cliver_pla)-(Lliver*(1-
Sigma_isf)*Cliver_isf)- ANRCL_liver_isf' 
 
INIT Aliver= 0 
Cliver_pla=Aliver/Vliver_pla 
INIT Aliver_isf= 0 
Cliver_isf=Aliver_isf/Vliver_isf 
 
ANRCL_liver_pla'=NRCL*Cliver_pla*VNRCL_liver_pla 
INIT ANRCL_liver_pla=0 
ANRCL_liver_isf'=NRCL*Cliver_isf*VNRCL_liver_isf 
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INIT ANRCL_liver_isf=0 
 
 
{Quality Check for Mass/Flow Balance} 
 
TOTAL=Alung+Aheart+Amuscle+Abone+Abrain+Askin+Athymus+Aother+Akidney+Aadipose+Aliver+
Apancreas+Aspleen+Alargeintestines+Asmallintestines+Alymph+ACLR+Aven_pla+Aart_pla+Alung_isf+
Aheart_isf+Amuscle_isf+Abone_isf+Abrain_isf+Askin_isf+Athymus_isf+Aother_isf+Akidney_isf+Aadip
ose_isf+Aliver_isf+Apancreas_isf+Aspleen_isf+Alargeintestines_isf+Asmallintestines_isf+ANRCL_ven+
ANRCL_art+ANRCL_heart_pla+ANRCL_lung_pla+ANRCL_muscle_pla+ANRCL_skin_pla+ANRCL_a
dipose_pla+ANRCL_bone_pla+ANRCL_brain_pla+ANRCL_kidney_pla+ANRCL_liver_pla+ANRCL_sm
allintestines_pla+ANRCL_largeintestines_pla+ANRCL_pancreas_pla+ANRCL_thymus_pla+ANRCL_sple
en_pla+ANRCL_other_pla+ANRCL_heart_isf+ANRCL_lung_isf+ANRCL_muscle_isf+ANRCL_skin_isf
+ANRCL_adipose_isf+ANRCL_bone_isf+ANRCL_brain_isf+ANRCL_kidney_isf+ANRCL_liver_isf+A
NRCL_smallintestines_isf+ANRCL_largeintestines_isf+ANRCL_pancreas_isf+ANRCL_thymus_isf+ANR
CL_spleen_isf+ANRCL_other_isf+Askin_depot+ANRCL_skin_depot 
ERROR = (DOSE-TOTAL)/(DOSE+1E-30)*100; ERROR should be close to 0 
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CHAPTER 6: POPULATION PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL 
INCORPORATING LYMPHATIC UPTAKE FOR A SUBCUTANEOUSLY ADMINISTERED 
PEGYLATED PEPTIDE 
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The contents of Chapter 6 were initially published as an original contribution manuscript by the PhD. 
candidate (Elliot Offman). The original manuscript has been edited and formatted according to thesis 
publication requirements. For reference purposes, the original publication is as follows: 
Offman E, Phipps C, Edginton AN. Population physiologically-based pharmacokinetic model incorporating 
lymphatic uptake for a subcutaneously administered pegylated peptide. In Silico Pharmacology; 
(2016);4(1):3 (Open Access Journal) 
 
The PhD candidate conducted much of pertinent research, wrote portions of the code for the described 
models, conducted the vast majority of described analysis, created all tables, plots and figures and wrote the 
entire manuscript. 
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6.1 Background 
The importance of the subcutaneous (SC) route to the drug development industry is evident in the growing 
number of drug products available for SC administration. In 2014, the U.S. Food & Drug Administration 
approved 41 new molecular entities and biological licensing applications, four of which had first approvals 
for subcutaneous (SC) administration.(33) The industry has also witnessed conversion of intravenous (IV) to 
SC routes for a number of therapies where treatment that was previously relegated to a hospital can now 
largely be addressed in an ambulatory setting (e.g. IV heparin to SC low molecular weight heparins for 
treatment of deep vein thrombosis). With a growing emphasis on SC administration as the primary route for 
development, reliance on reliable pharmacokinetic (PK) scaling methods (pre-clinical animal species to 
human) is correspondingly increasing. 
 
When designing clinical pharmacology (Phase 1) and in particular first-in-human (FIH) studies, there is 
considerable importance placed on predicting the peak (Cmax) and overall exposure (AUC). This is 
particularly critical when relating the exposure observed in pre-clinical species to observed adverse events. 
Appreciating the temporal relationship between dosing time and Cmax, as well as an estimate of the drug’s 
plasma half-life (T1/2), are useful for a priori design of early human research studies to mitigate the need 
for protocol amendments and reduce the burden of interim PK assessments. 
 
In traditional allometric theory, prediction of human PK from animals has largely focused on estimating 
mean human exposure by scaling the mean clearance value of three or more preclinical species.(82;123) For 
macromolecules, and particularly for monoclonal antibodies (mAbs) exhibiting linear PK, single-species 
(primates) simplified allometric techniques have yielded useful predictions.(55;61-64) These methods 
however, provide no information as to the time course of a drug after administration, and have principally 
been employed for the IV route of administration. Dedrick plots have been demonstrated to have some 
utility in predicting the time course of IV administered monoclonal antibodies (mAbs), but have not yet 
been reported to yield similar predictive capacity for SC administered proteins.(61) 
 
Predicting the SC time course of a drug in a population of humans from animal models is considerably more 
complex compared to prediction for a “mean human”. For macromolecules, this is further complicated by a 
lack of knowledge regarding extravascular bioavailability and/or non-linearity in PK. 
 
Whole body physiologically-based PK (WB-PBPK) modeling provides a rational mechanistic approach for 
predicting the time course of drugs in the vasculature and potentially other tissue compartments, and has 
demonstrated utility in describing the mean time course of IV administered macromolecules in both pre-
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clinical and human species.(47-51) To extrapolate to SC administration however, these models may require 
modification to better account for local lymphatic drainage from the SC depot site.  
 
The lymphatic system provides unidirectional transport for fluid and protein by collecting constituents from 
the interstitial space and returning them to the blood.(21) While transport is convective in nature, movement 
of lymphatic fluid and macromolecules transported into and by the lymphatics can be influenced by muscle 
contractions and ambient temperature.(21;23;24) Lymphatic vessels are categorized into capillaries, larger 
collecting vessels, nodes, trunks and ducts, and likely, many capillaries drain a single injection site.(21;22) 
Cannulation techniques in animal models have allowed for the quantitation of macromolecule uptake into 
the lymphatics, and whilst seminal in confirming lymphatic involvement in biodistribution and contributing 
to our understanding of how macromolecule size influences uptake, they do not address the actual local 
drainage dynamics from the depot into the immediate lymphatic capillaries.(16;17;22) Skin lymphatics 
include superficially spread, subpapillary fine mesh and deeper vessels which empty into larger vessels 
draining the SC space before reaching the collecting ducts.(124) Mathematical modeling lymphatic drainage 
remains challenging, as there is no non-invasive method for differentiating the volume of lymphatics 
attributed to local drainage at the site of drug administration and that attributed to the remainder of the 
lymphatic vessels.   
WB-PBPK models for macromolecules and particularly mAbs have universally incorporated a lymph node 
compartment with convective transport dragging drug across the organ vascular-interstitial interface, into 
the lymph node compartment and subsequently into venous circulation.(47-51;66) Although mean values 
for a lymph node compartment are reported, it is unclear as to whether the reported volumes relate to the 
sum of all nodes, ducts, collectors and capillaries or to what extent these vary among individuals. 
Furthermore, population PBPK algorithms, available in the public domain, have not reported compartment 
characteristics (i.e. mean, variance) for the lymphatic system or lymph flow, and consequently don’t readily 
lend themselves to the study of SC administration of macromolecules in a population of 
individuals.(125;126)  
 
Employing a WB-PBPK modeling approach, we previously characterized the SC time course of a novel 
pegylated peptide conjugate in primates which was then scaled to humans at three different dose levels in a 
FIH single ascending dose (SAD) trial.(66) Upon further examination across a wider range of doses, the 
model predictions suggested further model refinement in the lymphatic uptake processes would improve 
predictive capacity of the model, particularly in the very early portion of the concentration vs. time profile. 
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To further investigate the contribution of local lymphatic capillary drainage from the SC space on the time 
course and shape of the plasma concentration vs. time profile (CPT), and to improve our understanding as to 
which parameters influence the variability of the CPT in a population, we endeavored to expand on our 
previous work and develop a population PBPK model which incorporates both lymphatic drainage and 
overall lymphatic system compartments. 
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6.2 Methods 
6.2.1 Observed Datasets 
CPT data was obtained for a novel pegylated peptide conjugate (approximately 45 kDa) as it transitioned 
from preclinical to early clinical development. The compound (name and target withheld for commercial 
proprietary purposes), predominantly consists of a freely water soluble, linear PEG-40 conjugated to a small 
(approximately 1 kDa) peptide portion. The current evaluation includes concentration and anthropometric 
data from 20 healthy Australian male subjects, 18-55 years of age and within a weight range of 60-80 kg 
who participated in a FIH, SAD investigation. The investigation was conducted under good clinical practice 
and according to the ethical principles outlined in the Declaration of Helsinki. Each subject received a single 
SC dose between 45 mg and 720 mg into the abdominal region with sequential PK sampling post-dose until 
approximately 1050 hours. The concentration of the injection ranged from 100 mg/mL to 150 mg/mL with 
multiple injections for some dose levels such that the volume in any single injection would not exceed 2 mL.  
Plasma was analyzed employing an LC-MS/MS method with a limit of quantitation of 1 ug/mL. 
 
6.2.2 Model Structure 
The base model structure has been previously described (66), and was slightly modified  to better 
characterize the SC drainage into the lymphatics. Representative mass balance equations are provided for 
reference in Appendix 6.1. The proposed overall and sub-compartment structures are based in part on the 
PBPK platform developed previously by Shah and Betts and is depicted graphically in Figure 6.1a-b.(50) 
The overall structure consists of a unique compartment for each of the venous and arterial circulation, a 
lymph node compartment and 15 individual organs where each organ consists of a vascular and interstitial 
sub-compartment. The skin interstitial compartment is further sub-divided into a depot and residual space 
where the SC dose inputs directly into the depot. The SC depot volume was parameterized as being 
equivalent to the total injection volume, which varied from 0.45-4.8 mL depending on the dose level and 
concentration injected. Transport from the interstitium into the lymphatic space is via a convective flow with 
a small degree of resistance parameterized as lymph flow and a lymphatic reflection coefficient (σi), as 
proposed by Garg and Balthasar.(102) In our previously developed model based on primates,, drug in the 
SC depot space emptied directly into a lymphatic compartment.(66) In the current model, an intermediate 
anatomical volume was added in order to include the localized lymphatic drainage from the SC depot into 
adjacent lymph vessels, which we will refer to as the lymphatic drainage compartment (LDC). The LDC 
subsequently drains into the greater lymphatic system compartment. Lymphatic flow empties from the 
lymph compartment into the venous circulation and re-enters the interstitial space in a one-way circuit via 
the same lymphatic convective flow. Transfer from the organ plasma vascular space to the interstitial space 
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is similarly driven by convective flow and constrained by vascular reflection coefficients (σv) that were 
initially set at values proposed by Shah and Betts.(50) However, as per the previous model, all organ 
vascular reflection coefficients are scaled by the parameter σsf, which was previously optimized.(66) 
Fraction vascular (Fvv) and interstitial (Fvic) were retained at the same values as in the original model.(66)  
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Figure 6.1a: Structure of a whole-body PBPK platform 
(adapted from Shah & Betts 2012). Solid black arrows 
indicate plasma flow. Dark grey dashed arrows indicate 
lymphatic transport. S. Int. and L. Int. represent small and 
large intestines. Each organ compartment includes lymphatic 
flow emptying from the organ into the lymph nodes. For IV 
administration, drug is administered into the “Venous 
Supply”. For SC administration, drug is administered into the 
“Skin Compartment” interstitium. 
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Figure 6.1b: Sub-compartment model for all organs other than 
skin (top) and skin (bottom).  
 
6.2.3 Virtual Population Development 
Prior to simulation of a virtual population, the target population for simulation needs to be defined. Since the 
observed PK data was obtained in a group of Caucasian Australian men, average height and weight and 
corresponding coefficients of variations for these anthropometric measurements in non-obese Australian 
males were obtained from Craig et al.(127) As described by Willmann et al., first, height values were 
randomly drawn from a normal distribution for a population of 1000 male subjects followed by sampling of 
each organ compartment mass for each individual in the virtual population.(126) To mitigate the likelihood 
of individuals with the same height being allocated identical organ weights, organ masses were drawn either 
from a normal or log-normal distribution (Table  6.1) that was re-centered to the size of the individual 
employing an allometric scaling factor according to the ¾ power rule.(126) To avoid the selection of 
extreme outliers, organ mass distributions were symmetrically truncated to the 95
th
 percentile and, when 
necessary to prevent negative masses, constrained at the lower bound to one tenth the re-centered mean 
value. A visual check was then performed to evaluate the impact of truncation and constraining the lower 
bound by repeating the simulations for all dose levels in the observed data where parameters initially drawn 
from a normal distribution were then drawn from a log-normal distribution.  
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Table 6.1: Anatomical and physiologic parameters with distributions used in the population PBPK 
model 
 
 Mean* CV% Distribution  CV% Source 
Mean Weight 71 (kg) / / / 
Compartment Mass  % Body Weight / / 
 
/ 
Adipose 18.540 0.43 Log-normal (128) 
Brain 1.968 0.10 Normal (128) 
Blood 
(Arterial/Venous) 
8.005 0.22 Log-normal (129) 
Bone 13.952 0.14 Normal (128) 
Heart 0.448 0.19 Normal (130) 
Kidney 0.421 0.25 Normal (130) 
Large Intestines 1.52 0.2 Normal (125) 
Liver 2.707 0.23 Normal (130) 
Lung 1.569 0.36 Log-normal (130) 
Lymph 0.359 0.22 Log-normal Empirically 
assumed to be 
similar to 
circulatory system 
variability 
Muscle 40.702 0.16 Log-normal (128) 
Other Remainder not 
accounted for by 
0.2 Normal Empirically 
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other organs selected 
Pancreas 0.136 0.27 Normal (130) 
Skin 4.477 0.1 Log-normal Empirically 
selected 
Small Intestines 1.068 0.12 Normal (125) 
Spleen 0.244 0.56 Log-Normal (130) 
Thymus 0.008 0.05 Log-Normal Empirically 
selected 
     
Hematocrit 0.42 0.02  Normal (131) 
Renal Filtration 
Fraction 
0.20 0.0294 Normal (132) 
Vfrac 0.25 0.68  Fitted Parameter 
*Mean organ mass was obtained from the BioDMET database(115) 
 
All model compartments, with the exception of skin, blood and lymph were scaled according to Equation 
6.1, where the mean mass of each organ 𝑂, denoted 𝑀𝑂
𝑚𝑒𝑎𝑛, is dependent on a single variable, in this case 
the body height of the individual, 𝐻𝑖𝑛𝑑𝑖𝑣, via an equation of the form 𝑀𝑂
𝑚𝑒𝑎𝑛 = 𝑐𝐻𝑖𝑛𝑑𝑖𝑣
𝑝
, where 𝑐 is a sex- 
and race-dependent constant and 𝑝 is a chosen exponent. Organ masses for a reference individual (𝑀𝑂
𝑟𝑒𝑓) 
were obtained from the BioDmet database where 𝐻𝑟𝑒𝑓 is the height of a reference individual weighing 71 kg 
with a body mass index of 24 kg/m
2
 (corresponding to a height of 172 cm).(115) Where organ volume and 
or mass were to be interconverted, density values for organs were obtained from ICRP references.(133) 
MO
mean=MO
ref× (
Hindiv
Href
)
3/4
  (6.1) 
 
Body height has been identified previously by de la Grandmaison as a better predictor of organ size in the 
majority of cases and the formula is rooted in allometric theory.(130) An exponent of ¾, although 
previously reported, was largely empiric for the current report, and others have used a range of values, 
upwards of 2, in a similar fashion.(126;134) 
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Blood and lymph mass means were scaled based on reference body weight (𝑊𝑟𝑒𝑓, Equation 6.2) as blood 
and lymph vessels are assumed to increase with increasing body weight as opposed to height. 
 
MO
mean=MO
ref× (
Windiv
Wref
)
3/4
  (6.2) 
 
Skin mass was scaled based on body surface area (BSA) as per Equation 6.3 where BSA was estimated 
based on Equation 6.4 and where the constant values for a, b and c were as proposed by Gehan and George  
(𝑎 = 0.0235, 𝑏 = 0.515, 𝑐 = 0.422) (135). 
 
Mskin
mean=Mskin
ref (
BSAindiv
BSAref
)  (6.3) 
 
BSAindiv=a×(Windiv)
b(Hindiv)
c  (6.4) 
 
The total body mass (BM) of a virtual individual was then calculated as the sum of the bloodless organ 
masses, lymph mass, skin mass and blood mass and the BM of the final population individuals (n=1000) 
included only individuals within the range of 60-80 kg, consistent with the observed population. As 
previously suggested by Peters blood mass was partitioned as 2/3 venous and 1/3 arterial.(122) 
 
For the derivation of organ-specific blood flows in each individual, mean perfusion values were first 
calculated for each organ to serve as a reference value assuming that perfusion rates would be constant 
across the population. Organ reference perfusion values were obtained by multiplying the cardiac output in a 
reference 71 kg male (115) by the blood flow fraction to that organ and then dividing the reference blood 
flow by the mean organ mass. Individual organ blood flows (QB) were then obtained by multiplying the 
organ weight of the individual by the reference perfusion value. Plasma flow (QP) was derived by 
multiplying QB by a factor of 1-hematocrit (hct), where hct was assumed to be log-normally distributed 
(Table 6.1). 
 
Consistent with the PBPK model for a reference male, lymph flow was set at a constant fraction of blood 
flow (LO) where the previously employed value of 0.2% was used for all organs except skin (LS), which 
was set to 0.1%.(66) The fraction of 0.2% corresponds to the upper range of lymph flow reported by Swartz 
whereas 0.1% was obtained by optimization in the reference male model.(21) 
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Clearance of the pegylated protein was previously characterized by both renal (RCL) and non-renal 
clearance (NRCL). RCL was set at 0.1% of glomerular filtration rate (GFR) consistent with previously 
investigated PEG-conjugated therapeutics. To allow for incorporation of interindividual variation in GFR, 
the GFR was derived from the product of renal plasma flow and filtration fraction (FF) where FF was drawn 
from a log-normal distribution (Table 6.1).(25;66)The acronym FGFR is used to represent the fraction of 
glomerular filtration attributed to renal clearance. To avoid the risk of including individuals with GFRs in 
the impaired region of glomerular function, and to avoid extremely large values for GFR, only individuals 
with a GFR within the range of 90-150 mL/min were used in the simulation.(136) 
 
For the compound in question, NRCL was assumed to occur by both macrophagic uptake of the non-
pegylated moeity and by non-specific cleavage of the pegylated chain.(26) NRCL was optimized in 
primates in our previous model and for the current model NRCL in the primate was scaled to each simulated 
human based on the body weight ratio of a simulated human individual and the mean weight of the primate 
(3.4 kg).(66) The NRCL was then apportioned based on the relative volume of each compartment in which 
NRCL was assumed to occur. 
 
6.2.4 Optimization of LDC 
As the volume of drug product injected into the SC space increased, we hypothesized that there would be a 
proportional spreading of drug substance within the interstitial space, as opposed to expansion, thus 
increasing the surface area for lymphatic drainage. The volume then attributed to the LDC was considered 
proportional to the volume of the SC depot compartment. LDC volume was parameterized as a fraction of 
the SC depot compartment, denoted as Vfrac and estimated by fitting to the dose-normalized CPT data for 
all observed subjects.  For this procedure, the PBPK model for an average human was coded into Phoenix 
NLME (v1.3, Certara) and estimation of the population mean Vfrac and between subject variability (as a 
log-normally distributed random effect) was performed using the first-order conditional estimation with 
interaction algorithm (FOCE-ELS).  
 
Estimation was performed by considering the actual volume injected since the concentration varied across 
the five dose cohorts where all remaining parameters were fixed at the mean values previously optimized for 
a virtual human.(66) An additional sensitivity analysis was performed whereby the optimization of Vfrac 
was based solely on the CPT data obtained for a single dose level in the human investigation. An objective 
function calculated as the absolute, average deviation of the median predicted concentration vs. median 
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observed concentration at each nominal time point for each study cohort was employed to discriminate 
between models with and without an LDC. 
 
6.2.5 Model Qualification 
All simulations were performed using MATLAB® (v2014b, Mathworks). Adequacy of the model in 
describing the study population was assessed following simulation of 1000 virtual male subjects based on 
the study population characteristics with body weight constrained to the per protocol specified body weight 
(60-80 kg) and normal GFR (90-150 mL/min). Histograms were generated for height, weight and body mass 
index (BMI) to verify the generated population was consistent with the study population and included 
plausible individuals.  
 
6.2.6 Sensitivity Analysis 
A sensitivity analysis was performed to evaluate the model response to perturbation of the mean values of 
the parameters deemed to be the most uncertain and to evaluate the effect of incorporating or removing a 
distribution on certain parameters where the distribution was deemed uncertain. Mean parameter sensitivity 
was performed for Vfrac, σsf, σi, NRCL, LS and FGFR. For each perturbation, 100 individuals were 
simulated at the lowest dose level (45 mg) and one parameter at a time was perturbed by ±10%, except σsf, 
which was perturbed upwards of 1% to avoid any single organ σv from exceeding 1. To evaluate sensitivity, 
non-compartmental analysis was performed on the median (50
th
 percentile) simulated concentration vs. time 
profile to derive the AUC0-inf and Cmax. Change from the final model (with LDC) as a percent was 
expressed and plotted graphically by perturbation of the mean parameter value. 
A sensitivity analysis on distributions was also performed by simulating 1000 individuals and either 
perturbing or removing a parameter distribution one at a time. The simulations for each scenario were 
plotted and compared. This analysis was completed to define the importance of specific parameter 
distributions on overall CPT variability. 
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6.3 Results 
One of the primary objectives of this investigation was to develop a population generator with a lymphatic 
system component. As a population generator, the model produced a population consistent with the study 
population (Figure 6.2). With body height sampled from a normal distribution and total BM truncated to a 
range of 60-80 kg, the resultant BMIs fell largely within the typical range normally included in Phase 1 
healthy volunteer research (18-28 kg/m
2
), with only a few of the 1000 simulated individuals falling outside 
this range. The histogram for GFR, calculated as a product of the individual FF and renal plasma flow 
verified that the final population included only males with normal renal function within the specified range 
of 90-150 mL/min.  
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Figure 6.2: Model output anthropometric distribution of 
weight (upper left panel), height (upper right panel), body 
mass index (lower left panel) and derived glomerular filtration 
rate (lower right panel) for 1000 simulated individuals. 
 
Using the mean virtual human model and the observed dose-normalized data, Vfrac was estimated with high 
precision (16.8%) with a mean and interindividual coefficient of variation of 0.25 (68%). This value 
represents the volume of LDC expressed as a fraction of the SC depot volume. Although sampled from a 
normal distribution, Vfrac for each individual was greater than zero for simulated individuals due to the 
truncation and constraining methods applied to the organ mass distributions. A sensitivity analysis 
confirmed that similar results were obtained regardless of whether Vfrac is sampled from a normal 
distribution with constraints versus sampling from a log-normal distribution suggesting the type of 
distribution does not influence the predictive capacity of the model.(125;126)  
 
Figure 6.3, illustrates the comparison of the models with and without LDC when simulated for a population 
(n=1000, 200/dose level). Visual inspection of the log-log CPT (Figure 6.3, right panel) illustrates an over-
prediction of the absorption phase when a LDC is not incorporated. Inclusion of LDC resulted in a reduction 
of the objective function from 107.11 to 21.10, relative to the model excluding LDC and improved the 
prediction of the absorption phase, particularly in the first 10 hours post-dose. 
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The model, with LDC, predicted the interindividual variability in all phases of the CPT (i.e. absorption, peak 
and elimination) with observed data points falling on either side of the 50
th
 percentile curve and a few 
individual observations falling outside the 5
th
 - 95
th
 percentile ribbon. The one exception being a subject in 
the initial dose cohort (i.e. 45 mg dose) who clearly exhibited an anomalous profile, likely due to improper 
injection technique, as repeat analysis by the bioanalytical laboratory confirmed the measured concentration 
values.  
 
Figure 6.3: Model simulated and observed plasma 
concentrations of a linear PEG-40 conjugated peptide versus 
time in humans on linear scale (left panel) and log scale (right 
panel).  Within each panel, the left set of profiles represents 
the model without a lymph transit compartment and right side, 
with a lymph transit compartment incorporated. Closed 
geometric symbols represent unique individual subjects across 
5 dose levels. Solid lines and grey shaded ribbon represents 
the median and 5th-95th percentile simulated concentrations 
from respective models.  
 
Using the one-at-a-time sensitivity test for mean parameters demonstrated that in spite of a profound 
influence on the early portion of the time course for this particular drug, the impact of parameter 
perturbation on peak and overall exposure (i.e. Cmax and AUC) was relatively small (Figure 6.4). The 
largest effect in terms of % change from the final model resulted from a -10% perturbation of σsf on both 
 153 
 
Cmax and AUC. As described in the methods section, an upward perturbation was constrained to 1% to 
avoid any of the individual organ vascular reflection coefficients from exceeding 1. Even so, a one percent 
change in the mean vascular reflection coefficient scaling factor resulted in a visually detectable change in 
AUC and Cmax, confirming the model sensitivity to this parameter. Unsurprisingly, perturbations in FGFR 
and NRCL parameters, which influence renal and non-renal clearance, resulted in the next largest percent 
change in AUC, whilst having little influence on Cmax. 
 
Figure 6.4: Mean parameter sensitivity perturbations vs. 
percent change in AUC (top left), Cmax (top right) and Tmax 
(bottom left) for the 50th percentile following simulation of 
100 subjects. Closed geometric symbols represent 
perturbations as indicated in the legend.  
 
To illustrate the impact of varying parameter distribution assumptions on the three phases of the CPT, 
scenarios are presented on both linear and log scales (Figure 6.5). Of the parameters tested, applying a 
distribution assumption to LS, the parameter defining skin lymphatic flow as a fraction of skin blood flow, 
had the greatest influence on the interindividual variation in the absorption phase (Figure 6.5 panels 4 & 5). 
Whereas in the model development, only a mean valuefor LS was assumed, coefficients of variation of 10% 
and 50% were empirically selected and the width of the 5
th
-95
th
 percentile ribbon expanded as the variability 
increased. In addition to LS, variability assumptions for the Vfrac parameter also influenced the 
interindividual variability in the absorption phase of the CPT. Halving and doubling the estimated variability 
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assumption from 68% to 34% and 136%, respectively  resulted in a corresponding narrowing and widening 
of the simulated values supporting our hypothesis that the variability assumption for this parameter is 
important in the prediction an SC administered pegylated macromolecule CPT (Figure 6.5, panels 2 & 3). 
With respect to the peak portion of the CPT, variation in LS and blood volume appeared to be the most 
influential parameters when the distributional assumption was perturbed. For blood volume, the perturbation 
scenario included removing the variability in its entirety for this parameter and simulating a population 
based only on the mean blood volume value (Figure 6.5, panel 8). This change considerably narrowed the 
interindividual variability at the peak of the curve which leads to an imprecise prediction of Cmax, thus 
supporting the importance of including the selected blood volume variability employed in the final model.. 
Adding distributional assumptions to FGFR, which was assumed to be static for the final model simulations 
at 0.1% of GFR, resulted in an obvious broadening of the interindividual variability in the latter portion (i.e. 
elimination) of the CPT.(Figure 6.5, panel 11). Of the other parameters tested, none had obvious visually 
detectable effects across the stages of the concentration vs. time course.  
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Figure 6.5: Median (dashed line) and 5th-95th percentile 
(shaded ribbon) following simulation of 1000 virtual 
individuals on linear scale (left panel) and log scale (right 
panel). For sub-panels 1-11 in each panel, the following 
unique scenarios are presented: (1) Final model (2) 0.5-fold 
final model CV% for Vfrac (3) 2-fold final model CV% for 
Vfrac (4): Addition of 10% CV% on LS (5) Addition of 50% 
CV% on LS (6) Addition of  10% CV% on σi (7) Addition of 
50% CV% on σi (8) Removing distribution on blood mass (9) 
Removing distribution on lymph mass (10) Removing 
distribution on skin mass (11) Addition of a 20% CV% on 
FGFR. 
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6.4 Discussion 
The compound employed in the current evaluation and the base structural PBPK model were the same used 
in our previous publication illustrating the utility of incorporating a SC depot in the prediction of a human 
CPT directly from a single non-human primate species.(66) The molecule’s biodistributional properties 
were assumed to be largely attributable to the pegylated moiety, which represents >96% of the molecular 
weight. The current in silico investigation demonstrates the scale-up from monkeys directly to a population 
of humans across a range of body sizes as opposed to a virtual human (weighing 70 kg). 
 
The major objectives of this evaluation were two-fold and inter-related. The first being to develop a 
population PBPK model which incorporates distributional assumptions for the lymphatic system which 
could potentially be applied to large molecule PK predictions in a human population. The drug independent 
aspects of the model, being mechanistic in nature, can thus be applied to generating a population of 
individuals regardless of weight and height range and thus can be used to estimate the variability in a more 
diverse population than what was studied in the current report. 
 
Conversion of the model to a population model was non-trivial as there is a paucity of literature to support 
integrating lymphatic anthropometric variability into PBPK models. Initially, we followed previous authors 
in terms of the distribution type (i.e. normal vs. log-normal) and, where possible, employed similar 
variability estimates (Table 6.1).(125;126) For some organ compartments however, either there was no 
information to inform said distribution or the variability appeared unusually high. It may seem 
counterintuitive to employ normal distributions with respect to organ sizes given the possibility of drawing 
implausibly small or even negative values. However, to be consistent with reported literature we elected to 
retain distributions as previously reported. Instead we performed an informal sensitivity analysis which 
concluded no appreciable difference in the prediction interval across the simulated dose cohorts regardless 
of whether a distribution was log-normal or not. In our final model we employed two tiers of safeguards to 
mitigate the risk of drawing extreme outliers or negative values when the distribution was set as normal, 
with the first being truncation to the 95
th
 percentile of the distribution and the second, constraining the lower 
bound to one tenth the mean value. Intuitively, where future data supports, population simulations should 
consider log-normally distributions to avoid the likelihood of negative or uncharacteristically low values 
being drawn from the distribution.  
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Prior to truncation of GFR, values within the initial population led to values interpreted as renally impaired 
or unusually high. After a thorough investigation, we confirmed that kidney perfusion and renal plasma flow 
on a per gram of tissue basis were consistently within the expected range and consequently the root cause 
was attributed to a larger than likely coefficient of variation for male kidney mass used as an input into the 
model.(125;126;130) As a further safeguard against inflated variability in kidney mass, especially given the 
importance of renal elimination to the drug in question, the model was set to reject any virtual individuals 
with GFRs less than 90 mL/min, due to being associated with renal impairment, and above 150 mL/min 
range, which normal healthy individuals rarely achieve, even when normalized to 1.73 kg/m
2
 BSA.(137) 
This exercise suggests that reported values for kidney mass variability may necessitate further evaluation to 
ensure kidney function is appropriately simulated in the virtual population.  
 
As described in the Methods section, we empirically assumed that the variability in lymphatic system 
volume would be equal to that of the variability in blood volume. Although there is not specific data to 
inform this hypothesis, lymphatic vessels represent a parallel circulatory system and thus an assumption of 
blood volume based on individual size was deemed a reasonable approach. 
 
The second objective of this in silico investigation was to explore the advantage of incorporating a LDC to 
better represent local drainage from a SC depot space, to facilitate predictions of SC administered 
macromolecules. 
 
Lymph collector vessels which run through the SC space picking up macromolecules, are reported to not 
reach the deep fascia until a node is reached, and from the skin can follow an unpredictable course, draining 
to multiple lymph nodes.(138) To address the lymphatic drainage of the drug from the SC site of 
administration by lymphatic capillaries, and to quantify the volume and variability in vessel volume, we 
elected to parameterize this compartment as a fraction of injection volume. The rationale for this approach is 
predicated on the assumptions that (1) there are multiple afferent vessels draining the site and (2) the 
drainage volume would increase as the volume of injection increases due to spreading within the interstitial 
space.(22) Precedent for this position is based on comparisons of high pressure SC auto injector and manual 
SC injection of recombinant human growth hormone, where increased pressure from the auto injector 
resulted in a higher and earlier CPT peak compared to a manual syringe, which was attributed to greater 
spread of injected material in the SC space.(139) 
 
Other PBPK models with injection depots have employed varying assumptions for lymphatic drainage. Gill 
et.al. parameterized the SC depot as a fixed volume and lymph flow estimated from literature reports on 
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macromolecule disappearance from the SC site.(52) It’s unclear why the authors, however, elected to 
estimate lymph flow for each study rather than rely on a standardized the lymph flow rate for skin. 
Lymphatic flow is a physiologic process and expected to be driven by anthropometric characteristics 
variability; consequently, the methods outlined by Gill do not appear to readily lend themselves to 
population simulations. Moreover, an assumption of a fixed volume being attributed to the SC depot is not 
realistic as injection volume varies from compound to compound, and study to study based on drug 
physicochemical properties and tolerability to the injected drug concentration. Tegenge & Mitkus, in 
simulated intramuscular (IM) injections of squalene-containing compounds, parameterized the lymphatic 
drainage by taking the total lymph node volume and applying the fraction of lymph nodes assumed to drain 
directly from the IM depot space.(140;141) This approach, however assumes the drainage occurs directly 
from injection site to a single node. However, patterns of lymphatic drainage from the skin are reported to 
vary substantially among individuals, even from the same area of the skin.(138)  
 
Our model attempts to characterize local drainage by attributing a physical space representing the lymphatic 
capillary vessels the drug would journey through from the interstitial space to the lymph node, and is 
considered an additive volume to the lymphatic system as parameterized in the model proposed by Shah & 
Betts.(50) Although it is well established that lymphatic vessels drain from the skin, to our knowledge, an 
experimentally obtained value for this volume has not be determined. Consequently, it is challenging to 
build a purely mechanistic model describing this drainage. Gill et. al. considered the disappearance of 
labeled IgG from the SC space as a means of estimating the transit of drug from the injection site to the 
vasculature, and others have used estimation procedures to fit a transit time parameter.(50;52)  However, a 
time parameter is not entirely mechanistic and cannot necessarily be relied upon for scaling up from 
preclinical species to human. 
 
In contrast, parameterizing the LDC volume as a fraction of the injection volume represents an approach 
which assigns an anatomical volume to drug transit from the SC space to the lymph nodes relying on the 
skin lymph flow as a mechanistic driver of said transit. As this was the initial use of this methodology, no 
prior information was available to inform this value. Therefore we used mathematical estimation to optimize 
the value based on observed data obtained in the human population. Evaluation of the dose vs. exposure data 
suggested that the pharmacokinetic exposure was linear across the doses tested (unpublished data). 
Therefore we elected to perform the optimization based on all available observed data. However, as an 
informal sensitivity measure, we re-estimated Vfrac based on only a subset of the population which resulted 
in an indiscernible difference in the predicted vs. observed data (data not shown). 
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In the current model, the volume of the LDC was assumed to be dependent only on the injection volume, 
and independent of compound size. However, logically, spreading of drug particles within the SC space in 
theory could be influenced by the drug’s physicochemical characteristics such as fluid viscosity and inactive 
excipients. Therefore, the utility of our methodology requires qualification with compounds across a broad 
pharmacologic class and molecular weight, among other characteristics, to qualify this approach for more 
general use.  
 
Another consideration in developing PBPK models for PK predictions of macromolecules after SC 
administration is the bioavailability after SC injection. Macromolecules are reported to vary in terms of their 
SC bioavailability, independent of molecular weight.(18;39) The current compound was previously 
demonstrated to exhibit a relatively high SC bioavailability in primates at approximately 90% (data not 
shown). Our model was largely able to predict the exposure in humans when scaled from primates, by 
assuming non-renal clearance processes are proportional to the volume of the space clearance occurs in. The 
predictive capacity of our model requires additional work, testing broader group of macromolecules with a 
wide range of SC bioavailability, to be confidently applied in an a priori setting for drugs with unknown SC 
bioavailability.  
 
Based strictly on a percent change in AUC and Cmax, perturbation of the mean LDC does not appear as 
influential in terms of peak and overall exposure. In this scenario where the half-life was on average greater 
than 200 hours based on non-compartmental analysis (data not shown), relying on the % change in AUC 
and Cmax is misleading, as inclusion of an LDC clearly was necessary to achieve the same profile shape as 
the observed data and resulted in a considerably smaller objective function.  Inclusion of LDC only appears 
necessary to delay transit from the SC depot site immediately after administration. Following the initial 
transit through the lymphatics, drug mass that is not renally eliminated, recirculates to the organs. Drug 
mass that reaches the skin interstitial space that is not cleared by non-renal processes represents a relatively 
small proportion of the total circulating mass. Inclusion of a transit compartment draining from the full skin 
interstitial volume, parameterized identically to the drainage from the SC depot, consequently did not 
impact the model prediction (data not shown), and following the rule of parsimony, was excluded from the 
final model. However, incorporating lymphatic transit from the entire interstitial volume may have utility in 
other scenarios where multiple SC injection sites are being tested.  
 
Despite the uncertainty in the mean and variability values included as input into the model for the lymph 
node compartment, the model was largely insensitive to the  mean value of the lymph node. In contrast, the 
model exhibited the greatest sensitivity to the mean value for skin lymph flow likely as a consequence of the 
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route of administration being SC. This is consistent with our previously developed model for predicting the 
mean time course of the same drug in humans from primates.(66) We specifically observed a distinctly 
slower skin lymph flow was required relative to the current assumed range of 0.2-1% of blood flow to an 
organ (21) Lymph flow is inherently difficult to measure in humans and has been assumed to scale from 
animal values. As a fraction of blood flow, it may not be reasonable to assume lymph flow represents a 
similar fraction of blood flow across all organs, and in fact Baxter reported a wide range of organ lymph 
flow values in the mouse, with skin lymph flow representing the lowest rate as an absolute value across all 
organs reported.(101) Jones et. al. has stated that in spite of the wide range of reported lymph flows, many 
of the previously cited models fit the observed data well, and that this raises a fundamental question 
regarding model parameterization.(142) Jones goes on to state that approximately 0.07% of fluid entering 
the interstitial space returns to the blood via the lymph when considering net fluid recirculation.  It is 
interesting to note that in our previous work for the same compound (66), the optimized skin lymph flow 
was 0.1%, very close to the 0.07% of blood flow suggested by Jones et. al. More importantly, these results 
reinforce the argument that models being developed for IV administration cannot simply be applied to SC 
administration without consideration of specific lymphatic drainage from the SC depot site. 
 
Assuming interindividual variability of skin lymph flow resulted in a wider prediction ribbon in the 
absorption and peak portions of the curve. The shape of the ribbon, particularly around Cmax, confirms the 
vital importance of this parameter in models intended to simulate the SC profile of a macromolecule and 
also further supports the previously stated position that skin lymph flow may represent a smaller fraction of 
blood flow than previously assumed. 
 
Further evaluation of model sensitivity suggested clearance mechanisms are important for characterizing the 
interindividual variability of this pegylated peptide in a population.  As previously stated, despite the large 
molecular mass, pegylated compounds can be renally eliminated in primates and humans albeit slowly, at a 
rate of approximately 0.1% of GFR.(25) As renal clearance accounted for approximately one third of total 
body clearance we were particularly interested in whether changes in renal function would result in a change 
in peak and overall exposure.  Perturbation of FGFR, which in the current model represents a fraction of 
GFR, can be interpreted as a surrogate for a change in renal function and the results of the sensitivity 
analysis suggested that changes in renal function precipitate a change in AUC. Whether this percent change 
is sufficient to warrant a change in the recommended dose however, is a function of the drug’s safety profile 
and the relationship of exposure to safety.  
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6.5 Conclusion 
This is the first PBPK model incorporating lymphatic system anthropometric interindividual variability for 
the purposes of simulating macromolecule PK in a population. As a population generator, this model is 
capable of simulating a population of individuals across a wide range of body weight and heights for use 
with other compounds with lymphatic distribution and transport. A novel proposal of incorporating an 
anatomical space representing lymphatic drainage by lymphatic capillaries appears  critical in characterizing 
the early time course following drug absorption and the consequence of excluding the compartment results 
in poor prediction of the observed data in the early portion of the CPT. Variability in this lymph transit 
compartment and skin lymph flow exhibit the greatest influence on model prediction as it pertains to the 
absorption phase of the CPT following SC administration, whereas blood volume and renal clearance 
exhibit the largest apparent effect on Cmax and elimination phases of the curve, respectively. 
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CHAPTER 7: PREDICTION ACCURACY OF MODEL BASED METHODS, DISCUSSION AND 
CONCLUSIONS 
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7.1 Prediction Accuracy of Model Based Methods 
Previous chapters proposed empirical and mechanistic model-based approaches to predict the 
pharmacokinetics (PK) of a pegylated peptide conjugate (PPC) following subcutaneous (SC) administration.  
Chapters 4-6 primarily focused on the time course prediction after SC administration, and model 
discrimination was based on  qualitative improvements in the time course or in an objective function which 
was based on the difference in predicted vs. observed concentration values. To standardize the comparison 
of model-based and model-independent methods, a post-hoc analysis has been performed for the current 
chapter employing data obtained from the models described in chapter 4-6. Within the following sections a 
summary of the results for the model-based methods are presented (Section 7.2 and 7.3), followed by an 
overall comparison across model-based and model-independent methods (Section 7.4). Predictions were 
considered reasonable where the fold-error (FE), as described in Chapters 2 and 3, fell within a threshold of 
0.7-1.3.  
 
7.2 Prediction Accuracy of Model Based Scaling Scenarios in Chapter 4 
Chapter 4 tested the utility of first fitting concentration vs. time data obtained in  a single, nonhuman 
primate (NHP) species (i.e. cynomologus monkeys)  to a population compartmental PK model, then scaling 
the model to human via incorporation of allometric expressions on each of the typical population values 
obtained in NHP. Specifically, the NHP obtained typical PK parameter value for a parameter was multiplied 
by the ratio of body weights of the two species, exponentiated to an empiric scaling factor. For clearance 
(CL)  parameters (extravascular clearance, CL/F) and distributional CL, exponents of 0.85 and 1; for 
extravascular volume (V/F) and distributional volume an exponent of 1; and for first-order absorption 
processes exponents of -0.4 and 1 were each tested for prediction accuracy. Additionally, exponents for each 
parameter were fitted to the concentration vs. time data normalized to the initial lowest dose cohort (i.e. 45 
mg) from a group of healthy male subjects participating in a first-in-human (FIH) investigation. Scenario 3, 
which assumed an exponent of 1 for all CL and Vd parameters, with a negative exponent of -0.4 for first-
order absorption, exhibited the best visual agreement with the observed data. This scenario also resulted in 
the smallest objective function, which is a measure of difference between the observed and predicted results.  
As described in Section 7.1 of this chapter, prediction accuracy expressed by FE was the chosen metric for 
cross-method comparison and a FE falling within a threshold of 0.7-1.3 was considered a reasonable 
prediction. To facilitate the cross-method comparison, a vector of body weights (n=200 virtual human male 
subjects) was simulated corresponding to the range of actual body weight prescribed by the protocol for the 
FIH study described in Chapter 4. Concentration vs. time profiles were simulated for each virtual individual 
based on the model summarized in the above paragraph for Scenario 3, then non-compartmental analysis 
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(NCA) was used to obtain the secondary PK parameters. From the simulated NCA-derived PK parameters, 
an arithmetic mean value for each parameter of interest (See Table 7.1) was obtained. The simulations 
assumed the highest dose tested in the FIH study (i.e. 720 mg) and were compared to the arithmetic mean 
corresponding PK parameter from the observed data for subjects having received the same 720 mg dose 
(n=4). The 720 mg dose was selected as this dose resulted in concentrations which were quantifiable above 
the assay limit of quantitation for the longest duration of sampling post-dose.  
 
Table 7.1: Prediction accuracy measured by fold-error within 0.7-1.3 of the arithmetic mean 
predicted PK parameters obtained from simulation ( Chapter 4, Scenario 3) of a virtual population 
of male subjects (n=200) receiving a single, subcutaneous dose of 720 mg pegylated peptide 
conjugate compared to the  arithmetic mean of the corresponding PK parameters in a group of 
actual human subjects receiving the same dose and regimen of a pegylated peptide conjugate in a 
FIH investigation  
 
Parameter Units Predicted  
(Human) 
Observed  
(Human) 
Fold-Error Criteria 
Achieved 
Tmax hr 131 126 1.00 Yes 
Cmax μg/mL 128 139 0.92 Yes 
AUC0-t μg•hr/mL 50993 56446 0.90 Yes 
AUC0-inf μg•hr/mL 53241 59742 0.89 Yes 
CL/F mL 13.6 12.2 1.10 Yes 
Vz/F mL/hr 4012 4154 0.97 Yes 
T1/2 Hr 204 235 0.87 Yes 
PK parameters obtained via non-compartmental analysis 
 
Evaluation of the FE clearly demonstrates close agreement between predicted and observed values, 
especially as they pertain to Tmax and Cmax. These results, which were obtained by scaling a set of 
population PK model parameters by empiric allometric exponents, support the hypothesis that an inverse 
allometric relationship exists between species body weight (or at least between small monkeys and humans) 
and first-order absorption rate.  
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7.3 Prediction Accuracy of Physiologically-Based Pharmacokinetic Models in Chapters 5 and 6 
The physiologically-based pharmacokinetic (PBPK) model presented in Chapter 5 was developed with the 
intention to predict the PK time course of a SC administered PPC in a virtual 70 kg healthy human male  
subject and to compare said time course to the observed data from the first-in-human (FIH) dose escalation 
study. The NHP model was developed using anatomical and physiologic data corresponding to a NHP 
species, and simulation of the concentration vs. time profile following single-dose intravenous and 
subcutaneous administration of PPC to NHP demonstrated close agreement with the observed concentration 
data for the same species. The NHP model (was subsequently scaled to human anatomic and physiologic 
values for a typical 70 kg male. This model is referred to as the base PBPK model or base model for short.  
As described in Chapter 5, the base model did not allow for optimal characterization of the Tmax and Cmax 
of the observed data. Consequently the model was updated with a value for slower skin lymph flow (LS Opt 
model), which improved the model prediction of the time course of the drug, and particularly for Tmax. A 
further model revision was described in Chapter 6, developed to refine the prediction capacity of the 
absorption phase through incorporation of a local lymphatic drainage compartment from the SC depot space 
into the central lymphatics  (lymphatic drainage compartment or LDC ). Incorporation of a LDC (Vfrac 
model) resulted in a qualitative improvement based on graphical interpretation. Although the Vfrac model 
was originally presented in Chapter 6 in the context of a population PBPK model, to facilitate a cross-
method comparison NCA-derived PK parameters were obtained for a simulation following a single-dose of 
PPC via the subcutaneous route for a virtual 70 kg human. Similar to the prediction accuracy assessment for 
the population PK model described in Section 7.2, NCA-derived PK parameters for the three PBPK model 
versions were compared to the mean of the observed data using the FE common metric. As with the analysis 
in Section 7.2 the highest dose cohort was selected for cross-method comparison of model-based methods as 
this dose resulted in the greatest number of concentration samples above the limit of quantitation for the 
longest duration post-dose. 
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Table 7.2: Prediction accuracy measured by fold-error within 0.7-1.3 of PBPK model versions 
comparing the PK parameters derived from the concentration vs. time profile obtained from a 
simulation for a virtual 70 kg human male and the arithmetic mean corresponding PK parameter of 
the observed human male subjects receiving a 720 mg single, subcutaneous dose of a pegylated 
peptide conjugate in a FIH investigation 
  FE of predicted vs. observed  
Parameter Units Base  Criteria 
Achieved 
LS Opt  Criteria 
Achieved 
Vfrac  Criteria 
Achieved 
Tmax hr 0.57 No 0.76 Yes 0.95 Yes 
Cmax μg/mL 1.08 Yes 0.89 Yes 1.03 Yes 
AUC0-t μg•hr/mL 1.09 Yes 1.06 Yes 1.02 Yes 
AUC0-inf μg•hr/mL 1.33 No 1.31 No 1.28 Yes 
CL/F mL 0.79 Yes 0.80 Yes 0.82 Yes 
Vz/F mL/hr 1.11 Yes 1.14 Yes 1.27 Yes 
T1/2 hr 1.42 No 1.42 No 1.55 No 
PK parameters obtained via non-compartmental analysis 
Base: Base PBPK model empirically assuming skin lymph flow at 0.2% of blood flow 
LS Opt: Base PBPK model with skin lymph flow optimized (0.1% of blood flow) 
Vfrac: LS Opt PBPK model with a lymph drainage volume compartment parameterized as a fraction of the injection volume  
 
Model improvements in Tmax were most obvious when the model incorporated a LDC (Vfrac model), 
where the improvements in prediction were largely confined to the earliest time points, and did not have a 
substantial adverse or positive effect in prediction of Cmax or AUC parameters relative to the other two 
PBPK model versions. 
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7.4 Cross-Method Comparison 
7.4.1 Cross-Method Comparison of Key Pharmacokinetic Parameters 
While CL and Vd parameters are considered critical parameters for describing the rate of removal and 
distribution of a drug, alone these parameters do not inform the time course of an extravascularly 
administered drug.  In contrast, parameters such as Cmax and Tmax provide some insight into the time 
course and rate of drug input into the systemic circulation. Unfortunately, methods used to empirically scale 
a physiological process (e.g. CL) or a representation of a body compartment volume (Vd) such as single-
species simplified allometry as presented in Chapter 3, do not lend themselves to comparing prediction 
accuracy of secondary PK parameters (e.g. Cmax and Tmax). Dedrick plots, which are considered empirical 
and model independent methods, however can potentially be used to predict the time course of drugs, 
although most frequently employed for intravenously (IV) administered compounds. This method was also 
employed in Chapter 3 to determine if there is potential utility in the prediction of secondary PK parameters 
(i.e. Cmax and Tmax) for a SC administered macromolecule. Dedrick plots rely on transformation of time 
and concentration scales for interspecies predictions. If the PK sample collection interval for the animal 
species is truncated, unusually sparse in number of samples, as is common in animal PK studies due to 
blood volume limitation, this can bias the estimation of the apparent elimination rate constant (λ) when 
using NCA methods. Consequently T1/2 estimations would then be similarly biased since the T1/2 is simply 
the natural log of 2 divided by λ.  The preclinical dataset employed in this thesis for NHP terminated at 336 
hours post-dose. Once the time scale was transformed to human according to the methodology outlined in 
Chapter 3, the predicted human dataset terminated at approximately 500 hours post-dose. This is in contrast 
to the observed human profile, which extended to approximately 1000 hours post-dose. Thus, Dedrick plot 
scaling is limited in utility in predicting the T1/2 where the sampling time points are sparse or are 
prematurely terminated before a true elimination phase is characterized. Similarly, if the limit of assay 
quantitation is insufficient for, this case, the NHP plasma compared to human, this could also limit the 
utility of Dedrick plot prediction. As noted in Chapter 4 and 5, the limit of assay quantitation was the same 
for both human and NHP assays. 
 
Table 7.3 illustrates cross-method comparison of model-independent and model-based methods for 
estimating clearance and volume parameters. With the exception of single-species allometric (SSA) 
methods relying on a fixed exponent for CL of 0.85, the prediction accuracy criteria of FE within 0.7-1.3 
was achieved in all cases regardless of the method employed. Perhaps a more discriminating evaluation for a 
SC administered macromolecule is the cross-method comparison of secondary PK parameters which inform 
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the rate of absorption following administration (i.e. Cmax and Tmax). Table 7.4 illustrates the advantage of 
model-based evaluations here.  Since SSA methods only consider processes and not secondary PK 
parameters, the SSA method is omitted for said comparison. The sheer fact that this method is incapable of 
informing secondary PK parameters highlights one major disadvantage. As Dedrick plots do potentially 
allow for estimation of secondary PK parameters, it was included as the sole model-independent method in 
the following comparison.  
 
Table 7.3: Cross-method prediction accuracy of extravascular clearance (CL/F) and volume of 
distribution (V/F) for model-independent and model-based scaling methods measured by fold-error 
within 0.7-1.3  
 
Method Parameter Fold-Error Criteria Achieved 
SSA CL/F 0.67 No 
Dedrick Plot CL/F 0.72 Yes 
MMSA (Scenario 3) CL/F 1.10 Yes 
PBPK (base) CL/F 0.79 Yes 
PBPK (LS Opt) CL/F 0.80 Yes 
PBPK (Vfrac) CL/F 0.82 Yes 
    
SSA V/F 0.89 Yes 
Dedrick Plot V/F 0.93 Yes 
MMSA (Scenario 3) V/F 0.97 Yes 
PBPK (base) V/F 1.10 Yes 
PBPK (LS Opt) V/F 1.14 Yes 
PBPK (Vfrac) V/F 1.27 Yes 
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Table 7.4: Cross-method prediction accuracy of Cmax and Tmax for model-independent and 
model-based scaling methods measured by fold-error within 0.7-1.3  
 
Method Parameter Fold-Error Criteria Achieved 
Dedrick Plot Cmax 1.10 Yes 
MMSA (Scenario 3) Cmax 0.92 Yes 
PBPK (base) Cmax 1.10 Yes 
PBPK (LS Opt) Cmax 0.89 Yes 
PBPK (Vfrac) Cmax 1.00 Yes 
    
Dedrick Plot Tmax 0.67 No 
MMSA (Scenario 3) Tmax 1.00 Yes 
PBPK (base) Tmax 0.57 No 
PBPK (LS Opt) Tmax 0.76 Yes 
PBPK (Vfrac) Tmax 0.95 Yes 
 
Where Table 7.3 suggests any of the tested methods may be appropriate for interspecies scaling prediction 
of the human PK for PPC, comparison of Cmax and Tmax FE as expected, are more discriminating 
parameters. Dedrick plots were able to predict the peak with reasonable FE, however clearly fell short on 
Tmax. Referring back to Chapter 3, this failure to predict is likely based on the fact that Dedrick plots do not 
account for any interspecies differences in absorption processes. MMSA methods (Chapter 4, Scenario 3), 
which assumed CL and Vd were proportional to species body weights and where first-order absorption 
processes where inversely proportional to body weight performed quite well in terms of Cmax and Tmax. 
However, it should be noted that hypothesis for MMSA based scaling was that an exponent of 0.85 would 
be most appropriate for CL parameters, which was not the case. Lastly, PBPK based models, when 
accounting for slower skin lymph flow in humans relative to NHP as a fraction of skin blood flow, 
performed well for both Cmax and Tmax parameters (LS Opt model) and improved considerably when 
further model refinement considered a lymphatic drainage compartment (Vfrac model). 
 
7.4.2 Time Course Cross-Method Comparison 
Although qualitative in nature, predicting the shape of the concentration vs. time profile after extravascular 
administration is of critical importance as it helps inform future study design (e.g. optimal PK sampling 
strategy). Of the model independent methods assessed in this thesis, only Dedrick plots (Chapter 3) facilitate 
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time course scaling. However, evaluation of the predicted vs. observed human time course highlights the 
limitation of this method. The PK sampling schedule for NHP, as described earlier in this chapter, 
terminated prematurely such that when scaled to a human time scale characterized approximately 50% of 
the elimination profile (Figure 3.4a). Upon evaluation of the log-log scale for the Dedrick plot (Figure 3.4b) 
a clear over-prediction is evident during the absorption phase. This is an inherent limitation of Dedrick plots 
in extravascular administration which do not consider scaling/normalization of absorption processes. 
Figures 4.4a and 4.4b illustrate the predictive capacity of the time course for the various scenarios tested and 
although the FE for key PK parameters suggest Scenario 3 is an accurate method, (1) this method was 
entirely empiric and furthermore assumed an allometric scaling factor of 1 on CL (as opposed to 0.85) and 
(2) exhibits clear over-prediction at the earliest portions of the absorption phase. In contrast, when optimized 
for lymphatic flow rate, the Vfrac PBPK model (Chapter 6) qualitatively resulted in the best prediction of 
the observed data, across the entire sampling time profile. 
 
7.5 Discussion 
The genesis of this project originated from a perceived need for improved  macromolecule PK predictions 
following SC administration. Traditional methods have largely entailed scaling mean PK parameters such as 
total body CL across species based on empiric scaling factors. As discussed in several sections throughout 
this thesis, scaling of mean CL provides no information on the time course of a drug in the body following 
administration. Following extravascular administration, the concentration in the blood rises as drug is 
absorbed into the systemic circulation. With SC administration, CL at the site of administration or during 
lymphatic transit can potentially alter the bioavailability of the macromolecule. Additionally, the 
biodistribution pattern can alter the rate of transit into the systemic circulation with the contribution of 
lymphatic uptake as a major route of systemic absorption increasing correspondingly with molecular size of 
the drug.(16-18;143) Combined, these factors confer uncertainty in prediction of large molecule PK 
following SC administration from animal to human. 
 
In the simplest of terms, this thesis project evaluated the utility of model-based predictions of the time 
course of a macromolecule in the blood stream after SC administration relative to model-independent 
methods. Human PK of a PPC was projected from a single NHP . Fortuitously, an industrial benefactor 
provided concentration vs. time data for this compound following IV and SC in NHP and SC in humans. 
 
As with any prediction method, evaluation of a single compound is likely insufficient to draw any definite 
conclusions as to future predictions and is a limitation of the current thesis project. The results and 
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conclusions drawn from this thesis may however have broader application beyond the current molecule. The 
molecular weight of the pegylated moiety is approximately 44 kDa, which classifies the compound as a 
macromolecule. However, macromolecules vary in terms of their structural, physical and chemical 
properties. Being a pegylated peptide, it may be challenging to extrapolate the findings to other non-
pegylated compounds or those with much smaller or much larger molecular size. Pegylation has been 
reported to increase the hydrodynamic radius of conjugates beyond the molecular radius, resulting in a 
biodistribution pattern similar to larger macromolecules such as mAbs.(12;32) As such, the observations 
from the current thesis may have broader application than simply to pegylated peptides with a similar 
molecular weight to that of the current compound. 
 
Prior to exploring the prediction utility of computationally intensive model-based methods, a benchmark in 
terms of prediction accuracy had to be established. Chapter 2 reviewed a number of methods used for PK 
prediction from animal species, not all of which are applicable to macromolecules. As explained in the 
introductory chapter (Chapter 1), CL of macromolecules can occur following interaction of the drug with its 
target receptor. Interspecies differences in target expression and target affinity may preclude the usefulness 
of studying the drug PK in several species. Confirmation from the benefactor of data for the current 
compound confirmed that the activity of the drug is similar in NHPs and humans but not active in rodents or 
canine species. Consequently, only single-species methods were considered in Chapter 3 for the purposes of 
setting a benchmark of prediction accuracy of model independent methods. 
 
Chapter 2 also served to introduce a metric of prediction accuracy and to establish what would constitute 
reasonable prediction accuracy for both model-independent methods and model-based method development. 
Prediction accuracy throughout this thesis has been expressed in terms of FE with a perfect prediction 
resulting in a value of unity (i.e. 1).  FE is a logical and relatively easy method to interpret, applicable for 
expressing prediction accuracy of a single method for single compound; or averaged across a group of 
compounds to express the prediction accuracy of a single prediction method. Prediction error and root mean 
square error have also been reported by several authors, and is useful for rank ordering methods based on 
lower error, however an absolute threshold for what constitutes reasonable prediction accuracy has not been 
proposed.(75;96;144)  
 
For the work embodied within this thesis, and as proposed in Chapter 2, a 2-fold error was deemed too 
broad a threshold of acceptance.(145) A case study example in Chapter 2 was used to illustrate that such a 
wide threshold could potentially produce a false positive in terms of bioequivalence potential, when applied 
to a biosimilar. Consequently, a FE falling within 0.7-1.3 was proposed in this thesis as a more reasonable 
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threshold of prediction accuracy. Such a threshold would also be expected to provide a greater degree of 
confidence for a novel biologic transitioning from preclinical evaluation to a FIH investigation.  
 
In terms of single-species, model-independent methods, allometric scaling with fixed exponents, and 
Dedrick plots were employed to establish a benchmark for prediction accuracy. Based on the experience 
from several publications, Chapter 2 concluded that an exponent of 0.85-0.95 for CL and approximately 1 
for Vd, are reasonable empiric scaling factors for NHP to human extrapolation when model-independent or 
model-based methods were employed to estimate parameters of macromolecules exhibiting linear PK.(55) 
For empiric, SSA, a value of 1 was indeed accurate for volume parameters and when examining the 
molecules in Chapter 2, 0.85 resulted in reasonable prediction accuracy of CL for the many of compounds 
evaluated. For PPC however, following SC administration, an empiric assumption closer 1 was required to 
meet the acceptance criteria; however the reason for this is unclear.  
 
For benchmarking purposes exponents of 0.85 and 1 were initially tested for prediction accuracy of model-
independent CL and Vd parameters in Chapter 3. Consistent with previous observations, the Vd similarly 
scaled with an exponent of 1 with FE near unity. In contrast, CL/F required a scaling factor closer to 1 (as 
opposed to 0.85) to achieve good prediction accuracy. Although other authors have achieved successful 
prediction accuracy of single-species macromolecule CL using NHP data and scaling exponents >0.75 but 
less than 1, no particular trend in terms of type of macromolecule and scaling exponent has been offered to 
improve a priori predictions.(61) Unsurprisingly, model-independent methods did not perform especially 
well in informing the absorption profile of the drug after SC administration. Although the Dedrick plot 
approach employed in Chapter 3 predicted Cmax reasonably well, Tmax predictions fell outside the 
acceptance criteria. The discussion section of Chapter 3 addresses potential sources of poor prediction in the 
absorption phase with this method such as inconsistent or insufficient characterization of the PK in the NHP 
data, however additional testing of this method with SC administered macromolecules is warranted before a 
definitive conclusion can be made with respect to this method. 
 
Examination of an empiric relationship between NHP and humans in terms of macromolecule absorption 
from the SC space was the focus of Chapter 4. Model-based compartmental approaches proposed in Chapter 
4 allowed for derivation of parameters defining absorption processes. Only a few cases of macromolecule 
scaling after SC absorption using compartmental approaches have been published, however where 
evaluated, first-order rate processes suggest an inverse relationship between species size (body weight) and 
absorption rate.(91;104) Derivation of NCA parameters from the model simulated concentrations in Chapter 
4 exhibited excellent agreement with observed data, particularly in terms of Cmax and Tmax, when an 
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empirically selected exponent of -0.4 on absorption rates was used. In contrast, assumptions of an exponent 
ranging from 0 to 1 resulted in extremely poor prediction with the Tmax grossly under predicted as the 
exponent approached a value of one. The basis for this observation may be rooted in interspecies differences 
in skin anatomy and lymph flow from the skin, and were addressed in greater detail in Chapter 4.  
 
Despite the successful prediction accuracy with empiric scaling factors, there is still substantial uncertainty 
as to which parameters scale directly with body weight and which deviate from this direct weight-based 
relationship. In the current thesis project, an assumption was that all model parameters would scale to some 
degree with body weight and the scaling factor exponents were a priori selected based on theoretical 
knowledge or informed from some previous literature reports. This is an inherent limitation in all empiric 
allometric scaling methods, however results of the current investigation suggest this empiric modeling 
approach may work reasonably well for the purpose of planning a FIH study. 
 
In Chapter 5, an alternative mechanistically focused approach to scaling was attempted. At the point of 
writing of the work in this chapter, PBPK models capable of describing the time course of macromolecules 
with lymphatic uptake from the SC space had not been previously published. The absence of a predefined 
strategy for overcoming this uncertainty presented an opportunity to construct a novel means of addressing 
this problem. In contrast to several previous whole-body PBPK models incorporating lymphatic 
biodistribution for macromolecules following IV administration(48;50;51;101;102), the model developed as 
part of this thesis work offered a unique proposal whereby skin lymph flow was partitioned between the SC 
injection depot space and the remaining interstitial space proportionally based on the relative volume each 
space occupied. This modification allowed for incorporating lymph flow from the SC depot injection space 
whilst maintaining overall model flow balance (i.e. where flow into the lung equated to flow out of the lung 
compartment  - see Figures 5.2 a and b and Figures 6.1 a and b).  
 
A unique attribute of PBPK model-based scaling is that it allows for parameterization of local CL 
mechanisms. For the PBPK model in Chapter 5, CL was defined as both renal and non-renal processes, 
where the non-renal portion was estimated from the animal data and scaled based on body weight from NHP 
to humans. CL was then proportionally allocated to each anatomical space based on volume, which allowed 
for a portion to be allocated to the SC depot space. Although total non-renal CL was not mechanistically 
derived, apportioning of clearance was performed based on relative anatomical volume thus maintaining a 
mechanistic element. This base PBPK model was able to largely account for the bioavailability following 
SC administration to humans and produce concentrations with reasonable concordance to the observed data 
(Table 7.2), however failed to accurately predict the Tmax.  
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Prediction of bioavailability of macromolecules from animal species following SC administration 
historically has been challenging.(18) The root of these challenges may be in part due to a failure to 
adequately characterize CL processes in the animal species being studied, such that uncertainty in the 
scaling step is inflated. 
 
In the current thesis project, CL was parameterized as a linear process, as the dataset provided only a single 
dose level following IV and SC administration in NHP. Consequently non-linear processes could not be 
identified.  Estimating CL from a single dose level may be sufficient if the drug exhibits linear PK, however 
dose-dependency in absorption processes and  bioavailability have been observed with therapeutic 
macromolecules and should be tested experimentally.(41)  
 
Although the models in the current thesis did not incorporate non-linear processes, the workflow and 
processes developed in Chapters 4-6 are readily adaptable to incorporation of non-linear processes with the 
potential to scale across species. Chen et. al. characterized dose-dependent absorption of exenatide 
(approximately 4 kDa peptide) across several preclinical species with a Michaelis Mentin (MM) 
expression.(146) The MM constants Vmax and Km, were found to be proportional to the preclinical species 
and human body weight with scaling exponents of 0.392 and 0.605, respectively. Dong et. al. integrated 
MM expressions in clearance to characterize non-linear PK for a series of monoclonal antibodies (mAbs) in 
NHP for prediction in humans.(64) Vmax and Km were scaled with a theoretical exponent of 0.75 based on 
similar in-vitro binding of the receptor in both NHP and humans.  In contrast to other reports, first order 
absorption processes were assumed to scale directly with body weight between NHP and humans (as 
opposed to inversely).  
 
Another limitation in the model-based development, particularly as it pertains to Chapters 5 and 6, was the 
assumption of skin lymph flow. Zhao et. al.  suggested lymph flow is the most important driver of Tmax 
following SC administration of mAbs.(109) The value assigned for skin lymph flow in the PBPK models 
was carried over from a previous platform PBPK model developed for IV administered mAbs and where the 
source was reported for humans, and set at a fraction of the skin blood flow.(21;50) Sensitivity analyses 
performed in Chapters 5 and 6 confirm lymph flow from the skin is indeed a critically important parameter 
in predicting Tmax following SC administration. Precise quantitation of lymph flow is difficult to verify 
experimentally, and therefore remains a potential source of uncertainty for future extrapolations. 
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Chapter 6 expanded the model development in Chapter 5 to a population-based PBPK model to explore the 
impact of anthropometric variability in the prediction of the drugs time course after SC absorption. Upon 
further review from the models in Chapter 5 it was determined that further refinement of the model was 
possible to improve the prediction accuracy in the early time portion. As described in Chapter 6, an 
anatomical volume compartment representing lymphatic vessels draining from the SC depot was introduced 
into the model. As PBPK models are intended to be mechanistic in nature, an attempt was made to estimate 
this drainage volume from the NHP data. However, the sampling time points were too sparse in the early 
portion of the SC time course to reliably estimate a value for this parameter in the primates. Thus, the 
lymphatic drainage was parameterized as a fraction of the injection volume. Integrating the drainage volume 
resulted in a substantial improvement in the Tmax prediction (Table 7-2), along with smaller improvements 
in the Cmax and AUC parameters. The validity of this method of parameterization for routine extrapolation 
requires further evaluation with a broader group of compounds to confirm its generalizability. 
 
While the majority of this chapter has focused on cross-method comparisons of a mean PK parameter or 
mean concentration vs. time curve for a virtual human being, a major aspect of Chapter 6 was the 
development of a population based PBPK model. Mean PK values are inherently biased estimates. With 
respect to PK parameter estimation, a mean value may or may not be appropriate to use in predictions, 
depending on the intended application. For example, if the intention is to predict the PK of a novel drug in a 
relatively homogenous group of healthy male subjects for a FIH investigation, perhaps a mean virtual 
human prediction would suffice to guide study design and predict the dose needed to achieve a particular 
concentration of the drug in the blood stream intended for systemic action. However, if the intention is to 
apply a PBPK models in the prediction of a renally eliminated drug, for a range of renal impairment and 
normal renal function, prediction of a mean individual is likely insufficiently informative to guide a risk 
assessment. 
 
In contrast, a population PBPK simulation facilitates estimation of an unbiased population mean for the 
concentration vs. time profile, as well as a range of potential outcomes for systemic exposure. For 
macromolecule PBPK model development, incorporation of the lymphatics is crucial as it plays an 
important role in the biodistribution of macromolecules. Moreover, knowledge of the interindividual 
variability of the lymphatic system volume is an important input into a population PBPK model intended to 
simulate the PK of a macromolecule. At the time of this thesis work, published PBPK models for the 
prediction of macromolecules PK focused solely on a virtual human subject and thus did not consider 
interindividual variability. Published population PBPK models, which were likely developed for small 
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molecules, omitted a lymphatic system compartment. Thus, there was a dearth of knowledge to inform the 
development of a population based PBPK model for macromolecules.  
 
As the lymphatic system is considered a parallel circulatory system, and typically lymph vessels are 
collocated with blood vessels in many tissues, the interindividual variability for blood volume in humans 
was similarly applied to lymph volume. The resultant population PBPK model was capable of simulating 
the interindividual variability of the entire time course of a macromolecule following a single-dose SC 
administration.  
 
The most intuitive applications of said population model are direct scaling from animals to a population of 
individuals as opposed to a virtual human being. The potential advantage of this simulation-based approach, 
particularly in the context of a FIH investigation, is greater confidence in the prediction of systemic 
exposure of a novel compound, particularly when the intended study population participating in the trial is 
not especially homogenous and exhibits a wide range of body compositions. 
 
 Returning to the example of a renally cleared drug, for PPC, renal clearance represented a significant route 
of elimination. By altering mechanistic aspects of the model, such as glomerular filtration rate in the virtual 
population, the model could be theoretically extended to predict the range of systemic exposure in 
individuals with various degrees of renal impairment. As the drug may be administered to individuals with 
renal impairment, knowledge of the anticipated exposure in an impaired population can help inform dose 
adjustments for clinical use, or guide the design of a formal study in varying degrees of renal impairment. 
 
Accurate and reproducible prediction of macromolecule bioavailability across a wide range of compounds 
following SC administration remains elusive. The current model forms the basis for future assessment of 
mechanistic determinants of SC bioavailability in a population. In the event that local clearance processes in 
lymphatic tissue or interstitial fluid can be estimated in-vitro or ex-vivo, such processes can potentially be 
incorporated into the model. While evaluation of interstitial fluid has not been commonly reported, 
harvesting of lymph fluid in animals via cannulation techniques has been reported in the literature.(16;22) 
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7.6 Conclusion 
Scaling the PK of a therapeutic macromolecule is fraught with uncertainty. Where empiric allometric 
scaling factors may be useful for predicting overall exposure of drugs exhibiting linear PK, these methods 
are not useful for predicting the absorption processes following SC administration nor applicable for drugs 
exhibiting non-linear PK. Compartmental modeling offers an opportunity to predict the overall time course 
of a SC administered drug, and can potentially incorporate non-linear processes, however is highly 
dependent on the a priori selection of empiric scaling factors. At this point, it is unclear whether the 
prediction capacity of empiric model-based methods is compound specific or broadly applicable. As such, 
there is greater uncertainty with such predictions, particularly with respect to absorption processes. PBPK 
modeling offers a mechanistic approach to interspecies scaling and where data is available to inform 
mechanistic processes, also provides for the least uncertainty in predicting the SC time course. With respect 
to the pegylated peptide conjugate employed in the current thesis project, model-based methods provided 
superior prediction of absorption phase of a SC administered macromolecule. Moreover, PBPK methods 
provide the greatest potential for a priori prediction of the time course following SC administration. 
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8 Appendices 
8.1  Chapter 5 Appendix 5.1 
Representative Mass Balance Equations for a Generic PBPK Model for SC Administration of a Pegylated 
Protein Conjugate with Renal and Non-Specific Clearance 
Venous Plasma Circulation 
Vven
Cven
dt
=(Qheart – Lheart)* Cpla,organ +(Qadipose – Ladipose)* Cpla,adipose + (Qmuscle – Lmuscle)* Cpla,muscle + (Qkidney – 
Lkidney)* Cpla,kidney + (Qbone –Lbone)* Cpla,bone + (Qskin – Lskin)* Cpla,skin + (Qthymus – Lthymus)* Cpla,thymus + (Qother – 
Lother)* Cpla,other + ((Qliver – Lliver) + (Qsmallintestines – Lsmallintestines) + (Qlargeintestines – Llargeintestines) +(Qspleen – Lspleen) + 
(Qpancreas – Lpancreas))*Cpla,liver + (Llymph*Clymph) - (Qlung*Cven) – NRCLven*Cven  
Arterial Plasma Circulation 
Vart
Cart
dt
= ((Qlung-Llung)*Cpla,lung) – ((Qheart + Qadipose + Qmuscle + Qkidney+ Qbone + Qthymus + Qskin + Qbrain + Qliver + 
Qsmallintestines + Qlargeintestines + Qspleen + Qpancreas +Qother ) *Cart )  - NRCLart *Cart   
Lymph 
Vlymph
Clymph
dt
= Σ (Lorgan *(1-σisf)*Cisf,organ) - (Llymph*Clymph) 
Lung Vascular 
Vpla, lung
Cpla,lung
dt
= (Qlung*Cven) - (Llung*(1-(σv,sf*σv,lung))*Cpla,lung) - ((Qlung-Llung)*Cpla,lung)-
NRCLpla,lung*Cpla,lung 
Lung Interstitial 
Visf, lung
Cisf,lung
dt
= (Llung*(1-(σv,sf*σv,lung))*Cpla,lung) - (Llung*(1-σisf)*Cisf,lung)-NRCLisf,lung*Cisf,lung 
Kidney Vascular 
Vpla, kidney
Cpla,kidney
dt
= (Qkidney* Cart) - (Lkidney*(1-(σv,sf*σv,kidney))*Cpla,kidney) - ((Qkidney-Lkidney)* Cpla,kidney) - 
(GFR*FGFR*Cpla,kidney) - (NRCLpla,kidney * Cpla,kidney) 
Kidney Interstitial 
Visf, kidney
Cisf,kidney
dt
= (Lkidney*(1-(σv,sf*σv,kidney))*Cpla,kidney) - (Lkidney*(1-σisf)*Cisf,kidney) -
NRCLisf,kidney*Cisf,kidney 
Skin Vascular 
Vpla, skin
Cpla,skin
dt
=  (Qskin* Cart ) - ((Lskin + Ldepot )*(1-(σv,sf*σv,skin))*Cpla,skin) - ((Qskin-( Lskin + 
Ldepot))*Cpla,skin) – NRCLpla,skin 
 
Skin Interstitial 
 
Visf, skin
Cisf,skin
dt
=  (Lskin  *(1-(σv,sf * σv,skin))*Cpla,skin)  - (Lskin*(1-σisf)*Cisf,skin) - NRCLisf,skin*Cisf,skin 
 
Skin Subcutaneous Depot 
 
Vdepot
Cdepot
dt
=  (Ldepot  *(1-(σv,sf * σv,skin))*Cdepot)  - (Ldepot*(1-σisf)*Cdepot) – NRCLdepot*Cdepot 
 
Liver Vascular 
Vpla, liver
Cpla,liver
dt
=  = (Qliver * Cart) + ((Qsmallintestines-Lsmallintestines)*Cpla,smallintestines) + 
((Qlargeintestines-Llargeintestines)*Cpla,largeintestines) + ((Qspleen-Lspleen) * Cpla,spleen) +  
((Qpancreas-Lpancreas)*Cpla,pancreas) - (Lliver * (1-(σv,sf * σv,liver))*Cpla,liver)  - (((Qliver-Lliver) + (Qsmallintestines-Lsmallintestines) 
+ (Qlargeintestines-Llargeintestines) + (Qspleen-Lspleen) + (Qpancreas-Lpancreas))*Cpla,liver)- NRCLpla,liver*Cpla,liver 
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Liver Interstitial 
Visf, liver
Cisf,liver
dt
=   =  (Lliver * (1-(σv,sf * σv,liver))*Cpla,liver)  - (Lliver*(1-σisf)*Cisf,liver) - NRCLisf,liver*Cisf,liver 
 
Remaining Organs Vascular 
Vpla, kidney
Cpla,kidney
dt
= (Qorgan* Cart) - (Lorgan*(1-(σv,sf*σv,organ))*Cpla,organ) - ((Qorgan-Lorgan)* Cpla,organ) - 
(GFR*FGFR*Cpla,organ) - (NRCLpla,organ * Cpla,organ) 
Remaining Organs Interstitial 
Visf, kidney
Cisf,kidney
dt
= (Lorgan*(1-(σv,sf*σv,organ))*Cpla,organ) - (Lorgan*(1-σisf)*Cisf,organ) -NRCLisf,organ*Cisf,organ 
 
 
Abbreviations 
FGFR: Fraction of glomerular filtration rate attributed to renal clearance 
GFR: Glomerular filtration rate 
ISF (subscripted): Interstitial space  
L: Lymph flow 
NRCL: Non-Renal clearance 
Pla (subscripted): Plasma 
Q: Blood Flow 
Vart, Vven: Volume of the arterial and venous plasma space 
Vlymph: Volume of the lymph node space 
Visf,organ: Volume of the organ interstitial space 
Vpla,organ: Volume of the organ plasma vascular space  
σv,sf: Vascular reflection coefficient, scaling factor 
σv,organ: Organ vascular reflection coefficient 
σv,isf: Interstitial reflection coefficient  
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8.2  Chapter 5 Appendix 5.2:  
Monkey and Human Anatomical and Physiological Values 
 Monkey Human   
 Volume (mL 
per kg) 
Blood Flow 
Fraction of 
Cardiac 
Output 
Volume (per 
kg) 
Blood Flow 
Fraction of 
Cardiac 
Output 
Fraction 
Vascular 
Fraction 
Interstitial 
Organ       
heart  4.56 0.03 4.80 0.043 0.262 0.1 
lung  24.78 1 32.31 1 0.262 0.188 
muscle  527.96 0.18 423.63 0.188 0.026 0.12 
skin 108.77 0.11 48.00 0.065 0.019 0.302 
adipose 24.91 0.01 189.65 0.063 0.01 0.135 
bone 153.52 0.01 143.17 0.015 0.041 0.1 
brain 15.16 0.07 20.41 0.12 0.039 0.18 
kidney 4.40 0.15 4.67 0.204 0.105 0.2 
liver  30.13 0.06 30.18 0.074 0.115 0.163 
smallintestine  31.85 0.16 10.86 0.069 0.024 0.094 
largeintestine  45.27 0.16 15.43 0.072 0.024 0.094 
pancreas  2.01 0.02 1.46 0.017 0.2 0.173 
thymus 0.34 0.01 0.09 0.002 0.03 0.15 
spleen 0.96 0.01 3.12 0.036 0.282 0.15 
other  14.96 0.04 7.07 0.032 0.103 0.154 
lymph 4.04  3.86    
Blood 4.56  80.05    
Other: bladder, stomach, gallbladder, adrenals, thyroid 
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Additional 
Physiological 
Parameters 
Monkeys Humans  
Cardiac 
Output 
(mL/hr/kg) 
6472.26 4564.22 
Hematocrit 0.41 0.44 
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8.3 Chapter 6 Appendix 6.1 
Representative Mass Balance Equations for a Generic PBPK Model for SC Administration of a Pegylated 
Protein Conjugate with Renal and Non-Specific Clearance 
Venous Plasma Circulation 
 
𝑉𝑣𝑒𝑛 ∗
𝑑𝐶𝑣𝑒𝑛
𝑑𝑡
= (𝑄ℎ𝑒𝑎𝑟𝑡 − 𝐿ℎ𝑒𝑎𝑟𝑡) ∗ 𝐶𝑝𝑙𝑎,ℎ𝑒𝑎𝑟𝑡 + (𝑄𝑎𝑑𝑖𝑝𝑜𝑠𝑒 − 𝐿𝑎𝑑𝑖𝑝𝑜𝑠𝑒) ∗ 𝐶𝑝𝑙𝑎,𝑎𝑑𝑖𝑝𝑜𝑠𝑒
+ (𝑄𝑚𝑢𝑠𝑐𝑙𝑒 − 𝐿𝑚𝑢𝑠𝑐𝑙𝑒) ∗ 𝐶𝑝𝑙𝑎,𝑚𝑢𝑠𝑐𝑙𝑒 + (𝑄𝑘𝑖𝑑𝑛𝑒𝑦 − 𝐿𝑘𝑖𝑑𝑛𝑒𝑦) ∗ 𝐶𝑝𝑙𝑎,𝑘𝑖𝑑𝑛𝑒𝑦
+ (𝑄𝑏𝑜𝑛𝑒 − 𝐿𝑏𝑜𝑛𝑒) ∗ 𝐶𝑝𝑙𝑎,𝑏𝑜𝑛𝑒 + (𝑄𝑠𝑘𝑖𝑛 − 𝐿𝑠𝑘𝑖𝑛) ∗ 𝐶𝑝𝑙𝑎,𝑠𝑘𝑖𝑛 + (𝑄𝑡ℎ𝑦𝑚𝑢𝑠 − 𝐿𝑡ℎ𝑦𝑚𝑢𝑠)
∗ 𝐶𝑝𝑙𝑎,𝑡ℎ𝑦𝑚𝑢𝑠 + (𝑄𝑜𝑡ℎ𝑒𝑟 − 𝐿𝑜𝑡ℎ𝑒𝑟) ∗ 𝐶𝑝𝑙𝑎,𝑜𝑡ℎ𝑒𝑟 + (𝑄𝑏𝑟𝑎𝑖𝑛 − 𝐿𝑏𝑟𝑎𝑖𝑛) ∗ 𝐶𝑝𝑙𝑎,𝑏𝑟𝑎𝑖𝑛
+ [(𝑄𝑙𝑖𝑣𝑒𝑟 − 𝐿𝑙𝑖𝑣𝑒𝑟) + (𝑄𝑠𝑚𝑎𝑙𝑙𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠 − 𝐿𝑠𝑚𝑎𝑙𝑙𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠)
+ (𝑄𝑙𝑎𝑟𝑔𝑒𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠 − 𝐿𝑙𝑎𝑟𝑔𝑒𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠) + (𝑄𝑠𝑝𝑙𝑒𝑒𝑛 − 𝐿𝑠𝑝𝑙𝑒𝑒𝑛)
+ (𝑄𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠 − 𝐿𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠)] ∗ 𝐶𝑝𝑙𝑎,𝑙𝑖𝑣𝑒𝑟 + 𝐿𝑙𝑦𝑚𝑝ℎ ∗ 𝐶𝑙𝑦𝑚𝑝ℎ − 𝑄𝑙𝑢𝑛𝑔 ∗ 𝐶𝑣𝑒𝑛 − 𝑁𝑅𝐶𝐿𝑣𝑒𝑛
∗ 𝐶𝑣𝑒𝑛 
Arterial Plasma Circulation 
𝑉𝑎𝑟𝑡 ∗
𝑑𝐶𝑎𝑟𝑡
𝑑𝑡
= (𝑄𝑙𝑢𝑛𝑔 − 𝐿𝑙𝑢𝑛𝑔) ∗ 𝐶𝑝𝑙𝑎,𝑙𝑢𝑛𝑔 − (𝑄ℎ𝑒𝑎𝑟𝑡 + 𝑄𝑎𝑑𝑖𝑝𝑜𝑠𝑒 + 𝑄𝑚𝑢𝑠𝑐𝑙𝑒 + 𝑄𝑘𝑖𝑑𝑛𝑒𝑦 + 𝑄𝑏𝑜𝑛𝑒
+ 𝑄𝑡ℎ𝑦𝑚𝑢𝑠 + 𝑄𝑠𝑘𝑖𝑛 + 𝑄𝑏𝑟𝑎𝑖𝑛 + 𝑄𝑙𝑖𝑣𝑒𝑟 + 𝑄𝑠𝑚𝑎𝑙𝑙𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠 + 𝑄𝑙𝑎𝑟𝑔𝑒𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠 + 𝑄𝑠𝑝𝑙𝑒𝑒𝑛
+ 𝑄𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠 + 𝑄𝑜𝑡ℎ𝑒𝑟) ∗ 𝐶𝑎𝑟𝑡 − 𝑁𝑅𝐶𝐿𝑎𝑟𝑡 ∗ 𝐶𝑎𝑟𝑡 
Lymph 
𝑉𝑙𝑦𝑚𝑝ℎ ∗
𝑑𝐶𝑙𝑦𝑚𝑝ℎ
𝑑𝑡
= ∑(𝐿𝑜𝑟𝑔𝑎𝑛 ∗ (1 − 𝜎𝑖) ∗ 𝐶𝑖𝑠𝑓,𝑜𝑟𝑔𝑎𝑛) + 𝐿𝑑𝑒𝑝𝑜𝑡 ∗ 𝐶𝐿𝐷𝐶 − 𝐿𝑙𝑦𝑚𝑝ℎ ∗ 𝐶𝑙𝑦𝑚𝑝ℎ 
Lung Vascular 
𝑉𝑝𝑙𝑎,𝑙𝑢𝑛𝑔 ∗
𝑑𝐶𝑝𝑙𝑎,𝑙𝑢𝑛𝑔
𝑑𝑡
= 𝑄𝑙𝑢𝑛𝑔 ∗ 𝐶𝑣𝑒𝑛 − 𝐿𝑙𝑢𝑛𝑔 ∗ (1 − 𝜎𝑠𝑓 ∗ 𝜎𝑣,𝑙𝑢𝑛𝑔) ∗ 𝐶𝑝𝑙𝑎,𝑙𝑢𝑛𝑔 − (𝑄𝑙𝑢𝑛𝑔 − 𝐿𝑙𝑢𝑛𝑔) ∗ 𝐶𝑝𝑙𝑎,𝑙𝑢𝑛𝑔
− 𝑁𝑅𝐶𝐿𝑝𝑙𝑎,𝑙𝑢𝑛𝑔 ∗ 𝐶𝑝𝑙𝑎,𝑙𝑢𝑛𝑔 
Lung Interstitial 
𝑉𝑖𝑠𝑓,𝑙𝑢𝑛𝑔 ∗
𝑑𝐶𝑖𝑠𝑓,𝑙𝑢𝑛𝑔
𝑑𝑡
= 𝐿𝑙𝑢𝑛𝑔 ∗ (1 − 𝜎𝑠𝑓 ∗ 𝜎𝑣,𝑙𝑢𝑛𝑔) ∗ 𝐶𝑝𝑙𝑎,𝑙𝑢𝑛𝑔 − 𝐿𝑙𝑢𝑛𝑔 ∗ (1 − 𝜎𝑖) ∗ 𝐶𝑖𝑠𝑓,𝑙𝑢𝑛𝑔 − 𝑁𝑅𝐶𝐿𝑖𝑠𝑓,𝑙𝑢𝑛𝑔
∗ 𝐶𝑖𝑠𝑓,𝑙𝑢𝑛𝑔 
Kidney Vascular 
𝑉𝑝𝑙𝑎,𝑘𝑖𝑑𝑛𝑒𝑦 ∗
𝑑𝐶𝑝𝑙𝑎,𝑘𝑖𝑑𝑛𝑒𝑦
𝑑𝑡
= 𝑄𝑘𝑖𝑑𝑛𝑒𝑦 ∗ 𝐶𝑎𝑟𝑡 − 𝐿𝑘𝑖𝑑𝑛𝑒𝑦 ∗ (1 − 𝜎𝑠𝑓 ∗ 𝜎𝑣,𝑘𝑖𝑑𝑛𝑒𝑦) ∗ 𝐶𝑝𝑙𝑎,𝑘𝑖𝑑𝑛𝑒𝑦 − (𝑄𝑘𝑖𝑑𝑛𝑒𝑦 − 𝐿𝑘𝑖𝑑𝑛𝑒𝑦)
∗ 𝐶𝑝𝑙𝑎,𝑘𝑖𝑑𝑛𝑒𝑦 − GFR ∗ FGFR ∗ 𝐶𝑝𝑙𝑎,𝑘𝑖𝑑𝑛𝑒𝑦 − 𝑁𝑅𝐶𝐿𝑝𝑙𝑎,𝑘𝑖𝑑𝑛𝑒𝑦 ∗ 𝐶𝑝𝑙𝑎,𝑘𝑖𝑑𝑛𝑒𝑦 
Kidney Interstitial 
𝑉𝑖𝑠𝑓,𝑘𝑖𝑑𝑛𝑒𝑦 ∗
𝑑𝐶𝑖𝑠𝑓,𝑘𝑖𝑑𝑛𝑒𝑦
𝑑𝑡
= 𝐿𝑘𝑖𝑑𝑛𝑒𝑦 ∗ (1 − 𝜎𝑠𝑓 ∗ 𝜎𝑣,𝑘𝑖𝑑𝑛𝑒𝑦) ∗ 𝐶𝑝𝑙𝑎,𝑘𝑖𝑑𝑛𝑒𝑦 − 𝐿𝑘𝑖𝑑𝑛𝑒𝑦 ∗ (1 − 𝜎𝑖) ∗ 𝐶𝑖𝑠𝑓,𝑘𝑖𝑑𝑛𝑒𝑦
− 𝑁𝑅𝐶𝐿𝑖𝑠𝑓,𝑘𝑖𝑑𝑛𝑒𝑦 ∗ 𝐶𝑖𝑠𝑓,𝑘𝑖𝑑𝑛𝑒𝑦  
Skin Vascular 
𝑉𝑝𝑙𝑎,𝑠𝑘𝑖𝑛 ∗
𝑑𝐶𝑝𝑙𝑎,𝑠𝑘𝑖𝑛
𝑑𝑡
= 𝑄𝑠𝑘𝑖𝑛 ∗ 𝐶𝑎𝑟𝑡 − (𝐿𝑠𝑘𝑖𝑛 + 𝐿𝑑𝑒𝑝𝑜𝑡) ∗ (1 − 𝜎𝑠𝑓 ∗ 𝜎𝑣,𝑠𝑘𝑖𝑛) ∗ 𝐶𝑝𝑙𝑎,𝑠𝑘𝑖𝑛
− (𝑄𝑠𝑘𝑖𝑛 − (𝐿𝑠𝑘𝑖𝑛 + 𝐿𝑑𝑒𝑝𝑜𝑡)) ∗ 𝐶𝑝𝑙𝑎,𝑠𝑘𝑖𝑛 − 𝑁𝑅𝐶𝐿𝑝𝑙𝑎,𝑠𝑘𝑖𝑛 ∗ 𝐶𝑝𝑙𝑎,𝑠𝑘𝑖𝑛  
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Skin Interstitial 
𝑉𝑖𝑠𝑓,𝑠𝑘𝑖𝑛 ∗
𝑑𝐶𝑖𝑠𝑓,𝑠𝑘𝑖𝑛
𝑑𝑡
= 𝐿𝑠𝑘𝑖𝑛 ∗ (1 − 𝜎𝑠𝑓 ∗ 𝜎𝑣,𝑠𝑘𝑖𝑛) ∗ 𝐶𝑝𝑙𝑎,𝑠𝑘𝑖𝑛 − 𝐿𝑠𝑘𝑖𝑛 ∗ (1 − 𝜎𝑖) ∗ 𝐶𝑖𝑠𝑓,𝑠𝑘𝑖𝑛 − 𝑁𝑅𝐶𝐿𝑖𝑠𝑓,𝑠𝑘𝑖𝑛
∗ 𝐶𝑖𝑠𝑓,𝑠𝑘𝑖𝑛 
Skin Subcutaneous Depot 
𝑉𝑑𝑒𝑝𝑜𝑡 ∗
𝑑𝐶𝑑𝑒𝑝𝑜𝑡
𝑑𝑡
= 𝐿𝑑𝑒𝑝𝑜𝑡 ∗ (1 − 𝜎𝑠𝑓 ∗ 𝜎𝑣,𝑠𝑘𝑖𝑛) ∗ 𝐶𝑑𝑒𝑝𝑜𝑡 − 𝐿𝑑𝑒𝑝𝑜𝑡 ∗ (1 − 𝜎𝑖) ∗ 𝐶𝑑𝑒𝑝𝑜𝑡 − 𝑁𝑅𝐶𝐿𝑑𝑒𝑝𝑜𝑡
∗ 𝐶𝑑𝑒𝑝𝑜𝑡  
Skin Depot Lymph Drainage Compartment (LDC) 
𝑉𝐿𝐷𝐶 ∗
𝑑𝐶𝐿𝐷𝐶
𝑑𝑡
= 𝐿𝑑𝑒𝑝𝑜𝑡 ∗ (1 − 𝜎𝑖) ∗ 𝐶𝑑𝑒𝑝𝑜𝑡 − 𝐿𝑑𝑒𝑝𝑜𝑡 ∗ 𝐶𝐿𝐷𝐶 
Liver Vascular 
𝑉𝑝𝑙𝑎,𝑙𝑖𝑣𝑒𝑟 ∗
𝑑𝐶𝑝𝑙𝑎,𝑙𝑖𝑣𝑒𝑟
𝑑𝑡
= 𝑄𝑙𝑖𝑣𝑒𝑟 ∗ 𝐶𝑎𝑟𝑡 + (𝑄𝑠𝑚𝑎𝑙𝑙𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠 − 𝐿𝑠𝑚𝑎𝑙𝑙𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠) ∗ 𝐶𝑝𝑙𝑎,𝑠𝑚𝑎𝑙𝑙𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠
+ (𝑄𝑙𝑎𝑟𝑔𝑒𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠 − 𝐿𝑙𝑎𝑟𝑔𝑒𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠) ∗ 𝐶𝑝𝑙𝑎,𝑙𝑎𝑟𝑔𝑒𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠 + (𝑄𝑠𝑝𝑙𝑒𝑒𝑛 − 𝐿𝑠𝑝𝑙𝑒𝑒𝑛)
∗ 𝐶𝑝𝑙𝑎,𝑠𝑝𝑙𝑒𝑒𝑛 + (𝑄𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠 − 𝐿𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠) ∗ 𝐶𝑝𝑙𝑎,𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠 − 𝐿𝑙𝑖𝑣𝑒𝑟 ∗ (1 − 𝜎𝑣,𝑠𝑓 ∗ 𝜎𝑣,𝑙𝑖𝑣𝑒𝑟)
∗ 𝐶𝑝𝑙𝑎,𝑙𝑖𝑣𝑒𝑟
− [(𝑄𝑙𝑖𝑣𝑒𝑟 − 𝐿𝑙𝑖𝑣𝑒𝑟) + (𝑄𝑠𝑚𝑎𝑙𝑙𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠 − 𝐿𝑠𝑚𝑎𝑙𝑙𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠)
+ (𝑄𝑙𝑎𝑟𝑔𝑒𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠 − 𝐿𝑙𝑎𝑟𝑔𝑒𝑖𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒𝑠) + (𝑄𝑠𝑝𝑙𝑒𝑒𝑛 − 𝐿𝑠𝑝𝑙𝑒𝑒𝑛)
+ (𝑄𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠 − 𝐿𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠)] ∗ 𝐶𝑝𝑙𝑎,𝑙𝑖𝑣𝑒𝑟 − 𝑁𝑅𝐶𝐿𝑝𝑙𝑎,𝑙𝑖𝑣𝑒𝑟 ∗ 𝐶𝑝𝑙𝑎,𝑙𝑖𝑣𝑒𝑟 
Liver Interstitial 
𝑉𝑖𝑠𝑓,𝑙𝑖𝑣𝑒𝑟 ∗
𝑑𝐶𝑖𝑠𝑓,𝑙𝑖𝑣𝑒𝑟
𝑑𝑡
= 𝐿𝑙𝑖𝑣𝑒𝑟 ∗ (1 − 𝜎𝑠𝑓 ∗ 𝜎𝑣,𝑙𝑖𝑣𝑒𝑟) ∗ 𝐶𝑝𝑙𝑎,𝑙𝑖𝑣𝑒𝑟 − 𝐿𝑙𝑖𝑣𝑒𝑟 ∗ (1 − 𝜎𝑖) ∗ 𝐶𝑖𝑠𝑓,𝑙𝑖𝑣𝑒𝑟 − 𝑁𝑅𝐶𝐿𝑖𝑠𝑓,𝑙𝑖𝑣𝑒𝑟
∗ 𝐶𝑖𝑠𝑓,𝑙𝑖𝑣𝑒𝑟 
Remaining Organs Vascular 
𝑉𝑝𝑙𝑎,𝑜𝑟𝑔𝑎𝑛 ∗
𝑑𝐶𝑝𝑙𝑎,𝑜𝑟𝑔𝑎𝑛
𝑑𝑡
= 𝑄𝑜𝑟𝑔𝑎𝑛 ∗ 𝐶𝑎𝑟𝑡 − 𝐿𝑜𝑟𝑔𝑎𝑛 ∗ (1 − 𝜎𝑠𝑓 ∗ 𝜎𝑣,𝑜𝑟𝑔𝑎𝑛) ∗ 𝐶𝑝𝑙𝑎,𝑜𝑟𝑔𝑎𝑛 − (𝑄𝑜𝑟𝑔𝑎𝑛 − 𝐿𝑜𝑟𝑔𝑎𝑛)
∗ 𝐶𝑝𝑙𝑎,𝑜𝑟𝑔𝑎𝑛 − 𝑁𝑅𝐶𝐿𝑝𝑙𝑎,𝑜𝑟𝑔𝑎𝑛 ∗ 𝐶𝑝𝑙𝑎,𝑜𝑟𝑔𝑎𝑛 
Remaining Organs Interstitial 
𝑉𝑖𝑠𝑓,𝑜𝑟𝑔𝑎𝑛 ∗
𝑑𝐶𝑖𝑠𝑓,𝑜𝑟𝑔𝑎𝑛
𝑑𝑡
= 𝐿𝑜𝑟𝑔𝑎𝑛 ∗ (1 − 𝜎𝑠𝑓 ∗ 𝜎𝑣,𝑜𝑟𝑔𝑎𝑛) ∗ 𝐶𝑝𝑙𝑎,𝑜𝑟𝑔𝑎𝑛 − 𝐿𝑜𝑟𝑔𝑎𝑛 ∗ (1 − 𝜎𝑖) ∗ 𝐶𝑖𝑠𝑓,𝑜𝑟𝑔𝑎𝑛
− 𝑁𝑅𝐶𝐿𝑖𝑠𝑓,𝑜𝑟𝑔𝑎𝑛 ∗ 𝐶𝑖𝑠𝑓,𝑜𝑟𝑔𝑎𝑛  
 
 
Notation 
FGFR: Fraction of glomerular filtration rate attributed to renal clearance 
GFR: Glomerular filtration rate 
isf (subscripted): Interstitial fluid  
L: Lymph flow 
NRCL: Non-Renal clearance 
pla (subscripted): Plasma 
Q: Blood Flow 
Vfrac: Fraction of injection volume attributed to the lymph drainage vessels 
Vart, Vven: Volume of the arterial and venous plasma space 
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Vlymph: Volume of the lymph node space 
Visf,organ: Volume of the organ interstitial space 
Vpla,organ: Volume of the organ plasma vascular space  
σsf: Vascular reflection coefficient, scaling factor 
σv,organ: Organ vascular reflection coefficient 
σi: Interstitial fluid reflection coefficient  
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9 Copyright/permissions for reprinting published materials 
9.1  Chapter 1 reprint of Figure 1.1 permission 
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9.2 Chapter 2 reprint permission 
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9.3 Chapter 4 reprint permission 
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9.4 Chapter 5 reprint permission 
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9.5 Chapter 6 reprint permission 
 
 
